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Growing number of people with diabetes
The general term “diabetes mellitus” subsumes several metabolic conditi ons characterized 
by hyperglycemia (high blood glucose levels), resulti ng from insuffi  cient acti on of the 
hormone insulin on peripheral target ti ssues in the body or from an absolute defi ciency 
of insulin secreti on 1. Diabetes is aff ecti ng a growing number of people worldwide. 
Global prevalence esti mates are projected to rise from 171 million in 2000 to 366 million 
in 2030 2. Given the associated increased risk of disability 3, 4 and mortality 5, diabetes is 
considered one of the main threats to human health of the 21st century 6. Moreover, due 
to a relati vely long asymptomati c phase between the onset of hyperglycemia and an actual 
clinical diagnosis in most individuals with type 2 diabetes, almost half of the total diabetes 
populati on is unaware of their disease status 7. In The Netherlands, the scope of the problem 
is similar to these global trends, with approximately one million people having diabetes 8. 
Early epidemiological studies esti mated that up to 50% of all Dutch people with diabetes 
were  undiagnosed 9, but more recent fi gures suggest that the number of Dutch people 
with undiagnosed type 2 diabetes has decreased to approximately one quarter of the total 
diabetes populati on 8. This may be due to an increased awareness among citi zens and health 
care providers, improvements in screening and early diagnosis 8. 
Diabetes mellitus: pathophysiology
There are two main forms of diabetes, which diff er markedly in eti ology and clinical 
presentati on. Type 1 diabetes (5 – 10% of those with diabetes) is due to autoimmune 
destructi on of the insulin producing ß-cells of the pancreas, which leads to an absolute 
defi ciency of insulin secreti on 10. This conditi on commonly develops in children and young 
adults, but can occur at any age, even in the elderly 10. It oft en presents with acute diabetes 
symptoms and markedly elevated blood glucose levels, and most people are diagnosed 
soon aft er the onset of hyperglycemia 10. In type 2 diabetes, which accounts for about 90% 
of all diabetes cases in high-income countries 7, hyperglycemia is caused by a diminished 
response to insulin by peripheral target ti ssues in the body and abnormal insulin secreti on, 
either of which may predominate 6, 10. The risk of developing type 2 diabetes is most likely an 
interacti on between geneti c predispositi on, demographic factors (e.g. age, race / ethnicity), 
and lifestyle-related infl uences such as unhealthy dietary behaviors (e.g. high intake of 
saturated fats and a high caloric diet), obesity and lack of physical acti vity 10. As hyperglycemia 
tends to develop more gradually and symptoms are oft en not noti ced in the earlier stages of 
the disease, type 2 diabetes may go undiagnosed for many years 10. Although most people 
develop type 2 diabetes in middle age or later, it is now being increasingly diagnosed in 
young adults and children as well, paralleling the escalati ng rates of obesity across all age 




Leading a fulfilling and enjoyable life while having diabetes is certainly possible for many 
people but, for others, coping with the condition, its management and its complications 
can be both demanding and challenging. For example, diabetes can be accompanied by 
acute short-term complications, such as hypoglycaemia and ketoacidosis, and by long-term 
micro-vascular complications (e.g. retinopathy, neuropathy and nephropathy) and macro-
vascular disease (e.g. heart disease, stroke and peripheral arterial disease) 11. To date, 
diabetes remains a predominant cause of vision loss, renal failure and lower extremity 
amputations in developed countries 12. A large-scaled study among over 7,000 people 
with type 2 diabetes in eight European countries concluded that approximately 72% of the 
participants had at least one complication, while 24% of the total study group had both 
micro- and macrovascular complications 3. Vascular complications are common in type 1 
diabetes as well, with a recent study reporting a 30-year cumulative incidence of proliferative 
retinopathy, nephropathy, and cardiovascular disease of 50%, 25%, and 14%, respectively 
13. From previous landmark studies such as the Diabetes Control and Complications Trial 
(DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), we know that these 
vascular conditions can be prevented or delayed through optimal management of blood 
glucose levels and other cardiovascular risk factors such as blood pressure and cholesterol 14-
18. The importance of daily self-management is therefore unquestionable; yet, diabetes self-
care can place a heavy burden on individuals. Self-management encompasses a wide range 
of activities, including daily oral medication and / or insulin use, blood glucose monitoring, 
foot care, healthy eating (and, for some, carbohydrate counting), and engaging in regular 
physical activity. Unsurprisingly, having diabetes (and its complications) can have a serious 
negative impact on the emotional well-being and quality of life of people living with this 
condition 19-22. In turn, emotional distress may hamper self-care behaviors and increase the 
risk of adverse diabetes outcomes 23, 24. 
Depression is common in diabetes
Depression can be considered as a common complication of diabetes, affecting 10 – 30% of 
people with diabetes 19. Major depressive disorder is a psychiatric condition characterized by 
at least one of two core symptoms: depressed mood (dysphoria) and a markedly diminished 
interest or pleasure in all, or almost all, activities (anhedonia) 25. Additional symptoms may 
include significant weight loss or weight gain / decrease or increase in appetite, insomnia 
or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of 
worthlessness or excessive or inappropriate guilt, diminished ability to think or concentrate 
/ indecisiveness, and recurrent thoughts of death and suicide 25. Rather than encompassing a 
homogenous condition, depression is characterized by a variety of symptoms and subtypes, 




report questi onnaires are oft en uti lized to determine the presence of elevated depressive 
symptoms, but a syndromal diagnosis of major or minor depression can only be ascertained 
using a standardized diagnosti c interview 25. A meta-analysis of 42 studies concluded that 
the prevalence of depression in diabetes was signifi cantly higher when assessed by self-
report questi onnaires (31%) than by standardized diagnosti c interviews (11%) 19. 
Depression appears to be nearly twice as common in people with type 2 diabetes compared 
with those without (18% vs. 10%, OR = 1.6, 95% CI 1.5 – 1.7) 27, but a reliable comparison 
across studies with regard to the assessment method used to defi ne depression could 
not be given due to the small number of controlled studies using a diagnosti c interview. A 
systemati c review published in 2006 suggested that it would be premature to conclude that 
the prevalence of depression is elevated in type 1 diabetes 28, but a more recent study showed 
that adults with type 1 diabetes were twice as likely to report symptoms of depression and 
/ or use anti depressant medicati on, compared to age- and sex-matched individuals without 
diabetes 29. In outpati ent setti  ngs, about one-third of people with type 1 or type 2 diabetes 
report depression 30, while lower prevalence esti mates (15 – 20%) have been found for type 
2 diabetes in populati on-based studies 31, 32. Furthermore, the prevalence of depression 
appears to be increased among people with diabetes and (multi ple) co-morbid medical 
conditi ons 31, 33, 34. It is important to disti nguish depression from diabetes-specifi c emoti onal 
distress, which concerns negati ve emoti ons specifi cally related to living with diabetes and 
its self-management 21, 35, although these diabetes-specifi c emoti onal problems appear to 
be parti cularly common in people with diabetes and depression 36-38.
the complex interplay between diabetes and depression
A close link between depression and diabetes has been acknowledged for many years, but 
the exact nature of this relati onship remains unclear 39. For example, for type 2 diabetes, 
there is convincing evidence that the relati on with depression is bidirecti onal. Several meta-
analyses have identi fi ed depression as a risk factor for the development of type 2 diabetes 
40, 41 and the presence of type 2 diabetes may contribute to the onset of depression 40, 42. Any 
prospecti ve associati on between depression and the onset of type 1 diabetes is yet to be 
established. 
the adverse consequences of depression in people with diabetes
Co-morbid depression in diabetes not only has a profound negati ve impact on pati ent-
reported health outcomes such as quality of life 43, but may also be related to other poor 
health outcomes. A growing number of studies suggest that depression may predict the 
development of macrovascular disease and microvascular complicati ons 24, 44-50, although 
most work to date has exclusively used data from samples from the USA. Several prospecti ve 
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studies have shown that people with diabetes and co-morbid depression are more likely 
to die earlier than their non-depressed counterparts 51-55, where mortality risks appear 
to extend beyond cardiovascular-related causes 54. Moreover, having both diabetes and 
depression appears to have an association with health beyond that due to having either 
diabetes or depression alone 44, 51. Findings regarding the association between depression 
and suboptimal glycemic control are less consistent. A meta-analysis of 24 cross-sectional 
studies published up until 1999 concluded that depression was significantly associated 
with higher glycated hemoglobin (hbA1c) concentrations in people with type 1 and type 2 
diabetes (standardized effect size 0.17, 95% CI 0.13 – 0.21) 56, but subsequent studies have 
yielded mixed results 57. 
Aims and outline of thesis
While our understanding of the relation between diabetes and emotional distress has 
increased in the past twenty years 58, many important issues remain to be elucidated. The 
present thesis will address the following main questions:
- Does hyperglycemia and / or the burden of living with diabetes explain the high 
prevalence of depression in diabetes?
- What is the course of depression in type 2 diabetes?
- Is depression associated with timing of insulin therapy in type 2 diabetes? 
- Are symptom-clusters related to the two core features of depression (dysphoria, 
anhedonia) differentially associated with health-outcomes in people with type 2 
diabetes, and are there symptom-specific mechanisms in play?
- What is the role of other, more chronic forms of emotional distress in diabetes?
Understanding the high prevalence of depression in diabetes
Although the precise reasons for the higher prevalence rates of depression in people with 
diabetes are not fully understood, there are two dominant hypotheses focusing on the 
initial onset of depression in this group 59. The “emotional burden hypothesis” states that 
the higher rate of depression in people with diabetes results from the burden of having to 
manage a chronic condition on a daily basis and / or having to cope with its short- or long 
term complications 59. Alternatively, depression may be provoked by biochemical changes 
directly due to diabetes 59 such as hyperglycemia. One (indirect) way to study whether 
hyperglycemia affects mood would be to compare the prevalence of depression in people 
with normal glucose metabolism with the rate of depression in people who, by definition, 
have higher levels of blood glucose (those with impaired glucose metabolism or undetected 
type 2 diabetes). Additional support for the emotional burden hypothesis is found when 
people with known type 2 diabetes are more likely to report depression than people 




emoti onal distress of being diagnosed with or having to self-manage a chronic conditi on. 
Therefore, Chapter 2 will examine whether the prevalence of depression in people with 
impaired glucose metabolism or undiagnosed diabetes is elevated relati ve to individuals 
with normal glucose metabolism or decreased relati ve to those with previously diagnosed 
type 2 diabetes by reviewing the literature and conducti ng a meta-analysis of studies on this 
topic.
The course of depression in people with diabetes
Previous research among people with diabetes has mainly focused on prevalence esti mates 
of depression in cross-secti onal studies 19, 27, 28. Of the longitudinal studies that have been 
conducted, most have examined incident depression 42. however, few have taken history of 
depression before study onset into account, and should therefore be interpreted cauti ously 
with respect to incident depression in the strictest sense (i.e. fi rst occurrence) 42. Longitudinal 
studies in general community and primary care samples have provided ample evidence 
that depression (either measured with an interview or questi onnaire) can be regarded as 
a chronic and recurrent conditi on for many people, with approximately 20 – 30% showing 
persistent depression and up to 50% experiencing residual symptoms or recurrences 60-62. 
Much less is known about the course of depression in people with diabetes. An early, highly 
cited study suggests that the natural course of major depression in diabetes is malevolent, 
perhaps even more so than in depressed people who are otherwise medically well 63. 
Subsequent studies have mostly focused on elevated depressive symptoms rather than 
clinical diagnoses of depression, showing that approximately half of all people experiencing 
depressive symptoms at baseline also reported depression 1 to 5 years later 64, 65. While 
fl uctuati ng course types are best studied in designs with at least three measurements 62, 
only two studies have examined the course of depressive symptoms over more than two 
assessments. however, one did not provide strictly observati onal fi ndings, as depression 
was assessed in the framework of a psycho-educati onal program 66 and the other did not 
allow an evaluati on of specifi c course patt erns as persistence esti mates were combined 
across study waves 67. In additi on, litt le is known about which factors predict recurrent or 
persistent depression among people with diabetes. Previous studies have generally reported 
inconsistent results, fi nding a role for general risk factors such as low educati on and history 
of depression and diabetes-specifi c factors including the presence of multi ple complicati ons 
and emoti onal problems due to diabetes 64-66. 
More insights with respect to the course of depression and the health risks associated with 
emoti onal distress may come from the DiaDDZoB (Diabetes, Depression, Type D personality 
Zuidoost-Brabant) Study. Chapter 3 describes the rati onale and design of this prospecti ve 
cohort study among people with type 2 diabetes in primary care. Using data from this 
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study, the aim of Chapter 4 is to gain more insight in the course (incidence, recurrence / 
persistence) of depression in people with type 2 diabetes, and the demographic, medical 
and psychological factors predicting these different course patterns. 
Depression and insulin initiation
As type 1 diabetes is characterized by an absolute deficiency of insulin secretion 10, insulin 
suppletion therapy needs to be introduced immediately after diagnosis in order to effectively 
lower blood glucose levels. In the etiology of type 2 diabetes insulin resistance and abnormal 
insulin secretion may both play a role and therefore, the management of hyperglycemia 
in type 2 diabetes often follows a stepwise strategy 68-70. Unless significant hyperglycemia 
symptoms and / or high plasma glucose concentrations are present at diagnosis, glycemic 
management normally starts with diet and exercise recommendations, in combination 
with or followed by the prescription of an oral agent 68-70. Partly due to progressive loss of 
beta-cell function, glycemic control gradually deteriorates over time 71 and pharmacological 
monotherapy no longer suffices to attain target values for hbA1c 
72. Combination therapy 
with an additional oral or injectable agent may have merit, but ultimately a substantial 
number of people will need the addition of insulin therapy to obtain an hbA1c level below 
7% (53 mmol / mol) 70, 72. 
Several recent cross-sectional studies in insulin-naïve people with type 2 diabetes have 
shown an association between higher levels of depression and a more negative appraisal 
of insulin therapy 73-75. The motivational aspects of depression – including fatigue or loss of 
energy, low self-esteem, and a diminished ability to think, concentrate or make decisions 25 
– may underlie a more general reluctance to start insulin, which in turn could translate into a 
later initiation of insulin therapy 74. On the other hand, the association between depression 
and difficulties with diabetes self-care activities 76 and its ensuing negative impact on 
glycemic control may accelerate introduction of insulin therapy. At present, however, it is 
unclear whether depression actually plays a role in the timing of insulin therapy. Therefore, 
Chapter 5 focuses on the longitudinal association between depression and insulin initiation 
in people with type 2 diabetes, using data from the DiaDDZoB cohort.
The heterogeneity of depression and its implications for people with diabetes
In general psychiatry and cardiology, increased attention has focused on the heterogeneity 
of depression and its implications for health 77. One potentially relevant distinction centers 
around the two core features of depression, dysphoria and anhedonia 25. Dysphoria 
comprises negative emotions such as feelings of sadness and emptiness, while anhedonia 
is often conceptualized as a condition in which positive affect is reduced 78. Anhedonia – or 




in community-dwelling elderly and people with established coronary artery disease 79-84, 
and all-cause mortality in people with diabetes 85. A small study in older women without 
diabetes found a negati ve associati on between positi ve aff ect and hbA1c levels 
86. The relati ve 
importance of anhedonia and dysphoria in the associati on with health among people with 
diabetes is an underresearched area.
Therefore, in Chapter 6 cross-secti onal baseline data from a dynamic cohort study of people 
with type 2 diabetes in primary care are used to explore whether depression symptom 
clusters (dysphoria and anhedonia) are diff erenti ally associated with subopti mal glycemic 
control. Chapter 7 prospecti vely examines whether elevated depressive symptoms are 
associated with hospitalizati on for cardiovascular disease and all-cause mortality in the 
DiaDDZoB cohort, and whether symptoms of dysphoria and anhedonia are diff erenti ally 
associated with these end points. Furthermore, this chapter explores whether there are 
symptom-specifi c behavioral or pathophysiological mechanisms in play. The behavioral or 
physiological pathways through which depression may increase the risk of cardiovascular 
disease and mortality remain unclear. Subopti mal diabetes self-care behaviors may be one 
pathway 76. Depressed people with diabetes are less likely to engage in a range of self-care 
acti viti es, including eati ng a healthy diet, physical acti vity and medicati on taking 76, and 
even low levels of depressive symptoms have been associated with subopti mal self-care 
acti viti es in type 2 diabetes 23. Moreover, depression has been linked to other risk factors for 
macrovascular disease, including smoking and high body mass index 87, 88. The associati on 
between depression and (cardio)vascular risk factors such as cholesterol and blood pressure 
is less clear in people with diabetes 88 and has mostly been limited to HbA1c levels 
56. Whether 
there are symptom-specifi c mechanisms in play is yet to be determined.
Type D “distressed” personality
Depression has been associated with the development of microvascular complicati ons 
and macrovascular disease in people with diabetes 24, 44. however, measures of depression 
usually relate to the previous 1 – 2 weeks, while complicati ons might take several years 
to develop. Litt le is known about the risk imposed by more chronic forms of distress, for 
example those that are related to individual diff erences in personality 89. In recent years, the 
Type D or “distressed” personality has emerged in cardiovascular research as a risk factor 
for adverse health outcomes in people with a cardiovascular conditi on, including non-fatal 
myocardial infarcti on, revascularizati on and (cardiac) mortality 89-91. Individuals with a Type 
D personality tend to experience negati ve emoti ons across ti me and situati ons (Negati ve 
Aff ecti vity; NA), but are inclined to inhibit self-expression in order to avoid disapproval or 
rejecti on by others (Social Inhibiti on; SI) 92. The Type D scale (DS14) is a brief self-report 
measure of Type D personality that has been shown to possess adequate psychometric 
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properties in people with a cardiac condition 92-96, but has not been validated in people with 
diabetes. Therefore, Chapter 8 examines the psychometric properties and clinical correlates 
of the Type D personality construct and its assessment in people with type 2 diabetes from 
the DiaDDZoB cohort.
One potential mechanism through which Type D personality might exert a negative influence 
on health includes suboptimal self-care behavior. The studies conducted so far have involved 
a variety of populations (healthy young adults, community samples, and people at high risk 
of cardiovascular conditions or those with established cardiac disease), and indicate that 
individuals with a Type D personality are less like to engage in physical activity and healthy 
eating, less likely to follow recommended medication regimens, and are less likely to seek 
consultations with health professionals when needed 97-102. Type D personality has also been 
associated with anxiety, depression and other indicators of suboptimal mental health in 
people with cardiovascular and non-cardiovascular conditions and individuals from the 
general population 89, 103, 104. Type D personality may indirectly increase cardiovascular risk 
through its association with these negative emotional states. To date, no studies have 
examined the clinical correlates of Type D personality in people with diabetes. Chapter 9 
aims to establish whether Type D personality and its two constituent components – NA 
and SI – are differentially associated with three potential cardiovascular risk mechanisms in 
people with type 1 or type 2 diabetes participating in Diabetes MILES – The Netherlands, 
a national online cross-sectional observational study among people with diabetes in The 
Netherlands.
Chapter 10 concludes with a summary and a general discussion of methodological and 
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Objective: Meta-analyses have shown that the risk for depression is elevated in type 2 
diabetes. Whether this risk in individuals with impaired glucose metabolism (IGM) or 
undiagnosed diabetes (UDD) is elevated relative to normal glucose metabolism (NGM) or 
decreased relative to previously diagnosed type 2 diabetes (PDD) has not been the subject 
of a systematic review / meta-analysis. This study examined the prevalence of depression 
in IGM and UDD subjects relative to each other and to NGM and PDD subjects by reviewing 
the literature and conducting a meta-analysis of studies on this topic. 
Research design and methods: EMBASE and MEDLINE databases were searched for articles 
published up to May 2010. All studies that compared the prevalence of depression in 
subjects with IGM and UDD were included. Odds ratios (ORs) were calculated using fixed 
and random-effects models.
Results: The meta-analysis showed that the risk for depression was not increased in IGM 
versus NGM subjects (OR 0.96, 95% CI 0.85 – 1.08). Risk for depression did not differ between 
individuals with UDD and individuals with either NGM (OR 0.94, 95% CI 0.71 – 1.25) or IGM 
(OR 1.16, 95% CI 0.88 – 1.54). Finally, individuals with IGM or UDD both had a significantly 
lower risk of depression than individuals with PDD (OR 0.59, 95% CI 0.48 – 0.73 and OR 0.57, 
95% CI 0.45 – 0.74, respectively).
Conclusions: Results of this meta-analysis show that the risk of depression is similar for 
NGM, IGM and UDD subjects. PDD subjects have an increased risk of depression relative to 
IGM and UDD subjects.
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iNTrODuCTiON
Several meta-analyses have shown that the risk of elevated levels of depression and the risk 
of incident depression are increased in people diagnosed with type 2 diabetes compared 
with nondiabeti c control subjects 1, 2. Comorbid depression in people with diabetes forms a 
serious threat to quality of life 3. Moreover, people with both depression and diabetes have 
been found to be at increased risk for the development of cardiovascular complicati ons of 
diabetes and to have increased mortality rates and higher health care costs 4-6. 
The reasons for the high prevalence of depression in type 2 diabetes remain unclear, 
although it is likely that the burden resulti ng from having a chronic disease and / or its 
associated complicati ons plays an important role 7, 8. It is also possible that increased levels 
of blood glucose are implicated, although the exact nature of the relati onship between 
hyperglycemia and depression remains unclear 9. 
hyperglycemia (and insulin resistance) may contribute to depression by two mechanisms: 1) 
through its impact on symptoms, such as fati gue and diffi  culty concentrati ng 10, complicati ons, 
and fear of complicati ons 11, and 2) through physiological pathways, including infl ammatory 
processes, and reducti ons in neurotrophic functi on 12-14, which in turn may lead to reduced 
plasti city of neuronal networks and subsequently depression 15.
It is worth noti ng that depression is a common disorder in the general populati on and 
is not only increased in people with diabetes 1, 2, but also in people with other physical 
health problems, such as chronic pain, asthma, and heart disease 16. This would suggest 
that elevated blood glucose levels are not a necessary conditi on for developing depression.
One way to study whether elevated blood glucose levels aff ect mood is to investi gate the 
prevalence of depression in people with impaired glucose metabolism (IGM) or undetected 
type 2 diabetes (UDD) and compare these to prevalence rates of depression in people with 
normal glucose metabolism (NGM) and people with previously diagnosed type 2 diabetes 
(PDD).  Although people with IGM and people with UDD have, by defi niti on, elevated blood 
glucose levels compared with individuals with NGM, the level of glucose impairment varies, 
ranging from NGM to IGM to full blown type 2 diabetes. Moreover, people with IGM or UDD 
diff er from people with PDD, because they do not have the psychological burden of being 
diagnosed with the conditi on or having to self-manage it.  
As the prevalence of depression in people with UDD or IGM has not been evaluated in a 
systemati c review and meta-analysis, this report examines the relati onship between these 
categories of glycemic dysregulati on and risk of depression. We examined the combined 
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prevalence of depression in samples of people with NGM, IGM, UDD, or PDD by conducting 
a meta-analysis of studies published on this subject in the peer-reviewed literature.
ReseARCh DesiGN AND MethODs 
Retrieval of studies 
To identify the studies of interest, MEDLINE (1950 to May 2010) and EMBASE (1947 to May 
2010) databases were searched. The search terms are shown in Supplementary Table 1. 
Titles and abstracts of the retrieved studies were scanned by two authors (A.N. reviewed 
all abstracts, and the second reviews were divided among coauthors) to exclude studies 
that were clearly irrelevant. The full text of the remaining studies was then read by three 
authors (A.N., G.N., and F.P.) to determine whether the studies met our inclusion criteria. 
Furthermore, the reference lists of articles that studied our topic of interest were scanned 
to check for additional publications. 
inclusion / exclusion criteria 
In this systematic review and meta-analysis, we included all studies that examined the 
prevalence of depression either in UDD or IGM subjects, also defined as impaired glucose 
tolerance, impaired fasting glucose, and impaired glucose resistance, comparing these rates 
to those in NGM and / or PDD subjects.
Data extraction 
Three authors (A.N., G.N., and F.P.) independently extracted data from the studies, in 
particular regarding 1) name of first author, 2) publication year, 3) study design, 4) number 
of participants by category of glycemic (dys)regulation, 5) sex of participants, 6) age of 
participants, 7) method and criteria for depression assessment, 8) methods of diabetes 
and / or pre-diabetic state assessment, 9) number and percentage of case subjects with 
depression, 10) fasting plasma glucose, and 11) unadjusted and adjusted odds ratios (ORs) 
and 95% CIs.  This allowed comparison of IGM with NGM and PDD and comparison of UDD 
with NGM, IGM, and PDD.   
In the included studies, method of depression assessment could be either 1) a diagnosis 
of depression assessed by a diagnostic psychiatric interview, 2) assessment of depressive 
symptoms by a self-report questionnaire, 3) a diagnosis by a physician, or 4) in combination 
with a prescription of antidepressant medication. 
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stati sti cal analysis 
The odds of depression in each category (UDD or IGM) were compared with the odds of 
depression in NGM or PDD to calculate the unadjusted OR.  From these, pooled ORs were 
esti mated. Both the fi xed-eff ects model and the random-eff ects model were used. The 
fi xed-eff ects model assumes that variability between studies is exclusively due to random 
variati on, and individual studies are simply weighted by their precision. The random-eff ects 
model assumes that a diff erent true eff ect size exists for at least one study and takes this 
into considerati on as an additi onal source of variati on. A random-eff ects meta-analysis is 
more conservati ve than a fi xed-eff ects meta-analysis, since it may give wider CIs around the 
point esti mate and is recommended when it is suspected that individual studies may not be 
esti mati ng the same true eff ect size 17. A forest plot was made to show the OR and 95% CI of 
each study and the pooled OR and 95% CI. 
We followed recommendati ons in the Cochrane handbook 17 for investi gati ng reporti ng 
bias; these recommendati ons advise that harbord’s stati sti cal test for small study bias is 
appropriate when the outcome stati sti c is an OR and the number of studies is at least 10 to 
avoid false-positi ve results in the presence of study heterogeneity. Forest plots were used 
to visually assess homogeneity of the studies. This was also tested with the Cochran’s Q test 
and the I-squared stati sti c.  All stati sti cal analyses were performed using STATA 10.0 (STATA 
Corporati on, College Stati on, TX). 
rESuLTS
The MEDLINE search (1950 to May 2010) identi fi ed 3,357 arti cles, of which 12 met our 
inclusion criteria and were subsequently included in the systemati c review and meta-
analysis. The search in EMBASE (1947 to May 2010, total number of studies 4,337, excluding 
duplicates) identi fi ed one additi onal study meeti ng the selecti on criteria. Thus, a total of 
13 studies were included in the meta-analysis. The characteristi cs and the extracted data 
of the 13 included studies are presented in Table 1 and, for the (un)adjusted odds rati os, in 
Supplementary Table 2. 
In total, the included studies identi fi ed 1,483 case subjects with UDD, 6,236 case subjects 
with IGM, and 2,121 case subjects with PDD. however, because the number of studies 
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Depression in individuals with impaired glucose metabolism
Eleven studies 18-28 compared the prevalence of depression in individuals with IGM relati ve to 
individuals with NGM.  The forest plot (Figure 1) clearly shows that, compared with people 
with normal glucose regulati on, the prevalence of depression is not increased in pati ents 
with IGM (fi xed-eff ects OR 0.94, 95% CI 0.86 – 1.02; random-eff ects OR 0.96, 0.85 – 1.08). 
harbord’s test for reporti ng bias was negati ve (p = 0.2). Nine studies reported data on the 
prevalence of depression in individuals with IGM compared with individuals with PDD 18-23, 25, 
27, 28. Compared with individuals with PDD, people with IGM had an almost 40% lower risk of 
depression (fi xed-eff ects OR 0.61, 95% CI 0.52 – 0.71; random-eff ects OR 0.59, 0.48 – 0.73). 
In both analyses, the I-squared value was low, suggesti ng that the results of the fi xed-eff ects 
model may be appropriate for these comparisons.  Because of ambiguiti es in two studies, 
we conducted sensiti vity analyses to determine whether our analyti c decisions aff ected the 
results.  In one study 20, there appeared to be a discrepancy between the reported number 
of people with depressive symptoms (n = 10) and the percentage of parti cipants with 
depressive symptoms (2.2%). Therefore, we compared the results with the raw numbers 
and the recalculated data based on the reported percentages. Another study 21 reported 
the total number of parti cipants and ORs based on imputed data; therefore, we compared 
the results with the total number of parti cipants and with ORs based on imputed data. 
Results of these sensiti vity analyses showed that in both cases, using alternati ve data did 
not change the overall results.
Depression in undiagnosed type 2 diabetes  
Three comparisons were carried out for the prevalence of depression in UDD: 10 studies 18, 19, 
21, 22, 24-27, 29, 30 comparing with NGM, eight studies 18, 19, 21, 22, 24-27 comparing with IGM, and eight 
studies 18, 19, 21, 22, 25, 27, 29, 30 comparing with PDD. The I-squared stati sti c was moderately large 
for the comparison of UDD versus NGM (I-squared = 49.0%; p = 0.039 for the Cochran’s Q 
test for heterogeneity), suggesti ng that the random-eff ects model was the most appropriate 
for this comparison. however, a single study 30 accounted for all heterogeneity beyond that 
due to chance, and when this study was omitt ed from the analysis, the I-squared stati sti c 
diminished to 0% and the fi xed- and random-eff ects pooled esti mates became 0.98 (95% CI 
0.81 – 1.19). harbord’s test for reporti ng bias just reached stati sti cal signifi cance (p = 0.03). 
For consistency, only the random-eff ects models for each comparison were considered. 
The forest plots of the ORs and 95% CI of each study and the pooled OR for comparisons of 
UDD versus NGM are shown in Figure 2: the pooled OR of 0.94 (95% CI 0.71 – 1.25) indicated 
that the risk for being depressed was not signifi cantly diff erent. Furthermore, the odds of 
depression did not diff er signifi cantly between UDD versus IGM (OR 1.16, 95% CI 0.88 – 
1.54).  Finally, the risk of depression was signifi cantly lower in individuals with UDD versus 























IGM v NGM  
 Rajala et al., 1997 
Hiltunen et al., 1996 
Yaffe et al., 2004 
Golden et al., 2007 
Knol et al., 2007 
Adriaanse et al., 2008 
Rhee et al., 2008 
Aujla et al., 2009 
Gale et al., 2010 
Holt et al., 2009 
Bouwman et al., 2010  
I-V Subtotal  (I-squared = 24.7%, p = 0.208) 
D+L Subtotal 
IGM v PDD  
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Adriaanse et al., 2008 
Gale et al., 2010 
Holt et al., 2009 
Bouwman et al., 2010 




1.08 (0.65, 1.80) 
0.85 (0.44, 1.62) 
1.55 (0.81, 2.98) 
0.85 (0.74, 0.99) 
0.88 (0.71, 1.09) 
2.06 (1.10, 3.86) 
1.01 (0.61, 1.68) 
1.04 (0.86, 1.26) 
0.79 (0.52, 1.21) 
0.66 (0.29, 1.51) 
0.97 (0.71, 1.34) 
0.94 (0.86, 1.02) 
0.96 (0.85, 1.08) 
0.43 (0.18, 1.02) 
1.10 (0.46, 2.58) 
0.81 (0.34, 1.94) 
0.65 (0.53, 0.81) 
0.50 (0.31, 0.79) 
0.81 (0.43, 1.52) 
0.25 (0.11, 0.60) 
0.36 (0.11, 1.21) 
0.52 (0.33, 0.83) 
0.61 (0.52, 0.71) 
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less dep IGM  more dep IGM 
Figure 1 Forest plots showing the OR and 95% CI of depression in IGM compared with NGM and PDD. 
I-V, fixed-effects estimate (inverse variance method); D+L, random-effects estimate (Der Simonian and 
Laird method)
sensitivity analyses  
We conducted sensitivity analyses to determine whether using OR controlled for demographic 
factors affected the results.  In all the studies that provided adjusted OR, NGM was always 
the reference; thus, we were not able to conduct sensitivity analyses for comparisons of 
IGM or UDD with PDD or IGM with UDD.  Results did not change in the sensitivity analyses. 
A pooled OR of 0.93 (95% CI 0.85 – 1.04) was obtained for the comparison of IGM versus 
NGM 21-23, 26-28 and an OR of 1.04 (95% CI 0.85 – 1.28) for the comparison of UDD versus NGM 
21, 22, 26, 27, 30.
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UDD v NGM 
 Palinkas et al., 1991 
Rajala et al., 1997 
Hiltunen et al., 1996 
Golden et al., 2007 
Knol et al., 2007  
Icks et al., 2008  
Rhee et al., 2008 
Aujla et al., 2009 
Gale et al., 2010 
Holt et al., 2009 
I-V Subtotal  (I-squared = 49.0%, p = 0.039) 
D+L Subtotal 
UDD v IGM 
Rajala et al., 1997 
Hiltunen et al., 1996 
Golden et al., 2007 
Knol et al., 2007 
Rhee et al., 2008 
Aujla et al., 2009 
Gale et al., 2010 
Holt et al., 2009 
I-V Subtotal  (I-squared = 27.1%, p = 0.212) 
D+L Subtotal 
UDD v PDD 
Palinkas et al., 1991 
Rajala et al., 1997 
Hiltunen et al., 1996 
Golden et al., 2007 
Knol et al., 2007 
Icks et al., 2008 
Gale et al., 2010 
Holt et al., 2009 
I-V Subtotal  (I-squared = 0.0%, p = 0.500) 
D+L Subtotal 
Study Comparison  
0.84 (0.40, 1.79) 
0.99 (0.29, 3.40) 
1.05 (0.39, 2.80) 
0.83 (0.60, 1.15) 
1.06 (0.55, 2.07) 
0.40 (0.23, 0.67) 
1.69 (0.69, 4.17) 
0.81 (0.53, 1.22) 
1.42 (0.84, 2.41) 
2.01 (0.80, 5.09) 
0.88 (0.74, 1.06) 
0.94 (0.71, 1.25) 
0.91 (0.25, 3.27) 
1.24 (0.45, 3.41) 
0.97 (0.69, 1.36) 
1.21 (0.61, 2.41) 
1.67 (0.65, 4.28) 
0.77 (0.49, 1.21) 
1.80 (0.94, 3.46) 
3.05 (1.05, 8.87) 
1.09 (0.88, 1.35) 
1.16 (0.88, 1.54) 
0.33 (0.13, 0.87) 
0.39 (0.09, 1.62) 
1.36 (0.44, 4.21) 
0.63 (0.44, 0.91) 
0.60 (0.27, 1.32) 
0.42 (0.23, 0.77) 
0.46 (0.18, 1.15) 
1.10 (0.31, 3.95) 
0.57 (0.45, 0.74) 
0.57 (0.45, 0.74) 




























































































less dep UDD   more dep UDD 
1 .1 .5 2 10 
Figure 2 Forest plots showing the OR and 95% CI of depression in UDD compared with NGM, IGM, 
and PDD. I-V, fi xed-eff ects esti mate (inverse variance method); D+L, random-eff ects esti mate (Der 
Simonian and Laird method)
CONCLuSiONS
The results of the present meta-analysis clearly show that people who have impaired 
glucose metabolism or undiagnosed type 2 diabetes are not at increased risk for 
depression compared with people in the general populati on or people with normal glucose 
metabolism.  When compared with people with known type 2 diabetes, individuals with 
impaired glucose metabolism or unknown diabetes have signifi cantly lower risk of having 
depressive symptoms.  This result could be regarded as support for the “psychological 
burden hypothesis” 31, which states that the burden of knowing that you have diabetes 
and having a chronic illness to manage, or complicati ons to cope with contributes to higher 
levels of depression.  By defi niti on, people with IGM and undiagnosed diabetes have both 
higher levels of blood glucose than people with normal glucose metabolism or people in the 
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general population.  Results of the present meta-analysis indicate that higher blood glucose 
levels per se in the prediabetic or early diabetes stages are not associated with an increased 
level of depressive symptoms.  
One explanation for the lower risk of depression in UDD compared with PDD might relate to 
differences in the number of complications between people with UDD and people with PDD. 
Although diabetes complications can occur in people with undiagnosed diabetes, these are 
more likely to be found in people with longstanding diabetes 32, 33. The results of the current 
meta-analysis would then concur with a large cross-sectional population-based study that 
showed that, compared with healthy control subjects, diabetes alone did not increase the 
chances of depressive symptoms but having diabetes and diabetes complications did 34. 
however, a recent study showed that the risk of depressive disorder is increased in the 
2 years after diagnosis of type 2 diabetes in the absence of diabetes complications 35. In 
another study, it was found that diabetes distress did not become associated with depressive 
symptoms until after 1 year of living with diabetes 36.  In yet another study, people who were 
prescribed a more intensive treatment developed more depressive symptoms in the first 3 
years after detection of type 2 diabetes than individuals on less intensive treatment 37. These 
studies suggest that factors other than diabetes complications (e.g., fear of complications, 
burden of treatment) may increase the risk of depressive symptoms. however, because 
none of the studies included in the meta-analysis assessed diabetes complications, it 
was not possible to refute or support this argument. Future studies into depression and 
undiagnosed diabetes should assess diabetes complications in these groups. 
There are several limitations to this study. First, the number of people with undiagnosed 
diabetes in the included investigations was quite small despite the fact that many were 
large-scale population-based studies.  Second, the meta-analysis draws on observational 
cohort studies, and it is appropriate to analyze adjusted rather than unadjusted effect 
estimates.  however, because only half of the studies provided adjusted effect estimates 
and controlled for important demographic confounders, we used the unadjusted ORs in 
our analyses.  however, when calculating pooled ORs based on the studies that did provide 
ORs controlled for demographics, the outcome did not change. Given these results and 
the low heterogeneity, we are confident that the results in the current study are reliable. 
Third, although in all studies oral glucose tolerance tests were used to establish participants’ 
glucose metabolism classification, it is possible that unmeasured differences in blood 
glucose level between the previously diagnosed and undiagnosed diabetes groups may 
explain their differences in depression. Because these data were not routinely available in 
the published reports, we contacted authors of the more recent articles to obtain these 
data and used them to calculate weighted pooled mean blood glucose levels for each group. 
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Whereas blood glucose levels did not diff er between NGM (mean 5.1, 95% CI 3.9 – 6.3) and 
IGM (5.8, 4.6 – 7.0) and between UDD (8.8, 7.6 – 10.0) and PDD (8.3, 7.1 – 9.5), diff erences 
between the diabetes groups (UDD and PDD) and individuals without diabetes (NGM and 
IGM) were signifi cant.  These results suggest that despite diff erences in depression between 
those with versus those without diabetes, blood glucose levels did not diff er within these 
broader categories.  Fourth, the possibility of reporti ng bias cannot be ruled out. There was 
weak evidence of reporti ng bias for the comparison of undiagnosed diabetes versus normal 
glucose metabolism, but the number of studies here, as for other comparisons, was too low 
for strong inference.  
The relati vely low level of heterogeneity observed in most comparisons (I-squared ranging 
from 0 to 27%) was not amenable to producti ve explorati on using meta-regression; this 
was because it is recommended that at least 10 studies per study level variable explored 
are required if spurious associati ons are to be avoided, and a complete set of data for this 
number of studies was unfortunately not available for study level variables of interest (e.g., 
age, sex, fasti ng plasma glucose).  
Fift h, the studies in this meta-analysis used cross-secti onal data and therefore do not 
provide evidence regarding the ti me frame in which depression develops aft er the diagnosis 
of type 2 diabetes. A recent study reported that anti depressant medicati on use showed a 
temporary peak during the year of diagnosis of type 2 diabetes, suggesti ng that the risk 
of depressive symptoms is increased soon aft er diagnosis and recedes thereaft er in the 
absence of another incident risk factor 38.    
Finally, only one of the included studies 27 used diagnosti c criteria to determine depression 
status. In this study, the prevalence of depression was parti cularly increased in people with 
previously diagnosed diabetes (compared with NGM) and in people with undiagnosed 
diabetes, although for the latt er, this failed to reach signifi cance.  IGM was not signifi cantly 
associated with the increased prevalence of major depressive disorder. These fi ndings 
suggest that diabetes, but not IGM, is associated with increased prevalence of major 
depressive disorder. however, the numbers in this study were small, and further research 
is needed. 
Overall, the results of this meta-analysis show that the risk of depression is not directly 
related to elevated blood glucose levels.  One conclusion, in line with the results of the 
current meta-analysis, is that the burden of diabetes and its complicati ons are the main 
determinants of depressive symptoms in individuals with diabetes 16. Future research should 
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supplementary table 1 Search terms
1. exp Depression/ or depression.mp. 
2. depressive disorder$.mp. or exp Depressive Disorder/ 
3. mood disorder$.mp. or exp Mood Disorders/ 
4. dysthmic disorder$.mp. 
5. (depress$ adj3 (disorder$ or symptom$)).mp. [mp=title, original title, abstract, name of substance word,  
 subject heading word, unique identifier] 
6. or/1-4 
7. (impaired glucose adj3 (tolera$ or metaboli$)).mp. [mp=title, original title, abstract, name of substance   
 word, subject heading word, unique identifier] 
8. diabetes mellitus.mp. or exp Diabetes Mellitus/ 
9. glucose intolerance.mp. or exp Glucose Intolerance/ 
10. or/7-9 
11. 6 and 10
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Psychological risk factors of micro- and macrovascular 
outcomes in primary care pati ents with type 2 diabetes: 
rati onale and design of the DiaDDZoB study
Nefs G, Pouwer F, Denollet J, Pop V




Background: Depression is a common psychiatric complication of diabetes, but little is 
known about the natural course and the consequences of depressive symptoms in primary 
care patients with type 2 diabetes. While depression has been related to poor glycemic 
control and increased risk for macrovascular disease, its association with microvascular 
complications remains understudied. The predictive role of other psychological risk factors 
such as Type D (distressed) personality and the mechanisms that possibly link depression 
and Type D personality with poor vascular outcomes are also still unclear.
Methods / Design: This prospective cohort study will examine: (1) the course of depressive 
symptoms in primary care patients with type 2 diabetes; (2) whether depressive symptoms 
and Type D personality are associated with the development of microvascular and/or 
macrovascular complications and with the risk of all-cause or vascular mortality; and (3) 
the behavioral and physiological mechanisms that may mediate these associations. The 
DiaDDZoB Study is embedded within the larger DIAZOB Primary Care Diabetes study, which 
covers a comprehensive cohort of type 2 diabetes patients treated by over 200 primary care 
physicians in South-East Brabant, The Netherlands. These patients will be followed during 
their lifetime and are assessed annually for demographic, clinical, lifestyle and psychosocial 
factors. Measurements include an interviewer-administered and self-report questionnaire, 
regular care laboratory tests and physical examinations, and pharmacy medication records. 
The DiaDDZoB Study uses data that have been collected during the original baseline 
assessment in 2005 (M0; N = 2,460) and the 2007 (M1; N = 2,225) and 2008 (M2; N = 2,032) 
follow-up assessments.
Discussion: The DiaDDZoB Study is expected to contribute to the current understanding 
of the course of depression in primary care patients with type 2 diabetes and will also 
test whether depressed patients or those with Type D personality are at increased risk for 
(further) development of micro- and cardiovascular disease. More knowledge about the 
mechanisms behind this association is needed to guide new intervention studies.
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BACKGrOuND
The number of people with diabetes mellitus is increasing rapidly worldwide. Based on 
aging and other demographic changes, prevalence esti mates of this chronic metabolic 
disease are projected to rise from 171 million in 2000 to 366 million in 2030 1. As the disease 
progresses, diabetes pati ents are oft en confronted with long-term vascular complicati ons. 
While premature cardiovascular disease (including coronary artery disease, stroke and 
peripheral arterial disease) accounts for considerable morbidity and mortality, complicati ons 
of microvascular origin also contribute signifi cantly to adverse health outcomes 2. To date, 
diabetes remains a predominant cause of vision loss, renal failure and lower extremity 
amputati ons in developed countries 3. A large-scaled study among over 7,000 pati ents 
with type 2 diabetes in eight European countries concluded that approximately 72% of the 
parti cipants had at least one complicati on, while 24% of the total study group had both 
micro- and macrovascular complicati ons 4. Not surprisingly, the presence of these vascular 
conditi ons has a substanti al negati ve impact on both overall healthcare expenditures 4 and 
pati ents’ quality of life 5.
Depression is common in type 2 diabetes
Depression is another common and burdensome complicati on of type 2 diabetes. A recent 
meta-analysis of ten controlled studies showed that the prevalence of depression was 
signifi cantly higher in pati ents with type 2 diabetes compared with non-diabeti c controls (18 
vs. 10%, OR = 1.6, 95% CI 1.2 – 2.0) 6. Even though depression is a common co-morbidity in 
diabetes, litt le longitudinal research has been undertaken with respect to its natural course in 
type 2 diabetes 7. A meta-analysis of seven prospecti ve studies by Mezuk et al., all excluding 
prevalent cases of depression at baseline, concluded that the associati on between type 2 
diabetes and the incidence of depression is only modest (RR = 1.15, 95% CI 1.02 – 1.30) 8. 
however, a negati ve depression screening score at study entry cannot rule out a history of 
depression and therefore the conclusion by Mezuk et al., about the role of diabetes as a risk 
factor for “new” cases of depression, might be premature 9. Two meta-analyses showed that 
the reversed associati on, with depression as a risk factor for the onset of type 2 diabetes, is 
stronger. Depressed adults have a 30-60% increased risk of developing type 2 diabetes 8, 10. 
There is abundant evidence showing that depression can be regarded as a chronic conditi on 
for many pati ents, with periods of (parti al) remission and relapse in community 11 and 
primary care 12 samples. Although the existi ng literature suggests that depression is even 
more persistent in diabetes pati ents, these studies are hampered by relati vely small numbers 
of type 2 diabetes pati ents 7, 13, the inclusion of selected populati ons from specialised 
clinics 14 and the measurement of depression in a selected sample of pati ents who have 
parti cipated in an anti depressant drug trial 13 or diabetes educati on programme 7, 15. A large 
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study examining different aspects of the natural course (incidence, remission, recurrence) 
of depression in a representative sample of primary care patients with type 2 diabetes is 
currently lacking. 
Depression is associated with poor disease outcomes 
Depression in diabetes was found to be associated with poor glycemic control 16, a higher 
number of cardiovascular risk factors 17, micro- and macrovascular complications 18, and an 
increased mortality risk 19-22. Meta-analyses of prospective studies suggest that depression 
is associated with the onset or progression of cardiovascular disease in primary care and 
community samples 23 and post-myocardial infarction patients 24. An important limitation of 
the current diabetes literature is that most studies on the association between depression 
and vascular conditions used cross-sectional data 18, hence precluding any inferences about 
possible causal pathways. In recent years, a limited number of prospective studies have 
been published. While depression predicted the incidence of vascular complications 19, 25 
and greater all-cause mortality 19-22, its effect on mortality due to vascular causes still is 
unclear 20, 26. So far, the emphasis in these studies has been on macrovascular outcomes, in 
particular coronary heart disease. Only two large longitudinal studies have considered the 
association between depression and the incidence of microvascular conditions. One of these 
was conducted in a sample of elderly Mexican-Americans and used self-report to ascertain 
the presence of complications 19, while the other only examined advanced complications, 
including end-stage renal disease, low vision or blindness, and amputations 27.
type D personality and cardiovascular disease
Most research on the psychological aspects of diabetes has focused on depression, leaving 
the role of other dimensions of emotional distress, such as anxiety and more stable emotional 
traits, as understudied areas. An emerging risk factor in the cardiovascular research domain 
is “Type D (distressed) personality”, which is defined by the two stable personality traits 
“negative affectivity” and “social inhibition” 28. Individuals with this personality type tend 
to experience negative emotions across time and situations, but are inclined to inhibit the 
expression of emotions and behaviors in order to avoid disapproval or rejection 28, 29. Type 
D personality is relatively common, with prevalence estimates ranging from 21% in the 
general population to 28% in coronary heart disease patients and 53% in hypertensives 28. 
Accumulating evidence suggests that having a Type D personality is associated with a 2 to 
5-fold increased risk of adverse prognosis, impaired quality of life and emotional distress 
across cardiovascular patient groups, independent of standard biomedical risk factors 29, 30. 
No studies to date have been undertaken to examine the impact of Type D personality on 
disease-related outcomes in patients with type 2 diabetes, although vascular disease is 
relatively common in this group.
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Mechanisms that could link depression and type D with poor outcomes
Several plausible mechanisms have been hypothesized to mediate the associati on between 
emoti onal distress (depression, Type D) and poor vascular outcomes. Potenti al mediators 
include health behaviors, such as smoking, alcohol consumpti on and physical inacti vity, and 
biomedical factors (e.g. underlying cardiac disease severity, an unfavorable cardiovascular 
risk profi le / the “metabolic syndrome”, immune processes) 31-33. In the Heart and Soul Study, 
a cohort of more than 1,000 outpati ents with stable coronary heart disease, the associati on 
between depressive symptoms and adverse cardiovascular events was largely explained by 
behavioral factors, in parti cular physical inacti vity (32% change in eff ect size) 33. The extent 
to which these mechanisms account for the increased risk of vascular complicati ons in 
distressed diabetes pati ents, should this associati on exist, is sti ll unclear.
innovati ve aspects of the DiaDDZoB study
To summarize: (1) While there are numerous studies that aimed to determine the 
prevalence of depression in type 2 diabetes pati ents, litt le is known about the natural course 
of depression in diabetes (incidence, recurrence, remission). (2) The majority of studies 
examining the associati on between emoti onal distress and vascular disease had a cross-
secti onal design, focused on depression and had macrovascular disease as outcome. The 
role of other aspects of emoti onal distress and the associati on with common microvascular 
complicati ons is therefore sti ll unclear. (3) It is unknown which behavioral and / or biomedical 
mechanisms may account for the hypothesized associati ons between emoti onal distress 
and vascular conditi ons. The DiaDDZoB Study (Diabetes, Depression, Type D Personality 
Zuidoost-Brabant) will examine the abovementi oned issues in a cohort of primary care 
pati ents with type 2 diabetes.
MethODs / DesiGN
Aims and hypotheses
The DiaDDZoB Study was designed as a prospecti ve cohort study and aims to address the 
following main research questi ons:
1. What is the natural course (prevalence, incidence, recurrence, remission) of depressive 
symptoms in a sample of primary care pati ents with type 2 diabetes?
2. Do pati ents with type 2 diabetes and co-morbid emoti onal distress (as evidenced by an 
increased level of depressive symptoms and / or Type D personality) have an increased 
risk for the onset / progression of micro- and macrovascular complicati ons?
3. Do these types of emoti onal distress also increase the risk of all-cause or vascular mortality?
4. When a signifi cant relati on is found in (2) or (3): which factors mediate the associati on 
between emoti onal distress and diabetes outcomes?
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Based on the current literature, we hypothesize the following: Approximately one fifth 
of our sample will have an increased level of depressive symptoms at each separate 
measurement occasion (prevalence). In the group of patients without a self-reported 
history of depression, incident depression will be low (< 5%). In the patients with a history 
of depression, recurrence rates will be relatively high (at least 25%). Significant risk factors 
for depression most likely will be: (1) psychosocial factors such as stressful life events and 
loneliness and (2) the presence (onset or progression) of vascular complications. We also 
hypothesize that patients with co-morbid distress (either depressive symptoms or Type D) 
will be at increased risk for the development of micro- and macrovascular conditions and 
both all-cause and vascular mortality; these associations are (partly) explained by behavioral 
(smoking behavior, alcohol consumption, physical inactivity) and biomedical (cardiovascular 
disease history, characteristics of the metabolic syndrome) mechanisms.
study design
From 2005 onwards, data for the DiaDDZoB Study have been collected within the framework 
of the DIAZOB (Diabetes care Zuidoost-Brabant) project, a large-scale diabetes management 
programme for primary care patients with type 2 diabetes. To evaluate the implementation 
of this standard diabetes care programme in daily practice, an observational cohort study 
(the DIAZOB Primary Care Diabetes study) was designed, including annual assessments of 
a broad range of demographic, medical, lifestyle and psychosocial factors 34, 35. Follow-up 
surveys of the total DIAZOB population (N ≈ 12,000) are planned for the upcoming years. 
The DiaDDZoB Study builds upon data from three completed measurement occasions. 
The original baseline measurement (M0) took place in the second half of 2005. Follow-up 
assessments were realized in 2007 (M1) and 2008 (M2). 
subjects
The ongoing assessment of the DIAZOB-cohort is conducted in collaboration with over 200 
general practitioners who are currently allied to PoZoB (Praktijkondersteuning Zuidoost 
Brabant), a large managed care organisation responsible for the implementation of the 
DIAZOB standard care programme. The practices are located in the South-Eastern area of 
The Netherlands, mainly in the region south of the city of Eindhoven. The patient population 
is residing in rural and suburban areas. To be included in the DIAZOB Primary Care Diabetes 
study, the patient had to be formally diagnosed with type 2 diabetes according to the 
guidelines of the Dutch College of General Practitioners (as evidenced by either a fasting 
glucose concentration of > 6.9 mmol / l in venous plasma or > 6.0 mmol / l in capillary blood 
on two separate days or an arbitrary glucose level > 11.0 mmol / l in the presence of the 
classic hyperglycemia symptoms 36. These criteria are comparable to the recommendations 
of the American Diabetes Association 37. Other inclusion criteria were: the patient was 
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receiving treatment for diabetes in the DIAZOB diabetes care programme, had the primary 
care practi ce nurse as his / her main health care provider for diabetes issues, was at least 
18 years old (with no upper age limit) and had suffi  cient mastery of the Dutch language. 
Pati ents were excluded if they had a treatment or conditi on other than type 2 diabetes as 
the primary cause of the hyperglycemia and / or were physically / mentally incapable of 
completi ng a questi onnaire (e.g. co-morbid dementi a, terminal cancer), as judged by the 
primary care practi ce nurse.
Recruitment of pati ents
From 2005 onward, pati ents were invited by their primary care practi ce nurse to parti cipate 
in the DIAZOB standard care project. In the period of April (pilot) and June - December 
2005, the DIAZOB pati ents were informed of the evaluati on study and received a detailed 
descripti on of its practi cal and scienti fi c aim. Pati ents who were willing to parti cipate were 
asked to sign an informed consent form. Consent was sought for (a) using the anonymised 
data (questi onnaire and medical informati on) for reports and scienti fi c publicati ons; 
requesti ng informati on from the pati ent’s (b) pharmacist and (c) specialist; and (d) informing 
the general practi ti oner or primary care practi ce nurse of study results, if necessary. 
Parti cipant drop-out
In the beginning of 2005, the total number of type 2 diabetes pati ents in the area covered by 
the parti cipati ng general practi ti oners at that ti me was esti mated at 3,000 to 3,500. During 
the baseline inclusion period, 3,017 pati ents were considered for parti cipati on in the study. 
A detailed overview of the study’s parti cipati on and drop-out rate can be found in Figure 1. 
Reasons for baseline non-response could be grouped into “pati ent characteristi cs” (e.g. not 
meeti ng inclusion criteria / screening positi ve on exclusion criteria, refusing to parti cipate, 
not showing up at the baseline interview) and “practi ce nurse characteristi cs” (lack of 
ti me, omitti  ng to invite newly diagnosed or insulin-using pati ents). Of the resulti ng 2,460 
pati ents, 2,448 (99.5%) att ended the interview and 1,850 (75.2%) returned the self-report 
questi onnaire that had to be fi lled in at home. For the M1 and M2 assessments, 2,225 and 
2,032 pati ents were available, respecti vely.
Measures used in the DiaDDZoB study
The DIAZOB Primary Care Diabetes study measurements include an interviewer-
administered and self-report questi onnaire, results from regular care laboratory tests and 
physical examinati ons, and pharmacy medicati on records. An overview of the variables that 































































3,017 type 2 diabetes patients 




- Refused to participate (n = 51) 
- Language difficulties (n = 10) 
- Advanced age (n = 12) 
- Poor physical / mental condition (n = 81) 
- No show for baseline interview (n = 39) 
- Other reasons (n = 89) 
Primary care practice nurse: 
- Lack of time (n = 138) 
- Omitting to include a newly diagnosed patient (n = 95) 
- Omitting to include an insulin-using patient (n = 42) 
 
 M0: 2,460 patients included 
2,448 patients underwent M0 interview 
1,850 patients returned M0 self-report questionnaire 
Loss to follow-up M1: 
- Deceased (n = 66) 
- Moved (n = 36) 
- Poor physical / mental condition (n = 23) 
- Referral to secondary care (n = 37) 
- Remission of diabetes (n = 8) 
- Main health care provider is general practitioner (n = 4) 
- Refused to participate (n = 7) 
- Forms not returned by primary care practice nurse (n = 19) 
- Other reasons (n = 24) 
- Reason unknown (n = 11) 
M1: 2,225 patients included 
2,215 patients underwent M1 interview 
1,642 patients returned M1 self-report questionnaire 
 
M2: 2,032 patients included 
Loss to follow-up M2: 
- Deceased (n = 51) 
- Moved (n = 18) 
- Poor physical / mental condition (n = 13) 
- Referral to secondary care (n = 30) 
- Remission of diabetes (n = 21) 
- Main health care provider is general practitioner (n = 1) 
- Refused to participate (n = 1) 
- Forms not returned by primary care practice nurse (n = 31) 
- Other reasons (18) 
- Reason unknown (9) 
2,032 patients underwent M2 interview 
1,310 patients returned M2 self-report questionnaire 
 
Figure 1 Flow chart of the original DIAZOB cohort 
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Data acquired during an interview with the primary care practi ce nurse
The interview-administered questi onnaire was fi lled out by the practi ce nurse along with 
the pati ent during regular diabetes check-up and included questi ons about demographic 
factors, clinical parameters, hyperglycemia treatment and health behaviors.
Demographics
Informati on was gathered about age, gender and ethnicity.
Clinical parameters
At baseline, the primary care practi ce nurse recorded the number of months / years 
since diabetes diagnosis and took a basic medical history, including self-reported history 
of depression. Self-reported medical diagnoses were verifi ed through inspecti on of the 
medical record. At follow-up, onset and / or progression of vascular complicati ons and other 
conditi ons was recorded, as was mortality date and cause of death for those pati ents who 
deceased during the study.
Hyperglycemia treatment 
At each measurement occasion, the practi ce nurse documented whether pati ents were 
currently treated for their hyperglycemia by diet, oral agents, insulin or a combinati on of 
these treatment modaliti es. 
health behaviors / Lifestyle
A basic overview of current and former smoking behavior and alcohol consumpti on was 
collected at the baseline assessment. Changes to this baseline patt ern were recorded during 
follow-up. Physical acti vity was assessed by means of two items. Pati ents had to indicate 
how many hours per week they spent on (a) “acti ve” (all physical acti viti es other than 
practi cing sports, e.g. gardening, walking, cycling, climbing stairs) and (b) “sporti ve” physical 
acti viti es (e.g. sports, fi tness).
Data acquired using self-report questi onnaires
A second questi onnaire was completed by the pati ent at home and addressed several 
additi onal demographic variables and psychosocial factors. For practi cal purposes, the 
questi ons about health behaviors were transferred from the interview-administered to the 
self-report questi onnaire for the follow-up measurements. 
Demographics
The demographic measures included marital status (dichotomized as being single versus 
having a partner), living situati on (independent versus dependent of others), employment 
status (paid employment versus no paid employment / unemployed / disabled / reti red) and 




Depressive symptoms during the last seven days were assessed using a validated Dutch 
version of the Edinburgh Depression Scale (EDS) 38. This is a 10-item self-rating scale in which 
each item is scored on a four-point scale. Total scores range from 0 to 30 points. The EDS was 
originally developed to measure post partum depression 39, but has later been validated in 
non-postnatal women 40, women around menopausal age 41, men 42 and community samples 
43. Although cut-off points for predicting a diagnosis of clinical depression vary 44, a cut-off 
score of 12 or more seems to have satisfactory sensitivity and specificity 41, 43.
Type D personality
Type D personality was assessed using the Type D Scale-14 28. This questionnaire consists of 
14 items, which are scored on a five-point rating scale ranging from 0 = “false” to 4 = “true”. 
The DS14 comprises two scales, one measuring level of negative affectivity (NA) and the 
other social inhibition (SI). Subjects who obtain a score of ten or more on both scales are 
considered to have a Type D personality 28. Both scales have been shown to be internally 
consistent (Cronbach’s α = 0.88 for the NA scale and 0.86 for the SI scale), stable over an 
18-month period 45 and are independent of mood and health status 28, 45.
Other psychosocial factors 
Social support was measured using O’hara’s modified Social Support Scale 46, comprising 
three items. Answer categories range from 0 to 4 points, with 0 indicating “no social support 
at all” and 4 indicating “extensive social support”. The total social support score is obtained 
by adding scores on all three items. A single item was used to measure feelings of loneliness 
in the past 12 months, which were scored on a scale from 1 to 10 points, with a score of 1 
meaning “I never felt lonely” and a score of 10, “I always felt lonely”. To account for non-
diabetes related stressors, respondents were asked if they had experienced a stressful life 
event in the previous 12 months (e.g. loss of a loved one, a break-in, relationship problems, 
loss of work, serious financial problems, physical / mental abuse).
Laboratory tests and physical examinations
Biomedical parameters were derived from standard care laboratory tests and physical 
examinations carried out by the Diagnostic Centre Eindhoven, a primary care institution 
where biological records of the regional diabetes population are filed after each regular care 
check-up appointment. For the DIAZOB project, blood was drawn annually to determine 
glycemic control (glycosylated hemoglobin or hbA1C levels, fasting glucose), creatinin, the 
MDRD clearance (only at follow-up) and cholesterol values (total, LDL, hDL, triglycerides); 
urine samples were taken to assess albumin and the albumin-to-creatinin ratio. As for the 
physical examination, blood pressure measurements (systolic and diastolic), body mass 
index (BMI; weight in kilograms / length in metres2), and fundus photography and foot 
screening results were provided. To diagnose retinopathy, digital fundus photography was 
carried out by a biometrist and interpreted by an ophthalmologist. Foot screening included 
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a neurological and vascular examinati on (Doppler test), and inspecti on of feet and shoes 
by a podotherapist or a biometrist under supervision. For the baseline measurement, only 
the presence of abnormaliti es to the feet was recorded. During follow-up testi ng, the lower 
extremiti es were assessed for neuropathy, ischemia, wounds / ulcers and excessive coldness.
Pharmacy medicati on records
With the pati ent’s consent, informati on regarding prescribed medicati on was obtained 
from local pharmacists. In additi on to the medicati on applied for the management of 
hyperglycemia, the use of cardiovascular agents (including several anti hypertensives and a 
class of cholesterol-lowering drugs) was registered.
table 1 Measurements included in the DiaDDZoB Study
Variable Categories Measurement occasion
Demographic factors
Age M0
Gender Male, female M0
Ethnicity Dutch, other Caucasian (white Western) groups, 
other (Asian, black, Turkish / Moroccan)
M0
Marital status Married / living together, single, LAT relati onship, 
divorced / separated, widowed
M0, M1, M2
Living situati on Independent, residing with family / friends, residing 
in a nursing home
M0, M1, M2
Employment status Paid employment, unemployed, disabled, no paid 
employment, reti red
M0, M1, M2
Educati on level Primary school, primary vocati onal educati on, 
secondary school, secondary vocati onal educati on, 
higher vocati onal educati on, university
M0
Medical history
Disease durati on Months / years since diabetes diagnosis M0, M1
Medical history M0: lifeti me history:
arterial disease, bypass / angioplasty, myocardial 
infarcti on, stroke, angina pectoris, high cholesterol, 
kidney disease, asthma / COPD, cancer, rheumati c 
disorder, depression, burn-out
M1 and M2: during last 12 months:
arterial disease, bypass / angioplasty, myocardial 
infarcti on, stroke, angina pectoris, high cholesterol, 






None, diet, diet / oral agents, diet / insulin, diet / 
oral agents / insulin, other
M0, M1, M2
Medicati on use ACE inhibitors, β-blockers, calcium antagonists, 





Variable Categories Measurement occasion
Laboratory tests
HbA1c M0, M1, M2


















Length Length in metres M0, M1, M2
Weight Weight in kilograms M0, M1, M2
Body Mass Index (BMI) Weight in kilograms / (length in metres)2




Fundus photography Unassessable, normal, retinopathy M0, M1, M2
Foot examination M0: Normal, abnormal




Smoking behavior Current smoking: yes / no, number of cigarettes per 
day
Additional for M0: smoking history
M0, M1, M2
Alcohol consumption Current alcohol consumption: yes / no, number of 
consumptions per week
Additional for M0: history of alcohol consumption
M0, M1, M2
Physical activity hours per week of active physical activity 




Depressive symptoms Edinburgh Depression Scale (EDS) M0, M1, M2
Type D personality Type D Scale-14 (DS14) M1, M2
Social support O’hara’s modified Social Support Scale M0, M1, M2
Loneliness Single item concerning feelings of loneliness in the 
past 12 months
M0, M1, M2
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ethical principles
This study was planned and conducted in accordance with the medical professional codex 
and the helsinki Declarati on of 1996 47. Writt en informed consent was obtained from all 
parti cipants. The study protocol of the DiaDDZoB Study was approved by the medical 
research ethics committ ee of a local hospital, the Máxima Medical Centre in Veldhoven 
(NL27239.015.09).
Planned stati sti c analyses
Stati sti cal analyses will be performed using the latest version of the Stati sti cal Package for 
Social Sciences (SPSS). A p < 0.05 signifi cance level will be adopted in all stati sti cal tests. As 
the number of previous studies on these research topics is limited, we choose to use two-
sided tests in all analyses.
Frequencies will be provided for (1) the prevalence, (2) incidence (with / without self-
reported history of depression), (3) recurrence (high score across two or three assessments) 
and (4) other patt erns of relapse and remission of high depressive symptoms (EDS-score of 
12 or more). In additi on, logisti c regression analyses will be used to determine signifi cant 
predictors of these diff erent course patt erns. Baseline characteristi cs of pati ents with / 
without high depressive symptoms (EDS-score of 12 or more) and with / without a Type D 
personality will be compared using independent-samples t-tests and Χ2 tests. To evaluate the 
vascular risk associated with increased levels of emoti onal distress, we will perform logisti c 
regression analyses for (1) the development of each separate micro- and macrovascular 
complicati on and (2) a composite measure of vascular disease (the development of any 
vascular conditi on) during the two year follow-up period, with either depression or Type 
D personality as the independent variable. The group of parti cipants with low depressive 
symptoms or no Type D personality, respecti vely, will be used as the reference category. 
Analogous analyses will be used for mortality, with the dependent variable defi ned as (1) 
all-cause mortality or (2) (cardio)vascular mortality, as registered in primary care medical 
records up unti l December 2008. Before proceeding to the multi variate stati sti cs, several 
study variables will be evaluated for their potenti al as confounders or mediators in the 
associati on between emoti onal distress and disease outcomes (the onset / progression of 
micro- and macrovascular complicati ons, all-cause and vascular mortality). In line with the 
methods used in a study by Whooley et al. 33, we will adopt a > 5% change in the eff ect size 
(odds rati o) for emoti onal distress before and aft er adjustment for the variable in questi on 
as the criterion to identi fy suitable mediati ng or confounding factors. All variables sati sfying 
these conditi ons will be included in the fi nal logisti c regression models. In additi on, we will 
look at mediati ng variables more closely using one of the stati sti cal methods described in 




The sample size was determined using PASS 2008 49 and was based on the logistic regression 
analyses for the main research question (“Do patients with type 2 diabetes and co-
morbid emotional distress have an increased risk for the onset / progression of micro- and 
macrovascular complications?”). Assuming a power of 0.80, an alpha level of 0.05, two-
sided testing, and a baseline prevalence rate of 20% for the binary independent variable 
(either high levels of depressive symptoms or Type D personality), we calculated the sample 
size for a range of scenarios. Based on earlier primary care and community studies 19, 27 
and on known characteristics of the DIAZOB population, we expect a two-year cumulative 
event rate (the development of any vascular complication) of 10 - 15%. In psychological 
research, R2 (achieved when emotional distress is regressed on the other independent 
variables) usually ranges from 0.20 - 0.30. Assuming equivalence between OR / RR / hR 
due to the relatively low event rate of vascular outcomes, the majority of earlier studies 
on the risk of vascular disease in diabetes patients, primary care / community samples and 
post-myocardial infarction patients has found an effect size for depression of approximately 
1.5 - 2.0 23, 24, 27. Therefore, the entered values were either 0.10, 0.125 or 0.15 for P0 (the 
probability that a participant develops any vascular complication during the two year 
follow-up period, given that he / she has a low level of depressive symptoms or no Type D 
personality at baseline), 0.20, 0.25 or 0.30 for R2, and 1.5, 1.75 or 2.0 for the OR. Sample 
sizes ranged from 3905 in the most conservative scenario (P0 = 0.10, R
2 = 0.30 and OR = 1.5) 
to 764 in the least restricted scenario (P0 = 0.15, R
2 = 0.20 and OR = 2.0). When positing a 
middle-ground scenario (P0 = 0.125; R
2 = 0.25 and OR = 1.75), the study needs a total of 1499 
participants to detect an OR of 1.75. Anticipating an annual 10% loss to follow-up (death, 
serious illness, moving), we need to include approximately 1850 patients at baseline. As we 
expect a 40% non-response / exclusion rate, we will consider for eligibility the total patient 
group (n ≈ 3000).
DiSCuSSiON
As the prevalence of type 2 diabetes is high and the absolute numbers of patients with 
both diabetes and depression will continue to rise considerably in the next decades, it has 
become even more essential to further increase our understanding of the associations 
between diabetes and depression. Currently, our knowledge about this area is still limited. 
The present paper gives an outline of the theoretical background and methodology of the 
DiaDDZoB Study, a Dutch prospective cohort study in primary diabetes care, which aims 
to answer several key research questions regarding the course and vascular impact of 
depression and Type D personality in patients with type 2 diabetes. 
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The major strengths of the DiaDDZoB Study include its longitudinal design and relati vely 
large sample size, its focus on type 2 diabetes pati ents who are being treated in a primary 
care setti  ng, the wealth of detailed pati ent informati on that is available, and the policy to 
verify self-reported disease by inspecti on of medical records. The results of this study may 
lead to the identi fi cati on of high risk pati ents and could guide the development of future 
interventi on studies.
While the DIAZOB Primary Care Diabetes study aims to include a relati vely unselected pati ent 
populati on, depressive symptoms (including a depressed mood or markedly diminished 
interest, loss of energy and a diminished ability to think or concentrate) could have negati vely 
aff ected the initi al decision to parti cipate in those pati ents who would otherwise have 
screened positi ve for depression on the EDS. In a similar vein, as the nurse-led interview 
required a certain amount of openness and direct communicati on with a health provider 
about disease and concurrent complaints, social inhibiti on might have deterred pati ents 
with a Type D personality. In a study of 178 pati ents with chronic heart failure, pati ents with 
a Type D personality not only experienced and worried more about cardiac symptoms, they 
also were less likely to report these symptoms to their cardiologist or nurse 50. 
The sharp rise in the number of pati ents with type 2 diabetes has resulted in a gradual 
shift  from secondary to primary care, thereby placing considerable demands on primary 
health care teams 51. Secondary care consultati ons or referrals are indicated in case of 
more complex disease management, e.g. in the presence of complicati ons or poorly 
regulated blood glucose levels 52, 53. Seeing that approximately 3% (67 / 2,460) of all pati ents 
parti cipati ng in the baseline assessment dropped out of the study aft er a secondary care 
referral, future assessments should be planned and carried out in close cooperati on with 
hospital practi ti oners to keep the cohort intact. To alleviate some of the workload for 
general practi ti oners, the primary care nurse specialist has been introduced as the main 
care-provider for pati ents with type 2 diabetes in family practi ce 54. Since nurse practi ti oners 
generally provide longer consultati ons and are trained to focus on the medical, practi cal as 
well as the emoti onal aspects of diabetes 55, depression prevalence esti mates could have 
been lowered with more adequate detecti on and subsequent treatment of depression. 
Unfortunately, earlier work has shown that the reverse is probably true, i.e. the presence of 
emoti onal problems was recorded in the medical chart in only 20 – 30% of diabetes pati ents 
with high scores on questi onnaires measuring emoti onal distress 55.
Although a recent cohort study has investi gated whether depression runs a chronic course 
with high rates of recurrence in primary care 12, there is a paucity of research on the 
trajectory of emoti onal distress in specifi c chronic diseases. While our annual screening 
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method most likely will identify a subsample with recurrent, high levels of depressive 
symptoms, a prospective design with yearly follow-up assessments will by definition miss 
some patients with a relapsing-remitting symptom profile who happen to be in complete or 
partial remission at the assessment occasion. While an in-depth characterization of short-
term fluctuations in emotional distress goes beyond the initial goals of the DIAZOB project, 
a similar model offers interesting research perspectives for future studies.
A structured psychiatric interview using DSM-IV criteria is considered the gold standard for 
diagnosing clinical depression 56. While self-report questionnaires were originally developed 
to quantify the severity of depression, they are often adopted as time-efficient case-finding 
instruments in large samples 57. however, depression is not the only common emotional 
problem in diabetes patients 58, 59. Depression questionnaires may detect some 56, but 
certainly not all 58 components of distress. Given the tendency of psychosocial factors to 
cluster together within individuals 60, 61, the simultaneous assessment of multiple distress 
types seems justified to obtain a more precise risk stratification 60. Other studies have 
emphasized the importance of examining both episodic emotional states and more chronic 
psychosocial factors 60, 62. By extending the focus of our research from a cross-sectional 
assessment of depressive symptoms to repeated measurements of not only depression, but 
also Type D personality, we intend to take a step in this direction. 
Several other study limitations need to be mentioned. First, while laboratory determinations 
and physical examinations are part of regular care protocols and therefore did not impose 
an extra burden on the participating patients, we cannot avoid that for some patients these 
tests were scheduled several months before or after the official measurement occasion in 
question. In these cases, we used the test results that were the closest in time to the rest 
of the data. Secondly, although the prescription of antihyperglycemic and cardiovascular 
agents was documented relatively well, information on the concurrent use of psychotropic 
medication is lacking. Earlier studies have suggested that different classes of antidepressant 
drugs may exert a clinically relevant positive or negative effect on glucose-insulin homeostasis 
63. Requesting pharmacy information from large databases of pharmacy dispensing records 64 
might improve the accuracy of medication registration. Finally, although we aim to elucidate 
the mechanisms responsible for the adverse effect of emotional distress on vascular 
outcomes, no information was available on several interesting candidate mechanisms, 
including dysfunctional activity of the hypothalamic-pituitary-adrenal axis, neurotransmitter 
function or inflammatory processes 31-33.
General practice settings offer relatively favorable conditions for conducting longitudinal 
research, as the Dutch health care system is characterized by a high level of care continuity 
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between pati ents and family physicians 65. In enhancing the quality of longitudinal data 
collecti on, it is essenti al to ensure the provision of solid research faciliti es, standardizati on 
of data between practi ces and over ti me, and integrati on of scienti fi c and pati ent care 
data collecti on in a clinician-friendly manner 65. Planning and conducti ng longer term 
epidemiologic studies considerably challenges the moti vati on and benevolence of 
parti cipati ng health care providers. Apart from central coordinati on of the DIAZOB research 
infrastructure, PoZoB also contributes to a clinical translati on of scienti fi c fi ndings by 
organising feedback meeti ngs and training programmes, thus enabling an ongoing research 
commitment of general practi ti oners and their staff  65. Keeping an eye on the needs and 
developments in primary care daily practi ce, the collaborati on between PoZoB and CoRPS, 
Tilburg University, will provide an excellent framework to explore the wealth of informati on 
already available and at the same ti me ensure a conti nuing qualitati ve and innovati ve 
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the course of depressive symptoms in primary care 
pati ents with type 2 diabetes: results from the 
Diabetes, Depression, type D personality 
Zuidoost-Brabant (DiaDDZoB) study





Aims / hypothesis: The aim of the study was to examine the course (incidence, recurrence 
/ persistence) of depressive symptoms in primary care patients with type 2 diabetes and to 
identify significant predictors of these different course patterns.
Methods: A cohort of 2460 primary care patients with type 2 diabetes was assessed for 
demographic, clinical and psychological factors in 2005 and followed-up in 2007 and 2008. 
Depression was defined as a score of ≥ 12 on the Edinburgh Depression Scale. Multivariate 
logistic regression analyses were used to determine whether several depression-course 
patterns could be predicted by means of demographics, medical co-morbidities and 
psychological factors.
Results: A total of 630 patients (26%) met the criterion for depression at one or more 
assessments. In the subgroup with no baseline depression, incident depression at follow-
up was present in 14% (n = 310), while recurrence / persistence in those with baseline 
depression was found in 66% (n = 212).The presence of any depression was associated with 
being female, low education, non-cardiovascular chronic diseases, stressful life events and 
a self-reported history of depression. Incident depression was predicted by female sex, low 
education and depression history, while patients with a history of depression had a 2.5-fold 
increased odds of recurrent / persistent depression.
Conclusions / interpretation: Depression is common in primary care patients with type 2 
diabetes, with one in seven patients reporting incident depression during a 2.5 year period. 
Once present, depression often becomes a chronic / recurrent condition in this group. In 
order to identify patients who are vulnerable to depression, clinicians can use questionnaire 
data and / or information about the history of depression.
4
COURSE OF DEPRESSIVE SYMPTOMS IN TYPE 2 DIABETES
63
iNTrODuCTiON
Compared with controls without diabetes, the risk of depression is nearly doubled in 
individuals with type 2 diabetes, aff ecti ng approximately one in every fi ve pati ents 1. A 
recent meta-analysis has shown that individuals with previously diagnosed diabetes have 
an increased risk of depression relati ve to those with impaired glucose metabolism or 
undiagnosed diabetes 2. Co-morbid depression not only has a profound negati ve impact on 
pati ents’ quality of life 3, but is also related to worse glycaemic control 4, the development of 
macro- and microvascular complicati ons 5, 6 and a higher mortality risk 7. Despite the growing 
body of literature demonstrati ng the harmful eff ects of depression in this pati ent group, 
the course of depression in type 2 diabetes has received relati vely litt le research att enti on. 
Previous cross-secti onal research has mainly focused on prevalence esti mates of depression, 
fi nding parti cularly high rates in women, pati ents treated in specialist setti  ngs and those with 
co-morbid medical conditi ons 1, 8-11. Furthermore, the longitudinal studies that have been 
conducted have mainly focused on incident depression in type 2 diabetes. A recent meta-
analysis of 11 studies concluded that people with type 2 diabetes have a 24% increased 
odds of incident depression compared with people without diabetes 12. however, as only 
one of the studies excluded people with a history of depression in the years before study 
onset, the results of this study are likely to overesti mate the risk for incident depression in 
the strictest sense (i.e. fi rst occurrence) 12. Although a few studies have examined the course 
of depression once symptoms were present (recurrence / persistence, remission), most 
had considerable limitati ons: for example, a small sample size (n < 175) 13-15, recruitment 
from specialist setti  ngs 15 or only two assessments of depression 15, 16. Two studies did not 
provide strictly observati onal fi ndings as they assessed depression in the framework of 
an interventi on study 13, 14. One observati onal study of 506 pati ents with type 2 diabetes 
assessed depression three ti mes over a period of 18 months (with 9 month intervals) 17. 
however, the authors combined persistence esti mates into the categories “conditi on at only 
a single wave”, “conditi on at any two waves” and “conditi on at all three waves”, thereby 
impeding an evaluati on of specifi c course patt erns. 
To our knowledge, a large study simultaneously addressing diff erent aspects of the course 
of depression in primary care pati ents with type 2 diabetes is currently lacking. Therefore, 
the main aim of the present study was to examine several course trajectories of depressive 
symptoms (incidence, recurrence / persistence) using data from three separate assessments 
during a 2.5 year period and to gain insight in the demographic, medical and psychological 




Methods and response rates of the Diabetes, Depression, Type D [“distressed”] Personality 
Zuidoost-Brabant (DiaDDZoB) Study have been described in detail elsewhere 18. In short, 
2460 patients with type 2 diabetes (82% of those considered for study inclusion) treated 
within 77 primary care practices in South-East Brabant, The Netherlands, were recruited 
at the baseline assessment in the second half of 2005 (M0). Of these patients, nearly all 
(2448) attended a baseline nurse-led interview, while 75% (1850) returned the self-report 
questionnaire that had to be completed at home. This cohort was re-contacted for follow-
up assessments in 2007 (M1) and 2008 (M2), and included 2225 and 2032 participants, 
respectively. The study protocol of the DiaDDZoB Study was approved by the medical 
research ethics committee of a local hospital, the Máxima Medical Centre in Veldhoven 
(NL27239.015.09). Written informed consent was obtained from all participants.
Assessment of depression
Symptoms of depression during the last 7 days were assessed using a validated Dutch 
version of the Edinburgh Depression Scale (EDS) 19. The EDS was originally designed to 
assess postpartum depression 20, but has now been validated in non-postnatal women 21, 
women around menopausal age 22, men 23, community samples 24 and primary care patients 
with type 2 diabetes 25. The EDS is a ten-item self-report questionnaire, in which each item 
is scored on a four-point scale. Total EDS scores are determined by summing the scores of 
all ten individual items (total score range 0 – 30), with higher scores indicating higher levels 
of depressive symptoms. A total score of 12 or more is commonly used to identify patients 
with depression 24. Using this cut-off, we calculated dichotomised depression scores (no 
depression / depression) for all three measurements. Patients were considered to suffer 
from “any depression” if they obtained an EDS score ≥ 12 during at least one of the three 
measurement occasions. To specify the course trajectory of these depressive symptoms, 
we split the total sample into two groups based on the baseline (M0) EDS score. “Incident 
depression” was determined in the subgroup with an EDS score < 12 at M0 (no baseline 
depression). Patients in this group who obtained an EDS score ≥ 12 at M1 and / or M2 
were considered incident cases. Rates of “recurrence / persistence” were examined in the 
remaining group of participants who had an EDS score ≥ 12 at M0 (baseline depression). 
Depression was labelled “recurrent / persistent” if patients had at least one other high EDS 
score at M1 or M2. 
Baseline demographic, medical and psychological predictors
Baseline demographic data included sex, age, marital status (having a partner vs being single) 
and educational level (middle / high vs low), and were acquired during a patient interview 
led by the primary care practice nurse and also by means of a self-report questionnaire. 
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The primary care practi ce nurse took a medical history, aft er which all self-reported medical 
diagnoses were verifi ed through inspecti on of the medical record. Indicators of microvascular 
disease were derived from standard-care laboratory tests and physical examinati ons carried 
out by the Diagnosti c Centre Eindhoven, a primary care diagnosti c insti tute. The results from 
pati ents’ yearly digital fundus photography were available to ascertain reti nopathy (yes / 
no), while albumin level in a random urine sample was used as a proxy of nephropathy 26. 
Macro- and microalbuminuria were defi ned as urine albumin concentrati ons > 200 and 20 
– 200 mg / l, respecti vely. All medical co-morbiditi es were combined into three composite 
disease measures, i.e. cardiovascular diseases (myocardial infarcti on, bypass / angioplasty, 
stroke and / or arterial disease), microvascular complicati ons (reti nopathy and / or micro- 
/ macroalbuminuria) and other chronic conditi ons (kidney disease, asthma / chronic 
obstructi ve pulmonary disease [COPD], cancer, arthrosis and / or rheumatoid arthriti s). 
In additi on, pati ents were asked if they had ever suff ered from depression. Non-diabetes-
related stressful life-events in the previous 12 months (e.g. loss of a loved one, burglary, 
relati onship problems) were assessed by means of a single questi onnaire item.
Other pati ent characteristi cs
The interview included one questi on regarding ethnicity (white vs non-white). Baseline 
treatment for diabetes and diabetes durati on were documented by the primary care practi ce 
nurse. Standard-care determinati ons of hbA1c concentrati ons and BMI were provided by the 
Diagnosti c Centre Eindhoven.
stati sti cal analyses
Baseline sample characteristi cs and descripti ve stati sti cs for the EDS data at all three 
measurement occasions were calculated. To compare diff erences between men and women, 
Χ2 tests were used for categorical data and independent samples t-tests for conti nuous 
data. Of all demographic, clinical and psychological data needed for the analyses, 27% 
was missing. As complete case analysis would restrict the sample to 511 pati ents (21%), 
multi variate imputati on by chained equati ons was applied to impute missing values 
(Electronic supplementary material [ESM] Table 1), using the package MICE V2.0 27 and the 
soft ware program R 28. Adequate results can generally be obtained by creati ng fi ve to ten 
imputed datasets, retaining fi nal imputati ons per dataset aft er ten iterati ons 27, 29. For the 
present study, 20 imputed datasets were generated, allowing ten iterati ons per set. 
Following imputati on, depression prevalence rates and esti mates for any, incident and 
recurrent / persistent depression were calculated, pooling the results over the 20 individual 
datasets. Multi variate logisti c regression analyses were used to determine whether these 
diff erent depression course trajectories could be predicted by means of: (1) demographics 
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(female sex, age, low education, being single); (2) medical co-morbidities (prior cardiovascular 
disease, the presence of microvascular complications, other co-morbid conditions); (3) 
stressful life events; and (4) self-reported history of depression. As missing EDS baseline data 
were also imputed, the number of individuals classified in either the “incident depression” 
or “recurrent / persistent depression” subgroup varied slightly per individual imputed 
dataset. Therefore, in addition to reporting the pooled results of the regression analyses 
for incident and recurrent / persistent depression, the range of n across all 20 individual 
imputed datasets was provided. With the exception of the multiple imputation procedure, 
all analyses were performed using PASW Statistics version 17.0 (IBM SPSS Statistics, Somers, 
NY, USA). A p-value < 0.05 was considered to be statistically significant.
rESuLTS
Baseline sample characteristics
Table 1 presents the characteristics of the total DiaDDZoB sample before multiple 
imputation (n = 2460, 49% men, mean age 67 years) and the number of missing values 
per variable. Overall, participants were in relatively good glycaemic control (mean hbA1c 
6.7% [50 mmol / mol]), and the majority were being treated with a combination of diet 
and oral glucose-lowering agents. Co-morbid diseases were common, with vascular disease 
and other major (chronic) medical conditions being present in one-third and one-half of 
all patients, respectively. Advanced microvascular complications, including retinopathy 
and macroalbuminuria, were relatively rare. however, almost one in four patients had 
microalbuminuria. When examining results separately for men and women, women were 
shown to be significantly older, more commonly had a low educational level and were more 
likely to be single. Myocardial infarction, bypass / angioplasty procedures and albuminuria 
were more prevalent in men, while the medical history of women included more diagnoses 
of cancer, arthrosis and rheumatoid arthritis. Furthermore, women were more likely to 
report a history of depression and at least one stressful life event in the past year.
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table 1 Baseline characteristi cs before multi ple imputati on
All (n = 2460) n missing Men (n = 1192) Women (n = 1268) P value
Demographics
Age (years) 67 (11) 5 66 (11) 68 (11) <0.001
Non-white 3% (78/2424) 36 3% (36/1174) 3% (42/1250) 0.68
Low educati on level 64% (1140/1770) 690 53% (459/866) 75% (681/904) <0.001
Being single 25% (455/1831) 629 16% (144/893) 33% (311/938) <0.001
Medical history
Cardiovascular disease 36% (842/2368) 92 40% (458/1157) 32% (384/1211) <0.001
Myocardial infarcti on 12% (280/2353) 107 16% (188/1149) 8% (92/1204) <0.001
Bypass / angioplasty 13% (312/2358) 102 18% (207/1153) 9% (105/1205) <0.001
Stroke 7% (164/2360) 100 8% (88/1154) 6% (76/1206) 0.21
Arterial disease 24% (559/2349) 111 25% (287/1142) 23% (272/1207) 0.14
Microvascular disease 35% (612/1769) 691 38% (334/886) 32% (278/883) 0.006
Reti nopathy 5% (86/1767) 693 4% (37/878) 6% (49/889) 0.21
Microalbuminuria a 23% (477/2077) 383 26% (264/1003) 20% (213/1074) <0.001
Macroalbuminuria b 4% (72/2077) 5% (46/1003) 2% (26/1074)
Other chronic conditi ons 50% (1184/2377) 83 44% (510/1157) 55% (674/1220) <0.001
Kidney disease 4% (95/2339) 121 4% (47/1144) 4% (48/1195) 0.91
Asthma / COPD 13% (315/2360) 100 13% (153/1147) 13% (162/1213) 0.99
Cancer 9% (222/2351) 109 8% (90/1144) 11% (132/1207) 0.01
Arthrosis 34% (793/2365) 95 27% (309/1152) 40% (484/1213) <0.001
Rheumatoid arthriti s 7% (161/2352) 108 4% (44/1146) 10% (117/1206) <0.001
Clinical values
Hyperglycaemia treatment
No treatment 1% (19/2422)
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1% (9/1179) 1% (10/1243)
Diet only 18% (432/2422) 19% (219/1179) 17% (213/1243)
Diet, oral agents 75% (1821/2422) 76% (892/1179) 75% (929/1243) 0.04
Diet, oral agents, insulin 5% (114/2422) 4% (46/1179) 6% (68/1243)
Diet, insulin 1% (33/2422) 1% (10/1179) 2% (23/1243)
Other 0% (3/2422) 0% (3/1179) 0% (0/1243)
Diabetes durati on ≥3 years 61% (1467/2424) 36 59% (697/1175) 62% (770/1249) 0.24
HbA1c %; mmol / mol 6.7 (0.9); 50 (10) 61 6.7 (0.8); 50 (9) 6.7 (0.9); 50 (10) 0.28
BMI (kg / m2) 29 (5) 234 28 (4) 30 (5) <0.001
Psychosocial factors
History of depression 11% (248/2345) 115 9% (97/1146) 13% (151/1199) 0.001
Stressful life event(s) 35% (635/1800) 660 32% (280/881) 39% (355/919) 0.002
M0 depressive symptoms
EDS total score 6 (5)
715
5 (4) 7 (5) <0.001
EDS score ≥ 12 12% (216/1745) 8% (70/861) 17% (146/884) <0.001
M1 depressive symptoms
EDS total score 6 (5)
918
5 (4) 7 (5) <0.001
EDS score ≥ 12 14% (210/1542) 9% (66/741) 18% (144/801) <0.001
M2 depressive symptoms
EDS total score 6 (5)
1226
5 (5) 7 (5) <0.001
EDS score ≥ 12 15% (188/1234) 10% (60/580) 20% (128/654) <0.001
Values are mean (standard deviati on), unless otherwise specifi ed; a Albumin concentrati on of 20 - 200 mg / l; 




Figure 1 shows the number of patients with depression (EDS score ≥ 12) at the baseline 
assessment in 2005 (M0) and the two follow-up occasions (M1 and M2), after multiple 
imputation. Depression slowly increased from 13% (M0) to 14% (M1) to 16% (M2). This 
pattern was evident for both men and women after splitting by sex. Compared with men, 






























































































































































































































Figure 1 Prevalence of depression (EDS score ≥ 12) at baseline (M0) and the two follow-up assessments 
(M1, M2) for the total sample (n = 2460) and examined separately for men (n = 1192) and women (n = 
1268). Bars represent total group (black), men (dark grey) and women (light grey); the number shown 
above each bar represents the number with depression in that group. p < 0.001 for men vs women for 
all three assessments
Any depression, incidence and recurrence / persistence 
After multiple imputation, 26% of the total sample (n = 630) reported an EDS score ≥ 12 at 
M0, M1 and / or M2 (“any depression”). The presence of any depression was significantly 
more likely in women compared with men (32%, n = 412 vs 18%, n = 218; p < 0.001). In 
the subgroup of patients with an M0 EDS score < 12 (no depression; n = 2140), incident 
depression at M1 or M2 was present in 310 individuals (14%), with a higher rate for women 
(18%, n = 193 vs 11%, n = 116; p < 0.001). An additional Χ2 analysis showed that participants 
who were not depressed at baseline but did have a self-reported history of depression 
were significantly more likely to experience incident depression during follow-up than 
those without such a history (33%, n = 52 vs 13%, n = 257; p < 0.001). Of the 320 patients 
with an EDS score of ≥ 12 at M0, 66% also met the criterion for depression at M1 and / or 
M2 and were therefore considered to be recurrently / persistently depressed. The rate of 
recurrence / persistence was similar for female and male patients (69%, n = 151 vs 60%, n = 
61; p = 0.09), but was significantly higher in those with a self-reported history of depression 
(79%, n = 79 vs 60%, n = 133; p = 0.001). When considering specific patterns of remission 
and relapse, 34% (n = 109) of all initially depressed patients at M0 recovered and remained 
below the EDS score cut-off at M1 and M2, 15% (n = 47) relapsed at M2 and 38% (n = 123) 
were still depressed at both follow-ups.
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Baseline risk factors predicti ng any depression
Table 2 shows the pooled eff ect esti mates of a multi variate logisti c regression analysis 
predicti ng the presence of any depression (EDS score ≥ 12 at M0, M1 and / or M2) by several 
baseline characteristi cs. In the fi rst step, female sex and low educati on were the only 
signifi cant demographic predictors. In the second step, having co-morbid chronic medical 
conditi ons was positi vely associated with depression, while the presence of cardiovascular 
disease and microvascular complicati ons also increased the odds of depression but did 
not reach stati sti cal signifi cance (p = 0.27 and p = 0.09, respecti vely). In the third step, 
having experienced stressful life events during the past year nearly doubled the odds for 
depression, while in the fi nal step parti cipants with a history of depression had an almost 
fi vefold increased odds of reporti ng depression during at least one assessment occasion. 
In order to test whether sex was an eff ect modifi er, the same regression analysis (excluding 
sex in the fi rst step) was conducted for women (n = 1268) and men (n = 1192) separately. 
Aft er entry of all variables in the model, low educati onal level (fully adjusted OR = 1.93, 95% 
CI 1.24, 3.01 in women vs OR = 1.56, 95% CI 1.02, 2.39 in men), stressful life events (OR = 
1.90, 95% CI 1.40, 2.59 vs OR = 1.83, 95% CI 1.25, 2.68) and a history of depression (OR = 
4.53, 95% CI 2.95, 6.95 vs OR = 5.52, 95% CI 3.38, 9.01) were signifi cantly associated with 
depression for both sexes. In additi on, the non-cardiovascular chronic medical conditi ons 
played a signifi cant role in the model for women (OR = 1.51, 95% CI 1.12, 2.03), while for 
men no other signifi cant predictors were found (ESM Table 2).
table 2 Multi variate logisti c regression analysis predicti ng any depression (EDS score ≥ 12 at M0, M1 
and / or M2) by baseline demographic factors, medical co-morbiditi es, stressful life events and self-
reported history of depression (n = 2460)
Model 1 Model 2 Model 3 Model 4
1. Demographic factors
Female sex 1.86 (1.51, 2.29) 1.87 (1.51, 2.31) 1.82 (1.47, 2.25) 1.74 (1.39, 2.17)
Age 1.00 (0.99, 1.01) 0.99 (0.98, 1.00) 1.00 (0.99, 1.01) 1.00 (0.99, 1.01)
Low educati on level 1.66 (1.25, 2.22) 1.65 (1.24, 2.19) 1.66 (1.24, 2.23) 1.75 (1.28, 2.38)
Being single 1.28 (0.98, 1.68) 1.27 (0.97, 1.68) 1.19 (0.90, 1.57) 1.18 (0.88, 1.56)
2. Medical co-morbiditi es
Cardiovascular disease a 1.13 (0.91, 1.40) 1.12 (0.90, 1.39) 1.10 (0.88, 1.38)
Microvascular disease b 1.25 (0.97, 1.60) 1.24 (0.96, 1.60) 1.25 (0.96, 1.62)
Other chronic conditi ons c 1.50 (1.19, 1.87) 1.44 (1.15, 1.82) 1.36 (1.07, 1.73)
3. stressful life events 1.90 (1.51, 2.40) 1.86 (1.46, 2.38)
4. history of depression 4.90 (3.53, 6.82)
Values are OR (95% CI) 
a Myocardial infarcti on, bypass / angioplasty, stroke and / or arterial disease; b Reti nopathy and / or micro- / 
macroalbuminuria; c Kidney disease, asthma / COPD, cancer, arthrosis and / or rheumatoid arthriti s
Model 1: demographic factors; Model 2: model 1 + medical co-morbiditi es; Model 3: model 2 + stressful life events; 
Model 4: model 3 + history of depression
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Additional analyses in the total sample examining depression risk for each medical co-
morbidity separately revealed that after correction for demographics, arthrosis (OR = 1.57, 
95% CI 1.26, 1.96) and rheumatoid arthritis (OR = 1.57, 95% CI 1.04, 2.39) were the only 
significant predictors (ESM Table 3).
table 3 Multivariate logistic regression analysis predicting incident depression by baseline demographic 
factors, medical co-morbidities, stressful life events and self-reported history of depression, examined 
separately for men and women
Model 1 Model 2 Model 3 Model 4
MeN (range n = 1081 – 1096)
1. Demographic factors
Age 1.01 (0.99, 1.03) 1.00 (0.98, 1.02) 1.00 (0.98, 1.03) 1.00 (0.98, 1.03)
Low education level 1.56 (0.96, 2.54) 1.51 (0.92, 2.48) 1.54 (0.93, 2.54) 1.56 (0.94, 2.60)
Being single 1.11 (0.58, 2.14) 1.11 (0.57, 2.13) 1.08 (0.56, 2.07) 0.99 (0.50, 1.95)
2. Medical co-morbidities
Cardiovascular disease a 1.42 (0.87, 2.31) 1.42 (0.87, 2.31) 1.43 (0.87, 2.34)
Microvascular disease b 1.30 (0.79, 2.12) 1.30 (0.80, 2.14) 1.35 (0.82, 2.20)
Other chronic conditions c 1.28 (0.76, 2.15) 1.24 (0.74, 2.09) 1.20 (0.71, 2.04)
3. stressful life events 1.40 (0.82, 2.39) 1.38 (0.81, 2.36)
4. history of depression 3.99 (1.98, 8.04)
WOMeN (range n = 1042 – 1064)
1. Demographic factors
Age 1.01 (0.99, 1.03) 1.01 (0.98, 1.03) 1.01 (0.99, 1.03) 1.01 (0.99, 1.03)
Low education level 1.59 (0.95, 2.68) 1.59 (0.94, 2.68) 1.59 (0.94, 2.68) 1.69 (0.99, 2.88)
Being single 1.14 (0.75, 1.74) 1.12 (0.73, 1.72) 1.10 (0.71, 1.69) 1.11 (0.72, 1.70)
2. Medical co-morbidities
Cardiovascular disease a 0.92 (0.61, 1.39) 0.92 (0.61, 1.38) 0.91 (0.60, 1.37)
Microvascular disease b 1.35 (0.83, 2.19) 1.34 (0.82, 2.19) 1.34 (0.81, 2.20)
Other chronic conditions c 1.35 (0.94, 1.93) 1.34 (0.93, 1.92) 1.27 (0.88, 1.84)
3. stressful life events 1.24 (0.83, 1.86) 1.24 (0.82, 1.88)
4. history of depression 2.93 (1.64, 5.26)
Values are OR (95% CI) 
a Myocardial infarction, bypass / angioplasty, stroke and / or arterial disease; b Retinopathy and / or micro- / 
macroalbuminuria; c Kidney disease, asthma / COPD, cancer, arthrosis and / or rheumatoid arthritis
Model 1: demographic factors; Model 2: model 1 + medical co-morbidities; Model 3: model 2 + stressful life events; 
Model 4: model 3 + history of depression
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Baseline risk factors predicti ng incident and recurrent / persistent depression
A multi variate logisti c regression analysis identi cal to the model described in Table 2 was 
conducted to predict incident depression (range of n over all 20 datasets, 2131 – 2156; 
ESM Table 4). In the last step, female sex (OR = 1.63, 95% CI 1.20, 2.21), low educati on 
(OR = 1.62, 95% CI 1.12, 2.36) and self-reported history of depression (OR = 3.27, 95% CI 
2.05, 5.22) were all associated with incident depression, while microvascular disease, other 
chronic conditi ons and stressful life events increased the odds of depression by 25 – 33%, 
but did not reach stati sti cal signifi cance (p = 0.14, 0.18 and 0.14, respecti vely). Repeati ng 
the analysis (excluding entry of history of depression in the last step) in the group of pati ents 
reporti ng no history of depression and no M0 depression (range of n, 1967 – 1992) yielded 
similar results (data not shown). Aft er splitti  ng by sex, self-reported history of depression 
was associated with a three- to four-fold increased odds of incident depression in both men 
and women (Table 3). Low educati on increased the odds, but was not signifi cant (p = 0.09 
and 0.06 in men and women, respecti vely).
Self-reported history of depression was the only signifi cant predictor of recurrent / persistent 
depression (range of n, 304 – 329; OR = 2.54, 95% CI 1.23, 5.23). Similar results were found 
when examining results separately for men and women (women: OR = 2.69, 95% CI 1.06, 
6.82; men: OR = 2.76, 95% CI 0.64, 11.88), but failed to reach stati sti cal signifi cance in men 
(p = 0.18; ESM Tables 5 and 6).
DiSCuSSiON
Depression (defi ned as a high level of depressive symptoms) appeared to be a common 
co-morbid health problem in primary care pati ents with type 2 diabetes, with one in four 
pati ents suff ering from depression at least once during a 2.5 year period. New occurrences 
of depressive symptoms were frequently observed among those with no symptoms at 
baseline (14%). Once present, depressive symptoms tended to be recurrent / persistent 
over ti me in two-thirds of all cases.
The cross-secti onal prevalence esti mates of our study (13 – 16%) were slightly lower than 
the fi gure reported in a previous meta-analysis (18%) 1, but did slowly increase over ti me. 
This may refl ect cohort aging and the ensuing development of additi onal co-morbiditi es and 
accompanying functi onal limitati ons. In line with the results of a previous study 17, expanding 
the ti me frame from cross-secti onal analyses (point prevalence) to a total esti mate across 
successive assessments (“any depression”) revealed a higher prevalence rate in a 2.5 year 
period, suggesti ng that prevalence esti mates taken at one point in ti me underesti mate the 
true scope of the problem. 
ChAPTER 4
72
The onset of depression in diabetes has been examined several times before, but most of 
these studies (including ours) have defined incident depression as the presence of depression 
at a distinct follow-up time point in those without baseline depression, rather than also 
taking incident cases during the whole follow-up period into account 12. This definition does 
not allow for a correction for variable follow-up length across studies by calculating annual 
incidence rates, as studies with longer follow-up periods are likely to miss more incident 
cases and as a consequence would substantially underestimate true yearly incidence rates. 
Our finding that depressive symptoms have a high rate of recurrence and chronicity in 
diabetes patients is in line with previous research showing that approximately half of all 
patients experiencing depressive symptoms at baseline also reported depression 1 to 5 years 
later 15, 16. Furthermore, over 40% of diabetes patients with elevated depressive symptoms 
appear to develop major depression within 2 years 30. however, to our knowledge, only two 
previous studies have examined the course of depressive symptoms over more than two 
assessments. In one study, 20% of all participants obtained scores ≥ 16 on the Center for 
Epidemiological Studies – Depression questionnaire at least twice 17. A second study among 
245 diabetes patients (65% with type 2 diabetes) measured depressive symptoms at the 
beginning and end of a 1 week diabetes education programme and at 6 month follow-up. 
While the authors concluded that only 13% of their total sample was persistently depressed 
(i.e. exceeded the criterion for depression symptoms at all three time points), recurrent 
depression (depressed at least once during follow-up) was found in two-thirds of the 
patients depressed before the start of the programme 14. Even though this study included a 
psycho-educational intervention programme incorporating coping skills training, the results 
were roughly comparable with those from our study.
With regard to prognostic factors, female sex, a low educational level, non-cardiovascular 
chronic medical conditions, stressful life events and a self-reported history of depression 
were associated with the presence of any depression. Previous cross-sectional studies 
have shown an association between prevalent depression and the presence of co-morbid 
chronic diseases in diabetes patients 8, 9 and have suggested that a large number of general 
life stressors, in addition to more diabetes-specific distress, can contribute to depressive 
symptoms 8. however, the logistic regression analysis predicting incident depression in the 
subgroup with no baseline depression limited the results to female sex, low education and 
history of depression, while recurrent / persistent depression in those patients with baseline 
depression left only depression history as a significant predictor in the model. 
Two previous studies aiming to identify baseline predictors of “persistent” depressive 
symptoms reported conflicting results. In one study, low level of education, the presence 
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of multi ple complicati ons and a treatment without insulin signifi cantly predicted persistent 
depression 14, while the other described an important role for more psychologically orientated 
factors, including baseline severity of depression, emoti onal problems due to diabetes and 
the extent to which depression disrupted the pati ent’s quality of life 15. Even though vascular 
complicati ons are oft en cited as an important determinant of disease burden in diabetes, 
macro- and microvascular conditi ons were not associated with depression in any of the 
present analyses. One possible explanati on may lie in the fact that our study focused on 
baseline and pre-baseline factors as potenti al predictors of depression. however, the onset 
or progression of medical conditi ons and cardiovascular procedures during follow-up are 
likely candidates to trigger new cases of depression or hamper recovery from already existi ng 
emoti onal problems. This hypothesis is partly supported by a study in which coronary 
procedures during follow-up (but not incident macro- and microvascular complicati ons) 
were associated with major depression at the 5 year follow-up 16. Alternati vely, rather 
than examining the mere presence of any macro- or microvascular conditi ons, it could 
be that having multi ple (vascular) co-morbiditi es (and probably accompanying functi onal 
limitati ons) is what parti cularly increases the odds of depression 8-10. 
Self-reported history of depression was the only factor that consistently identi fi ed those 
individuals who had increased odds of experiencing any kind of depression during a period 
of 2.5 years, even aft er controlling for demographics, medical co-morbiditi es and stressful 
life events. These results are valuable for primary care, as they clearly show that a simple 
self-report questi on is highly predicti ve of future depression. Additi onal monitoring may be 
required in pati ents who report a history of depression. 
Some limitati ons of the present study need to be menti oned. First, depression was assessed 
by means of a self-report questi onnaire, while the gold standard for a diagnosis of depression 
is a standardised psychiatric diagnosti c interview. Although 30 – 40% of pati ents with an 
increased level of depressive symptoms are clinically depressed 11, 31, self-reported depressive 
symptoms have been shown to predict the development of major depression 30 and adverse 
health outcomes 5 in diabetes pati ents. Second, a more accurate measurement of incident 
depression can be achieved in studies also covering the ti me period(s) between separate 
measurement occasions, for example by using handheld computers for the assessment of 
depression. In case researchers do not want or are not able to use these devices, other 
authors have argued that fl uctuati ng course types are best studied in designs with at least 
three measurements 32. Third, although we aimed to study the course of depression in 
this cohort, no informati on was available on either pharmacological or psychotherapeuti c 
treatment of depression during the study. however, this potenti al source of bias is most 
likely restricted to a minority, as depression oft en goes unrecognised and untreated in 
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patients with diabetes 33. Fourth, while interpreting our results, it has to be borne in mind 
that 27% of all demographic, clinical and psychological data needed for the analyses were 
missing and imputed using multivariate imputation techniques. however, several authors 
have argued that multiple imputation is preferred over other missing data approaches, 
including complete case analysis, in the case of complex incomplete data problems 27, 29. 
Finally, the vast majority of individuals in our sample (97%) were white, which may not 
be representative of other diabetes populations. The strengths of the study include the 
large sample of primary care patients with type 2 diabetes, the prospective observational 
design with multiple depression assessments and the policy to verify self-reported medical 
diagnoses by inspection of medical records.
In sum, our results show that as many as one in four primary care patients with type 2 
diabetes are confronted with depression during a 2.5 year period. Once present, depression 
often becomes a chronic / recurrent condition in this group. Monitoring of emotional well-
being / depression seems warranted and does not necessarily have to be very elaborate, 
but should be embedded in collaborative care approaches 34. Moreover, given that a 
considerable number of patients do not benefit from the current pharmacological and 
psychotherapeutic treatment modalities, future research efforts are required to further 
optimise depression outcomes for depressed patients with type 2 diabetes 34. Web-based 
treatment of depression in diabetes appears to be effective and can be employed to help to 
battle this common problem in patients with diabetes with low costs 35.
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esM table 1 Overview of all variables included in the imputati on process
Variables used in subsequent regression analyses a
All ten individual baseline (M0) EDS items (5 response categories)
All ten individual follow-up 1 (M1) EDS items (5 response categories)
All ten individual follow-up 2 (M2) EDS items (5 response categories)
Sex (men vs women)
Age (conti nuous)
Educati onal level (middle / high vs low educati onal level)
Marital status (having a partner vs being single)
Myocardial infarcti on (no vs yes)
Bypass / angioplasty (no vs yes)
Stroke (no vs yes)
Arterial disease (no vs yes)
Results of fundus screening (normal vs reti nopathy)
Albuminuria (conti nuous)
history of kidney disease (no vs yes)
Asthma / COPD (no vs yes)
Cancer (no vs yes)
Arthrosis (no vs yes)
Rheumatoid arthriti s (no vs yes)
Stressful life event(s) in past year (no vs yes)
history of depression (no vs yes)
Auxiliary variables b
Ethnicity (white vs non-white)
hyperglycaemia treatment (6 response categories)
Diabetes durati on (< 3 years vs ≥ 3 years)
HbA1c (conti nuous)
BMI (conti nuous)
a For the subsequent regression analyses, several imputed variables are redefi ned into summary or composite 
variables (see main manuscript text); b Variables not used in subsequent analyses, but used to improve imputati ons
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esM table 2 Multivariate logistic regression analysis predicting any depression (EDS score ≥ 12 at M0, 
M1 and/or M2) by baseline demographic factors, medical co-morbidities, stressful life events and self-
reported history of depression, examined separately for men and women
Model 1 Model 2 Model 3 Model 4
MeN (n = 1192)
1. Demographic factors
Age 1.00 (0.99, 1.02) 1.00 (0.98, 1.01) 1.00 (0.98, 1.02) 1.00 (0.98, 1.02)
Low education level 1.53 (1.03, 2.26) 1.49 (1.01, 2.20) 1.52 (1.02, 2.27) 1.56 (1.02, 2.39)
Being single 1.52 (0.98, 2.34) 1.51 (0.98, 2.32) 1.43 (0.92, 2.22) 1.36 (0.85, 2.16)
2. Medical co-morbidities
Cardiovascular disease a 1.33 (0.94, 1.88) 1.33 (0.93, 1.89) 1.30 (0.90, 1.86)
Microvascular disease b 1.18 (0.83, 1.69) 1.19 (0.83, 1.69) 1.21 (0.85, 1.72)
Other chronic conditions c 1.30 (0.91, 1.86) 1.23 (0.85, 1.77) 1.17 (0.80, 1.72)
3. stressful life events 1.89 (1.30, 2.75) 1.83 (1.25, 2.68)
4. history of depression 5.52 (3.38, 9.01)
WOMeN (n = 1268)
1. Demographic factors
Age 1.00 (0.98, 1.01) 0.99 (0.98, 1.01) 1.00 (0.98, 1.01) 1.00 (0.98, 1.02)
Low education level 1.80 (1.20, 2.71) 1.81 (1.20, 2.74) 1.81 (1.19, 2.73) 1.93 (1.24, 3.01)
Being single 1.20 (0.85, 1.70) 1.19 (0.83, 1.69) 1.09 (0.76, 1.57) 1.08 (0.75, 1.56)
2. Medical co-morbidities
Cardiovascular disease a 1.01 (0.76, 1.34) 0.99 (0.74, 1.32) 0.98 (0.73, 1.32)
Microvascular disease b 1.29 (0.93, 1.80) 1.28 (0.90, 1.81) 1.29 (0.90, 1.84)
Other chronic conditions c 1.64 (1.24, 2.18) 1.61 (1.21, 2.14) 1.51 (1.12, 2.03)
3. stressful life events 1.93 (1.44, 2.59) 1.90 (1.40, 2.59)
4. history of depression 4.53 (2.95, 6.95)
Values are OR (95% CI) 
a Myocardial infarction, bypass / angioplasty, stroke and / or arterial disease; b Retinopathy and / or micro- / 
macroalbuminuria; c Kidney disease, asthma / COPD, cancer, arthrosis and / or rheumatoid arthritis
Model 1: demographic factors; Model 2: model 1 + medical co-morbidities; Model 3: model 2 + stressful life events; 
Model 4: model 3 + history of depression
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esM table 3 Associati on between specifi c medical co-morbiditi es and any depression (adjusted for 
demographics a)
Medical co-morbidity (n = 2460) OR (95% Ci)
Myocardial infarcti on 1.30 (0.91, 1.84)
Bypass / angioplasty 1.35 (0.99, 1.85)
Stroke 1.29 (0.86, 1.92)
Arterial disease 1.12 (0.88, 1.44)
Reti nopathy 1.26 (0.67, 2.37)
Micro- / macroalbuminuria 1.24 (0.97, 1.59)
Kidney disease 0.89 (0.48, 1.65)
Asthma / COPD 1.24 (0.93, 1.67)
Cancer 0.96 (0.67, 1.38)
Arthrosis 1.57 (1.26, 1.96)
Rheumatoid arthriti s 1.57 (1.04, 2.39)
a Sex, age, educati onal level and marital status
esM table 4 Multi variate logisti c regression analysis predicti ng incident depression by baseline 
demographic factors, medical co-morbiditi es, stressful life events and self-reported history of 
depression (range n = 2131 – 2156)
Model 1 Model 2 Model 3 Model 4
1. Demographic factors
Female sex 1.65 (1.23, 2.21) 1.69 (1.25, 2.29) 1.68 (1.24, 2.27) 1.63 (1.20, 2.21)
Age 1.01 (0.99, 1.02) 1.00 (0.99, 1.02) 1.01 (0.99, 1.02) 1.01 (0.99, 1.03)
Low educati on level 1.57 (1.10, 2.26) 1.55 (1.08, 2.23) 1.56 (1.08, 2.26) 1.62 (1.12, 2.36)
Being single 1.13 (0.80, 1.59) 1.13 (0.80, 1.59) 1.10 (0.78, 1.55) 1.09 (0.77, 1.54)
2. Medical co-morbiditi es
Cardiovascular disease a 1.11 (0.80, 1.52) 1.10 (0.80, 1.51) 1.10 (0.80, 1.51)
Microvascular disease b 1.32 (0.91, 1.93) 1.32 (0.90, 1.92) 1.33 (0.91, 1.95)
Other chronic conditi ons c 1.32 (0.96, 1.81) 1.30 (0.95, 1.78) 1.25 (0.91, 1.72)
3. stressful life events 1.30 (0.93, 1.82) 1.30 (0.92, 1.83)
4. history of depression 3.27 (2.05, 5.22)
Values are OR (95% CI) 
a Myocardial infarcti on, bypass / angioplasty, stroke and / or arterial disease; b Reti nopathy and / or micro- / 
macroalbuminuria; c Kidney disease, asthma / COPD, cancer, arthrosis and / or rheumatoid arthriti s
Model 1: demographic factors; Model 2: model 1 + medical co-morbiditi es; Model 3: model 2 + stressful life events; 
Model 4: model 3 + history of depression
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esM table 5 Multivariate logistic regression analysis predicting recurrent / persistent depression by 
baseline demographic factors, medical co-morbidities, stressful life events and self-reported history of 
depression (range n = 304 – 329)
Model 1 Model 2 Model 3 Model 4
1. Demographic factors
Female sex 1.43 (0.80, 2.55) 1.40 (0.77, 2.53) 1.39 (0.77, 2.51) 1.36 (0.74, 2.50)
Age 1.00 (0.97, 1.03) 0.99 (0.96, 1.02) 1.00 (0.96, 1.03) 1.00 (0.97, 1.03)
Low education level 1.28 (0.64, 2.56) 1.28 (0.63, 2.57) 1.25 (0.61, 2.55) 1.30 (0.63, 2.66)
Being single 1.19 (0.66, 2.16) 1.17 (0.64, 2.13) 1.13 (0.61, 2.09) 1.15 (0.61, 2.16)
2. Medical co-morbidities
Cardiovascular disease a 1.15 (0.62, 2.13) 1.14 (0.62, 2.11) 1.10 (0.59, 2.04)
Microvascular disease b 1.03 (0.49, 2.15) 1.03 (0.49, 2.16) 1.01 (0.48, 2.12)
Other chronic conditions c 1.37 (0.71, 2.64) 1.36 (0.70, 2.62) 1.33 (0.68, 2.58)
3. stressful life events 1.26 (0.68, 2.35) 1.26 (0.66, 2.41)
4. history of depression 2.54 (1.23, 5.23)
Values are OR (95% CI) 
a Myocardial infarction, bypass / angioplasty, stroke and / or arterial disease; b Retinopathy and / or micro- / 
macroalbuminuria; c Kidney disease, asthma / COPD, cancer, arthrosis and / or rheumatoid arthritis
Model 1: demographic factors; Model 2: model 1 + medical co-morbidities; Model 3: model 2 + stressful life events; 
Model 4: model 3 + history of depression
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esM table 6 Multi variate logisti c regression analysis predicti ng recurrent / persistent depression by 
baseline demographic factors, medical co-morbiditi es, stressful life events and self-reported history of 
depression, examined separately for men and women
Model 1 Model 2 Model 3 Model 4
MeN (range n = 96 – 111)
1. Demographic factors
Age 1.00 (0.95, 1.06) 1.00 (0.95, 1.05) 1.01 (0.95, 1.06) 1.01 (0.96, 1.07)
Low educati on level 1.96 (0.68, 5.65) 2.00 (0.66, 6.00) 1.79 (0.55, 5.82) 2.04 (0.60, 6.92)
Being single 1.35 (0.44, 4.12) 1.35 (0.42, 4.35) 1.32 (0.40, 4.33) 1.54 (0.43, 5.51)
2. Medical co-morbiditi es  
Cardiovascular disease a 1.71 (0.63, 4.61) 1.73 (0.62, 4.85) 1.55 (0.52, 4.62)
Microvascular disease b 1.01 (0.33, 3.09) 0.94 (0.30, 2.92) 0.85 (0.26, 2.79)
Other chronic conditi ons c 0.77 (0.28, 2.12) 0.71 (0.25, 2.05) 0.65 (0.23, 1.90)
3. stressful life events 1.71 (0.54, 5.35) 1.68 (0.51, 5.51)
4. history of depression 2.76 (0.64, 11.88)
WOMeN (range n = 204 – 226)
1. Demographic factors
Age 0.99 (0.96, 1.03) 0.99 (0.95, 1.03) 0.99 (0.95, 1.03) 1.00 (0.95, 1.04)
Low educati on level 0.88 (0.30, 2.59) 0.90 (0.31, 2.62) 0.91 (0.31, 2.62) 0.90 (0.31, 2.61)
Being single 1.20 (0.55, 2.58) 1.14 (0.51, 2.54) 1.11 (0.49, 2.56) 1.08 (0.45, 2.57)
2. Medical co-morbiditi es
Cardiovascular disease a 0.96 (0.44, 2.06) 0.95 (0.44, 2.04) 0.94 (0.44, 2.02)
Microvascular disease b 0.99 (0.36, 2.73) 1.00 (0.36, 2.75) 1.01 (0.37, 2.79)
Other chronic conditi ons c 1.76 (0.76, 4.06) 1.77 (0.77, 4.10) 1.79 (0.77, 4.19)
3. stressful life events 1.13 (0.52, 2.45) 1.14 (0.51, 2.55)
4. history of depression 2.69 (1.06, 6.82)
Values are OR (95% CI) 
a Myocardial infarcti on, bypass / angioplasty, stroke and / or arterial disease; b Reti nopathy and / or micro- / 
macroalbuminuria; c Kidney disease, asthma / COPD, cancer, arthrosis and / or rheumatoid arthriti s
Model 1: demographic factors; Model 2: model 1 + medical co-morbiditi es; Model 3: model 2 + stressful life events; 
Model 4: model 3 + history of depression

ChAPteR 5
the longitudinal associati on between depressive symptoms 
and initi ati on of insulin therapy in people with 
type 2 diabetes in primary care
Nefs G, Pop V, Denollet J, Pouwer F




Objective: To examine whether depressive symptoms are associated with time to insulin 
initiation in people with type 2 diabetes in primary care.
Research design and methods: 1,389 insulin-naïve people with type 2 diabetes completed 
the Edinburgh Depression Scale (EDS) in 2005 and were followed until: 1) insulin therapy 
was started, 2) death, 3) an oral antihyperglycemic drug (OAD) prescription gap > 1 year, 
4) last OAD prescription in 2010 or 5) the end of the study period (December 31, 2010). 
Cox regression analyses were used to determine whether there was a difference in time 
to insulin initiation between people with a low versus a high depression score at baseline, 
adjusting for potential demographic and clinical confounders, including hbA1c levels. 
Results: The prevalence of depression (EDS ≥ 12) was 12% (n = 168). After a mean follow-up 
of 1,597 ± 537 days, 253 (18%) participants had started insulin therapy. The rate of insulin 
initiation did not differ between depressed and non-depressed participants. People with 
depression were not more likely to start insulin therapy earlier or later than their non-
depressed counterparts (hR = 0.98, 95% CI 0.66 – 1.45), also after adjustment for sex and 
age (hR = 0.95, 0.64 – 1.42). Adding individual candidate confounders to the age- and sex-
adjusted base model did not change the hR by more than 4% and the association remained 
non-significant. Similar results were found for continuous depression scores.
Conclusions: In the present study, depression was not associated with time to insulin 
initiation. The hypothesis that depression is associated with delayed initiation of insulin 
therapy merits more thorough testing, preferably in studies where more information is 
available about patient-, provider- and health care system factors that may influence the 
decision to initiate insulin.
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iNTrODuCTiON
Results from the United Kingdom Prospecti ve Diabetes Study (UKPDS) have shown that 
improved glycemic control can prevent or delay diabetes complicati ons, in parti cular those 
of microvascular origin, in people with type 2 diabetes 1, 2. Since these landmark fi ndings 
were published, opti mal management of blood glucose levels has become one of the top 
prioriti es in diabetes care 3. The management of hyperglycemia in type 2 diabetes oft en 
follows a stepwise strategy, starti ng with diet and exercise recommendati ons and followed 
by the prescripti on of oral agents 3-5. Partly due to progressive loss of beta-cell functi on, 
glycemic control gradually deteriorates over ti me 6 and pharmacological monotherapy 
no longer suffi  ces to att ain target values for hbA1c 
7. Eventually, even treatment with a 
combinati on of oral anti diabeti cs increased to their maximum doses will fail in most people 
and the majority will require insulin therapy 7. Approximately 5 – 10% of people initi ally 
treated with oral anti hyperglycemic therapy switch to insulin on a yearly basis 8. 
Although nati onal and internati onal guidelines and treatment algorithms advocate rapid 
treatment modifi cati ons when target glycemic goals are not achieved or sustained 3-5, 
several studies have shown a delay in insulin initi ati on of up to fi ve years aft er failure of oral 
glucose-lowering agents 9, 10. While provider atti  tudes and aspects of the health system are 
likely to be implicated 11, 12, a reluctance to start insulin therapy has been shown to occur 
in at least one-quarter of insulin-naïve people with type 2 diabetes 13. This phenomenon 
is oft en termed “psychological insulin resistance” and may encompass a range of negati ve 
atti  tudes towards insulin, including weight concerns, needle phobia and the belief that 
initi ati on of insulin therapy signifi es failure to self-manage diabetes 14. 
A factor that might be of parti cular relevance in this context is depression. Comorbid 
depression is present in approximately 20% of people with type 2 diabetes 15 and is 
associated with worse quality of life 16, subopti mal glycemic control 17, an increased risk for 
the development of vascular complicati ons 18, 19 and a higher mortality risk 20. Several recent 
studies have suggested that in insulin-naïve people with type 2 diabetes, higher levels of 
depression are associated with a more negati ve appraisal of insulin therapy 21-23. Depression 
is oft en characterized by fati gue or loss of energy, low self-esteem and a diminished ability 
to think, concentrate or make decisions 24. These moti vati onal aspects may underlie a 
general reluctance to start insulin, which in turn could translate into a later initi ati on of 
insulin therapy 22. however, preliminary results from a small Dutch primary care study (n 
= 152) suggest that people who switch over to insulin therapy due to secondary failure 
more frequently suff er from depression 25. hence, the associati on between depression and 
diffi  culti es with diabetes self-care acti viti es 26, and its ensuing impact on glycemic control 
may be implicated in this process. 
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To our knowledge, the role of depressive symptoms in the timing of insulin therapy has not 
been examined in a large-scale study. Therefore, the primary aim of the present study was 
to establish whether depressive symptoms are associated with time to insulin initiation in 
a sample of people with type 2 diabetes in primary care. In addition, we sought to identify 
demographic and clinical confounders of this relation.
MethODs
Procedure
The DiaDDZoB (Diabetes, Depression, Type D personality Zuidoost-Brabant) Study was 
designed as a prospective cohort study among people with type 2 diabetes in primary care in 
South-East Brabant, The Netherlands 27. A total of 2,460 individuals (82% of those considered 
for study inclusion) participated in the 2005 baseline assessment, consisting of a nurse-
led interview and the completion of a self-report questionnaire. To increase the accuracy 
of prescription data, record linkage was sought with the PhARMO Database Network 
28, a population-based patient-centric data tracking system which started in 1986 that 
includes high quality and complete information of patient demographics, drug dispensings, 
hospitalizations, clinical laboratory, pathology and general practitioner information of 3.2 
million community-dwelling inhabitants of 65 municipal areas in The Netherlands. As both 
the DiaDDZoB and PhARMO databases only contain de-identified patient information, 
record linkage was realized based on the combination of date of birth, sex, first initial, first 
letter of family name, first letter of marital name (women only) and zip code. This procedure 
resulted in successful record linkage for 81% (n=1,982) of the original DiaDDZoB cohort. 
Participants
The present sample (n = 1,389) includes all DiaDDZoB participants for whom linkage with 
the PhARMO Database Network could be realized, who completed at least nine items of 
the EDS during the 2005 baseline assessment, and who had not been prescribed insulin 
in the six-month period leading up to the baseline assessment. These individuals did not 
differ significantly from the rest of the DiaDDZoB cohort (n = 1,071) with respect to sex, 
age, educational level, the presence of chronic co-morbidities (other than cardiovascular 
disease) or body mass index. however, they were somewhat less likely to have a non-Western 
ethnicity (2% vs. 5%, p = 0.001), to be single (23% vs. 29%, p = 0.01), or to have a diabetes 
duration of more than three years (59% vs. 63%, p = 0.02). In addition, they had a slightly 
lower mean hbA1c level (6.7% vs. 6.8%, p = 0.003) and were less likely to have a history of 
cardiovascular disease (33% vs. 39%, p = 0.005), in particular arterial disease (22% vs. 27%, 
p = 0.002), or to have microvascular complications (32% vs. 38%, p = 0.02), which was mainly 
driven by differences in the presence of micro- and / or macroalbuminuria (25% vs. 29%, p = 
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0.03). All 1,389 parti cipants were followed from the baseline assessment in 2005 to the date 
on which insulin was added to the treatment regimen (end point), date of death, date of last 
OAD prescripti on in 2010 or, for those without any prescripti on of oral anti hyperglycemic 
drugs (OADs) during follow-up, the end of the study period (December 31, 2010), whichever 
occurred fi rst. To correct for the possibility that peoples’ OAD prescripti ons might have been 
(temporarily) transferred to a pharmacy not included in the PhARMO registry, individuals 
who were initi ally prescribed OADs but who showed a period of more than twelve months 
without any OAD prescripti on or initi ati on of insulin were censored on the day of the last 
OAD prescripti on before the prescripti on gap. The DiaDDZoB study protocol was approved 
by the medical research ethics committ ee of a local hospital, the Máxima Medical Centre in 
Veldhoven (NL27239.015.09). Writt en informed consent was obtained from all parti cipants. 
The PhARMO compliance committ ee gave permission to establish the link between the 
DiaDDZoB cohort and the PhARMO Database Network. 
Assessment of depression
Symptoms of depression during the last seven days were assessed using a validated Dutch 
version of the Edinburgh Depression Scale (EDS) 29. Originally designed to assess postpartum 
depression 30, this questi onnaire has now been validated in several other (male and female) 
strata, including people with type 2 diabetes from a primary care setti  ng 31. Total EDS scores 
are determined by summing the scores of all ten individual items (four-point scale for each 
item, total score range 0 – 30), with higher scores indicati ng higher levels of depressive 
symptoms. A total score of 12 or more is commonly used to identi fy people with depression 
32. For parti cipants who only completed 9 items, we replaced the missing value with the 
mean of the remaining items before calculati ng the total EDS score.
Anti hyperglycemic medicati on
All dispensed drugs registered in the PhARMO outpati ent pharmacy database are coded 
according to the Anatomical Therapeuti c Chemical Classifi cati on (www.whocc.no). Baseline 
hyperglycemia treatment was determined from dispensing records in the six-month period 
leading up to the baseline assessment and – based on the sample at hand – subdivided into the 
general categories lifestyle recommendati ons only, metf ormin monotherapy, monotherapy 
with an agent from a diff erent OAD class, combinati on of metf ormin and sulfonylurea, other 
combinati on of agents from two OAD classes, and combinati on of metf ormin with agents 
from two or three diff erent OAD classes. We did not diff erenti ate between a switch in OAD 
classes or add-on therapy, but summarized the classes that were used in the six-month 
period. The fi rst appearance of the A10A* code (insulin and analogues) in the dispensing 




Baseline demographics, medical history and clinical values
Information regarding sex, age, ethnicity ([white] western vs. non-[white] western), 
educational level (middle / high vs. low), marital status (having a partner vs. being single) 
and diabetes duration (less than three years vs. three years or more) was obtained during an 
interview with participants by the primary care practice nurse or was part of the questionnaire 
booklet that had to be filled in at home. The primary care practice nurse took a medical 
history, after which all self-reported medical diagnoses were verified through inspection of 
the medical record. The Diagnostic Centre Eindhoven, a primary care diagnostic institute, 
provided results from standard care laboratory tests (hbA1c and albumin levels) and physical 
examinations (body mass index, eye screening). The results from yearly digital fundus 
photography were available to ascertain retinopathy (no / yes), while albumin level in a 
random urine sample was used as a proxy for nephropathy 33. Micro- and macroalbuminuria 
were defined as urine albumin concentrations 20 – 200 and > 200 mg / l, respectively. 
Additional medical co-morbidities included cardiovascular disease (myocardial infarction, 
bypass / angioplasty, stroke and / or arterial disease) and other chronic conditions (kidney 
disease, asthma / chronic obstructive pulmonary disease [COPD], cancer, arthrosis and / or 
rheumatoid arthritis).
statistical analyses
Baseline differences in demographic and clinical characteristics between people with and 
without high depressive symptoms were examined using independent samples t-tests for 
continuous data and X2 tests for categorical data. For both groups, time to insulin initiation 
was visualized by means of Kaplan-Meier curves, using the log-rank test to compare the 
two survival curves. A univariable Cox regression analysis was used to provide an effect size 
for the association between depression and time to insulin initiation, reporting the hazard 
ratio with corresponding 95% confidence interval. The proportional hazards assumption 
was checked by visual inspection of the Kaplan-Meier survival curves, Cox regression with 
a time-dependent covariate and the harrel and Lee test based on the Schoenfeld residuals. 
To evaluate whether the association between depression and time to insulin initiation was 
confounded by specific demographic or clinical factors, we first calculated the percentage 
change in effect size (hR) for depression before and after adjustment for sex, and repeated 
this procedure for age. In a next step, we constructed a sex- and age-adjusted base model 
of the association between depression and time to insulin initiation and examined the 
percentage change in hR when individual candidate confounders were introduced to this 
base model. Meaningful confounding was defined as a more than 5% change in effect size 34. 
All analyses were performed using PASW Statistics version 19 (IBM SPSS Statistics, Somers, 
NY, USA). A p-value < 0.05 was considered to be statistically significant.
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rESuLTS
The total sample consisted of 1,389 parti cipants (50% female), with a mean age of 67 ± 10 
years (range 35 - 91), mostly self-identi fying as (white) western. Overall, parti cipants were 
in relati vely good glycemic control (mean hbA1c 6.7%, 49 mmol / mol), and the majority 
were being treated with lifestyle recommendati ons only (27%), metf ormin monotherapy 
(20%), monotherapy with an agent from a diff erent OAD class (17%; sulfonylurea derivati ve, 
thiazolidinedione or repaglinide), or a combinati on of metf ormin and sulfonylurea 
derivati ve(s) (31%). Co-morbiditi es were common, with vascular disease and other major 
(chronic) medical conditi ons being present in one-third and one-half of all parti cipants, 
respecti vely. Twelve percent (n = 168) had an EDS-score ≥ 12, indicati ng depression. 
Compared with those with an EDS-score < 12, parti cipants with depression were more 
likely to be female, to have a non-western ethnicity, a low educati onal level and no partner. 
Furthermore, their medical history was more likely to include a diagnosis of a chronic medical 
conditi on (other than cardiovascular), in parti cular asthma / COPD and arthrosis (Table 1).
During a mean follow-up period of 1,597 ± 537 days (range 17 – 1,964), 253 (18%) 
parti cipants added insulin to their treatment regimen. The rate of insulin initi ati on did not 
diff er between people with and without high depressive symptoms (17%, n = 28 vs. 18%, 
n = 225; p = 0.58). When examining the Kaplan-Meier curves, we also did not observe a 
diff erence in ti me to insulin initi ati on for both groups (log-rank test X2[1] = 0.01, p = 0.92), 
with a mean ti me to event of 1,783 (95% CI 1,758 – 1,807) and 1,749 (95% CI 1,671 – 1,828) 
for those without and with depression, respecti vely (Figure 1). As only 18% of the total 
sample switched to insulin therapy in the follow-up period, median survival ti mes could not 
be reported. In univariable Cox regression analysis (n = 1,387; two cases censored before 
the earliest event in stratum), we found a non-signifi cant hR of insulin initi ati on (0.98, 95% 
CI 0.66 – 1.45, p = 0.92). 
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Female sex 0 50% (699/1389) 48% (590/1221) 65% (109/168) <0.001
Age, years 0 67 ± 10 67 ± 10 67 ± 10 0.81
Non-western ethnicity 15 2% (30/1374) 2% (20/1207) 6% (10/167) <0.001
Low educational level 65 64% (843/1324) 62% (723/1167) 76% (120/157) <0.001
Being single 15 23% (321/1374) 22% (271/1208) 30% (50/166) 0.03
Medical history
Diabetes duration ≥ 3 years 13 59% (805/1376) 58% (703/1209) 61% (102/167) 0.47
Cardiovascular disease 24 33% (453/1365) 33% (391/1198) 37% (62/167) 0.25
Myocardial infarction 27 11% (153/1362) 11% (135/1195) 11% (18/167) 0.84
Bypass / angioplasty 22 13% (178/1367) 13% (152/1200) 16% (26/167) 0.30
Stroke 21 7% (94/1368) 7% (79/1200) 9% (15/168) 0.26
Arterial disease 29 22% (292/1360) 21% (252/1193) 24% (40/167) 0.40
Microvascular disease 363 32% (332/1026) 32% (286/906) 38% (46/120) 0.14
Retinopathy 368 5% (46/1021) 4% (38/903) 7% (8/118) 0.21
Micro- and / or 
macroalbuminuria
171 25% (301/1218) 24% (261/1072) 27% (40/146) 0.42
Other chronic conditions 17 48% (661/1372) 47% (565/1205) 58% (96/167) 0.01
Kidney disease 30 3% (46/1359) 3% (40/1192) 4% (6/167) 0.87
Asthma / COPD 23 12% (168/1366) 11% (137/1199) 19% (31/167) 0.009
Cancer 27 9% (123/1362) 9% (106/1195) 10% (17/167) 0.58
Arthrosis 17 32% (440/1372) 31% (372/1205) 41% (68/167) 0.01
Rheumatoid arthritis 21 7% (95/1368) 7% (78/1200) 10% (17/168) 0.08
hyperglycemia treatment
Number of OAD classes 0 1 ± 0.8 1 ± 0.8 1 ± 0.8 0.26
Lifestyle only
0
27% (368/1389) 27% (329/1221) 23% (39/168)
0.70
Monotherapy metformin 20% (277/1389) 20% (243/1221) 20% (34/168)
Monotherapy other OAD 
class
17% (238/1389) 17% (208/1221) 18% (30/168)
Metformin + SU derivative(s) 31% (424/1389) 31% (373/1221) 30% (51/168)
Other combination of two 
OAD classes
4% (51/1389) 4% (43/1221) 5% (8/168)
Metformin + two or three 
different OAD classes
2% (31/1389) 2% (25/1221) 4% (6/168)
Clinical values
HbA1c, % (mmol / mol) 21 6.7 ± 0.8 (49 ± 9) 6.7 ± 0.8 (49 ± 9) 6.6 ± 0.8 (49 ± 8) 0.64
Body Mass Index (kg / m2) 105 29 ± 5 29 ± 5 29 ± 5 0.88
Values are mean ± standard deviation, unless otherwise specified; COPD = chronic obstructive pulmonary disease; 
OAD = oral antihyperglycemic drug; SU derivative = sulfonylurea derivative
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Figure 1 Kaplan-Meier curves EDS score < 12 vs. EDS score ≥ 12
To check the assumpti on of proporti onal hazards, we fi rst examined the Kaplain-Meier curves 
for people with and without depression (Figure 1). Although the curve for the depression 
group followed a marginally lower course overall before converging with the non-depressed 
group at the end of follow-up, both lines appeared to converge briefl y at 1000 days. 
Therefore, we conducted a Cox regression with a ti me-dependent covariate (splitti  ng the 
follow-up period in the period before and aft er 1000 days). When added to the unadjusted 
regression model, the interacti on term of this dichotomous ti me indicator and depression 
was not signifi cant (p = 0.25), suggesti ng that the proporti onal hazard assumpti on was not 
violated. The correlati on between the Schoenfeld residuals and ranked survival ti me was 
signifi cant, but marginal in magnitude (r = -0.15, p = 0.01).
In the univariable Cox regression analysis, unadjusted confounding could have obscured 
the associati on between depression and ti me to insulin initi ati on. Therefore, in a next 
step, potenti al demographic and clinical confounders were taken into account. Examined 
separately, neither sex nor age changed the hR of the associati on between depression and 
ti me to insulin initi ati on by more than 2%. Aft er simultaneous adjustment for sex and age, 
the associati on remained non-signifi cant (hR 0.95, 95% CI 0.64 – 1.42, p = 0.81). None of 
the demographic and clinical factors that were introduced individually to the sex- and age 
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adjusted base model changed the strength of the association between depression and time 
to insulin initiation by more than 4% (Table 2). For none of the candidate confounders, 
adjustment produced a statistically significant association between depression and time to 
insulin initiation.
Similar results were found when examining the association between the continuous EDS 
total score and time to insulin initiation, with an unadjusted hR of 1.01 (95% CI 0.98 – 1.03, 
p = 0.68) and a sex- and age adjusted hR of 1.00 (95% CI 0.98 – 1.03, p = 0.81). None of the 
selected demographic and clinical candidate confounders changed the HR by more than 
0.5%, and in all models the association between depressive symptoms and time to insulin 
initiation stayed non-significant.
DiSCuSSiON
In a sample of 1,389 people with type 2 diabetes, depression (defined as a high level of 
depressive symptoms) was not associated with an earlier or later start of insulin therapy over 
a mean follow-up period of 1,597 ± 537 days. After adjustment for potential demographic 
and clinical confounders, including baseline HbA1c levels, people with depression still did not 
differ from their non-depressed counterparts with respect to the time before insulin was 
introduced to their diabetes management.
Although the present study did not find support for an association between depression and 
treatment intensification with insulin, we believe that further examination of this relation 
in other samples is warranted, for several reasons. With respect to the sample at hand, 
relatively few participants (18%) started insulin therapy during the study’s five year follow-
up. This was presumably linked to the fact that, at baseline, most participants had hbA1c levels 
well within the optimal range and one-fourth were managing their blood glucose levels with 
lifestyle recommendations only. Moreover, in the present sample, few participants (12%) 
had elevated depression scores 15, 35. Taking these factors into account, five years of follow-
up might not have been long enough to detect any meaningful differences in time to insulin 
initiation between those with and without depression. 
The management of hyperglycemia in type 2 diabetes can be complex for people with 
diabetes and health care providers alike, as the benefits of optimizing glycemic control 
through treatment intensification need to be balanced with the needs, preferences and 
drug tolerances of each individual person 3-5. Ultimately, the decision to initiate or refrain 
from insulin therapy stems from a combination of individual patient and provider factors 
and characteristics of the health care system, and depression may feed into these processes 
in a myriad number of ways. 
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If depression systematically leads to an earlier start of insulin therapy in some people but 
to later insulin commencement in others, these opposite effects may cancel each other out 
when averaged at the group level. Therefore, it may be hard to characterize the association 
between depression and insulin initiation, without knowing more about the driving factors 
behind these treatment decisions. Furthermore, depression itself is a heterogeneous 
condition, both in terms of severity and subtypes 24. It is possible that there is a relation 
between depression and insulin initiation, but only when certain depression characteristics 
are present, e.g. fatigue or loss of energy, low self-esteem and / or diminished ability to 
think, concentrate or make decisions.
From the patient perspective, we know that at least one in four insulin-naïve people with 
type 2 diabetes is reluctant to start insulin therapy 13 and that this process of psychological 
insulin resistance is associated with the presence of depressive symptoms 21-23. Whether 
there only is a relation with a later start of insulin therapy in those people for whom the 
motivational aspects of depression cause a general reluctance to start insulin, is yet to be 
determined in a prospective study. Importantly, these studies should also clarify the context 
of insulin timing, as a later start can either signify an inappropriate delay of insulin therapy 
or a longer period of optimal glucose control. Although negative appraisals of insulin therapy 
do not by definition lead to a delay of insulin therapy, it would be interesting to see if an 
inappropriate delay of insulin therapy is among the factors that explain why depression is 
a risk factor for adverse outcomes such as the development of vascular complications and 
mortality in people with diabetes 19, 20.
Given its close relation with suboptimal glycemic control 17, depression may also be related 
to an earlier start of insulin therapy. Although time to insulin initiation was not taken into 
account, a small primary care study (n = 152) suggested that people with type 2 diabetes 
switching to insulin therapy were 14-times more likely to have co-morbid depression than 
those individuals who did not start insulin 25. however, the wide 95% confidence interval 
around this estimate (2.7 – 74.9) hints to a relatively small number of individuals with 
depression in this sample and consequently, this study does not allow any firm inferences 
about the association between insulin use and depression. We do know, however, that 
depression is associated with suboptimal medication taking across a range of chronic 
diseases 36 and that problems with self-management appear to figure prominently in 
providers’ considerations when choosing antihyperglycemic medications 11, 37, 38. Perceived 
problems with self-management on the part of the person with diabetes have been identified 
as a significant barrier to insulin initiation for health care providers 37, 38, but providers also 
appear to be more willing to delay insulin initiation if they perceive people with diabetes as 
more adherent to their medication or appointment regimens 11. 
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Consultati on practi ces may also play a role in the relati on between depression and insulin 
initi ati on. Co-morbid depression in diabetes has been associated with increased health 
care use, including a higher number of ambulatory visits 39. As a result of this higher 
contact frequency, physicians may have more opportuniti es to introduce insulin to the 
hyperglycemia treatment of depressed people with diabetes. On the other hand, competi ng 
demands during care contacts may decrease the likelihood of treatment intensifi cati on 40. 
In people with diabetes and co-morbid depression, priority might be given to more urgent 
mood problems. 
Recent guidelines and treatment algorithms emphasize the need for early additi on of insulin 
therapy in people who do not meet target goals, in order to reduce the ti me people are 
exposed to hyperglycemia 3. however, previous work suggests that a substanti al number of 
health providers delay insulin therapy unti l absolutely necessary 11 and there appears to be a 
tendency to postpone insulin treatment if it is possible to add other oral agents 12. Of course, 
there are legiti mate clinical reasons to refrain from initi ati ng insulin therapy, including 
decreased life expectancy and incapacitati ng comorbiditi es 3, 4. Knowing that depression is 
also more common in people with type 2 diabetes who have co-morbid chronic conditi ons 
41, studies examining the associati on between depression and insulin initi ati on should take 
the potenti al confounding role of these co-morbid conditi ons into account. Although we did 
examine medical history in terms of cardiovascular disease, microvascular complicati ons 
and the presence of several non-cardiovascular chronic conditi ons, we were unable to verify 
the burden of these conditi ons at baseline. 
Several additi onal study limitati ons need to be menti oned. First, we used a self-report 
questi onnaire assessing depressive symptoms, while the gold standard for a clinical diagnosis 
of depression is a structured psychiatric diagnosti c interview. In additi on, we only focused 
on baseline depression, while parti cipants’ depression status may have changed over the 
follow-up period. In a similar vein, by only examining the role of baseline hbA1c levels, we 
might have missed clinically relevant changes in average blood glucose levels during follow-
up that could have shed more light on the associati on between depression and insulin 
initi ati on. Second, the exact reason(s) for insulin initi ati on were unknown. In some instances 
insulin is prescribed on a temporary basis, for example in case of corti costeroid use or acute 
illness such as infecti ons 4. By focusing solely on community pharmacy dispensings and not 
including prescripti ons from the (inpati ent) hospital pharmacy during hospital admissions, we 
have tried to cancel out some of this confounding. For people who do initi ate insulin therapy 
during a hospital stay as part of their regular hyperglycemia treatment, prescripti ons will 
be transferred to the community pharmacy once they are discharged, thereby introducing 
only a minor distorti on in insulin therapy start date. Third, we cannot rule out that some 
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participants have used insulin in the past. Although we have excluded all people who were 
prescribed insulin in the six-month period leading up to the baseline assessment, initial 
insulin therapy may have been withdrawn for some obese individuals due to significant 
weight loss before that time. Furthermore, insulin may be the first agent prescribed to newly 
diagnosed individuals with severely uncontrolled diabetes 3, 4. Fourth, our analyses were 
based on pharmacy prescriptions, which may not represent actual medication taking. In 
addition, pharmacy prescriptions only record the start of insulin therapy, and do not provide 
information about the date on which insulin therapy was first offered to a participant. Fifth, it 
is unclear whether the introduction of new blood glucose lowering drugs, such as glucagon-
like peptide-1 receptor agonists, during follow-up may have influenced insulin initiation. 
Finally, we cannot rule out that a small minority of our sample have latent auto-immune 
diabetes of adulthood rather than type 2 diabetes. 
Strengths of the study include the large sample of people with type 2 diabetes from a 
primary care setting, and the detailed medication dispensing data available in the PhARMO 
Database Network. In The Netherlands, the dispensing records of community pharmacies 
generally provide an accurate account of all outpatient drug prescriptions. Missing outpatient 
prescription data (an estimated 5% or less of all outpatient records) are mostly covered 
by dispensings of antibiotics and analgesics from emergency pharmacies. Furthermore, 
Dutch community pharmacies dispense the vast majority of outpatient drug prescriptions 
from both general practitioners and specialists. Therefore, it is unlikely that we would have 
missed the initiation of insulin therapy due to a referral from primary to secondary care.
In sum, the results of the first longitudinal study examining the role of depressive symptoms 
in the timing of insulin therapy showed that depression was not associated with time to 
insulin initiation. Additional studies in other samples, preferable incorporating more 
information about the decision making process behind insulin initiation, are needed to 
further elucidate whether or not depression is associated with initiation of insulin therapy. 
These studies may also explore the role of other psychological or behavioral factors. 
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subopti mal glycemic control in type 2 diabetes: 
a key role for anhedonia?
Nefs G, Pouwer F, Denollet J, Kramer h, Wijnands - van Gent C, Pop V




Recent studies examining the relationship between depression and glycosylated hemoglobin 
(hbA1c) concentrations in patients with type 2 diabetes have yielded mixed findings. One 
explanation may lie in the heterogeneity of depression. Therefore, we examined whether 
distinct features of depression were differentially associated with suboptimal glycemic 
control. Cross-sectional baseline data from a dynamic cohort study of primary care patients 
with type 2 diabetes from the Eindhoven region, The Netherlands, were analyzed. A total of 
5772 individuals completed baseline measurements of demographic, clinical, lifestyle and 
psychological factors between 2005 and 2009. The Edinburgh Depression Scale was used to 
assess symptoms of depressed mood, anhedonia and anxiety. Suboptimal glycemic control 
was defined as hbA1c values ≥ 7%, with 29.8% of the sample (n = 1718) scoring above this 
cut-off. In univariate logistic regression analyses, anhedonia was significantly associated 
with suboptimal glycemic control (OR 1.29, 95% CI 1.09 – 1.52), while both depressed mood 
(OR 1.04, 0.88 – 1.22) and anxiety (OR 0.99, 0.83 – 1.19) were not. The association between 
anhedonia and glycemic control remained after adjustment for the other depression 
measures (OR 1.33, 1.11 – 1.59). Alcohol consumption and physical activity met criteria 
for mediation, but did not attenuate the association between anhedonia and glycemic 
control by more than 5%. Although diabetes duration was identified as a confounder and 
controlled for, the association was still significant (OR 1.20, 1.01 – 1.43).  Studying different 
symptoms of depression, in particular anhedonia, may add to a better understanding of the 
relationship between depression and glycemic control.
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iNTrODuCTiON
Depressive symptoms are common among individuals with type 2 diabetes, aff ecti ng up to 
30% of pati ents 1. A growing number of studies indicate that depressed diabetes pati ents 
are at increased risk for various adverse health outcomes, including the development of 
macro- and microvascular complicati ons and higher mortality rates 2, 3. Findings regarding 
the associati on between depression and glycemic control are less consistent. Although 
a meta-analysis based on 24 cross-secti onal studies published up unti l 1999 concluded 
that depression was signifi cantly associated with higher glycosylated hemoglobin (hbA1c) 
concentrati ons (eff ect size 0.17, 95% CI 0.13 – 0.21) 4, subsequent studies in pati ents with 
type 2 diabetes have yielded mixed results 5. 
One explanati on may lie in the heterogeneity of depression. Rather than encompassing a 
homogeneous conditi on, depression is characterized by a variety of symptoms and subtypes, 
which do not all have to be present in individual pati ents 6. Core characteristi cs range from 
depressed mood (dysphoria) to a loss of interest or pleasure (anhedonia), and additi onal 
symptoms may even include anxiety 7. While dysphoria comprises negati ve emoti ons such 
as feelings of sadness and empti ness, anhedonia is oft en conceptualized as a conditi on in 
which positi ve aff ect is reduced 8. Low positi ve aff ect has been associated with a higher 
risk of cardiovascular conditi ons and mortality in community-dwelling elderly and pati ents 
with established coronary artery disease 9-13 and was found to predict all-cause mortality in 
people with diabetes 14. A small study in older women without diabetes showed an adverse 
eff ect of low positi ve aff ect on hbA1c levels 
15, but this associati on has not been examined in 
pati ents who already have diabetes. 
Therefore, the primary aim of this study was to explore whether the two core features 
of depression – dysphoria and anhedonia – are diff erenti ally associated with subopti mal 
glycemic control. Knowing that anxiety symptoms may fi gure prominently in depression and 
appear to adversely aff ect pati ent outcomes 16, anxiety was included in the analyses as a 
second measure of negati ve aff ect. As the mechanisms behind the associati on between 
emoti onal distress and glycemic control are sti ll unclear but likely include less adequate 
self-care behaviors 17, we also examined the role of body mass index and several health 





The DIAZOB Primary Care Diabetes study is an ongoing dynamic cohort study in primary 
care patients with type 2 diabetes and is conducted in collaboration with over 200 general 
practitioners from the Eindhoven region (The Netherlands). Measurements include the 
annual assessment of a broad range of demographic, medical, lifestyle and psychosocial 
factors and are performed within the framework of the DIAZOB (Diabetes care Zuidoost-
Brabant) standard care project, a diabetes management programme for patients with type 
2 diabetes in which a primary care practice nurse provides regular diabetes care. Within 
DIAZOB, diabetes is diagnosed according to the guidelines of the Dutch College of General 
Practitioners. These criteria are comparable to the current recommendations of the 
American Diabetes Association. A more detailed description of the DIAZOB Primary Care 
Diabetes study and related projects can be found elsewhere 18. The present study includes 
cross-sectional baseline data from 5772 patients with type 2 diabetes who joined DIAZOB 
between April 2005 and January 2009 and had complete data regarding gender, age, hbA1c 
and depressive symptoms. These patients did not differ significantly from those with missing 
depression data (n = 6405) with respect to gender (48.6% versus 50.3% women, p = 0.060), 
but were somewhat older (mean age 66.8 versus 66.4 years, p = 0.045) and had a clinically 
irrelevant, slightly lower mean hbA1c (6.72 versus 6.75, p = 0.044). The study was approved 
by the medical research ethics committee of a local hospital, the Máxima Medical Center 
Veldhoven. Written informed consent was obtained from all participants.
suboptimal glycemic control
Suboptimal glycemic control was defined as hbA1c values ≥ 7%, in line with the Dutch Primary 
Care Guidelines for type 2 diabetes. HbA1c was assessed at the Diagnostic Center Eindhoven 
(a primary care diagnostic laboratory), the Elkerliek hospital Deurne / helmond and the St. 
Anna hospital Geldrop, using ion-exchange high performance liquid chromatography.
Depressive symptoms
Presence of the two key elements of depression (dysphoria, anhedonia) and additional 
symptoms of anxiety during the last seven days was assessed using a validated Dutch version 
of the Edinburgh Depression Scale (EDS) 19. The EDS is a 10-item self-rating scale in which 
each item is scored on a four-point scale, with total scores ranging from 0 to 30 points. Even 
though the EDS was originally designed to assess postpartum depression, later evidence 
showed that it is also valid for use in other (male and female) strata 20-23. It has become clear 
that the EDS actually measures three different symptom dimensions: depressed mood (4 
items: e.g. “I have felt sad or miserable”, “I have been so unhappy that I have been crying”), 
anhedonia (2 items: “I have been able to laugh and see the funny side of things”, “I have 
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looked forward with enjoyment to things”), and anxiety (3 items: e.g. “I have been anxious 
or worried for no good reason”, “I have felt scared or panicky for no very good reason”) 24. In 
the present study, the Cronbach’s alpha of the diff erent subscales was 0.76, 0.78 and 0.70, 
respecti vely. As the previously published cut-off  values of the ten-item EDS (usually ≥ 12) 
20, 21, 23 generally correspond to the upper 90th percenti le score, high scores on its subscales 
were also defi ned using the 90th percenti le cut-off  (depressed mood ≥ 4, anhedonia ≥ 3, 
anxiety ≥ 6) in this study.
Potenti al demographic, clinical and lifestyle-related confounding or mediati ng factors
Informati on regarding age, sex, ethnicity (Caucasian versus non-Caucasian), educati onal 
level (middle/high versus low educati on), diabetes durati on (less than three years versus 
three years or more) and health behaviors was obtained by a nurse-led interview and a 
self-report questi onnaire. Lifestyle factors included smoking status (no versus one or 
more cigarett es / day), alcohol intake (14 or less versus more than 14 drinks / week) and 
physical acti vity as defi ned by hours of “acti ve” (daily acti viti es including gardening, walking, 
climbing stairs) and “sporti ve” acti viti es (e.g., sports, fi tness) per week. Pati ents’ body mass 
index (BMI; weight in kilograms / length in metres2) was derived from standard care physical 
examinati ons. BMI was dichotomized into BMI < 30 versus ≥ 30 kg / m2. Dichotomizati on 
of variables was employed to improve clinical interpretability by allowing a comparison of 
low-medium versus high risk groups based on several Dutch and internati onal health care 
guidelines 25-27.
stati sti cal analyses
A confi rmatory factor analysis was used to examine the fi t of the three factor EDS structure 
(depressed mood, anhedonia, anxiety) to our data. Demographic, clinical and lifestyle 
characteristi cs of pati ents with and without high levels of symptoms on the three subscales 
of the EDS were compared using Χ² tests (dichotomous variables) and independent samples 
t-tests (conti nuous variables). To test whether the EDS subscales were associated with 
subopti mal hbA1c, univariate logisti c regression analyses were performed, followed by a 
multi variate model in which all measures of emoti onal distress were entered simultaneously. 
In case we found a signifi cant associati on between an EDS subscale and hbA1c, several 
candidate confounders or mediators were examined. 
To establish mediati on, selected variables (BMI, smoking, alcohol consumpti on and the 
two measures of physical acti vity) had to meet the four mediati on criteria formulated by 
Baron and Kenny 28. To this end, a series of logisti c regression analyses was conducted. In 
a fi rst step, the independent variable had to be associated with the mediator (regressing 
the candidate mediator on the EDS subscale). Second, the independent variable had to be 
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associated with the dependent variable (as was done in the previously mentioned univariate 
analyses, by regressing glycemic control on the EDS subscales). Third, the mediator had to 
be associated with the dependent variable, after controlling for the independent variable 
(regressing glycemic control on both the mediator and the EDS subscale). Finally, the 
effect of the independent variable on the dependent variable in regression 3 had to be 
smaller than in step two. When a candidate variable met all four criteria, we evaluated 
the plausibility of the mediator by examining the magnitude of the change in a last step. 
To do so, we determined the percentage change in the effect size (odds ratio) of the 
association between the EDS subscale and suboptimal glycemic control before and after 
adjustment for the potential mediator using hierarchical regression analyses, in line with 
the methods used in the Heart and Soul Study 29. If a variable resulted in a more than 5% 
change 29 and fulfilled all four criteria by Baron and Kenny 28, it was marked as a mediator. 
The (Aroian) Sobel method was used as a test of significance for the indirect effect of the 
independent variable on the dependent variable via the mediator 28. As our mediation 
analyses involved a dichotomous outcome variable and candidate mediators, we made the 
regression coefficients comparable across the equations using the computational model by 
Herr 30 before entering coefficients and standard errors into the commonly used Sobel test 
calculation tool by Preacher and Leonardelli 31. however, in light of clinical considerations, a 
significant mediation effect accompanied by a marginal change in effect size (≤ 5%) was not 
taken to signify meaningful mediation.
Variables that did not meet the assumptions for mediation were then evaluated as potential 
confounding factors, along with several other variables (gender, age, ethnicity, education, 
diabetes duration). A variable was considered to meaningfully confound the association 
between an EDS subscale and glycemic control when it changed this association by more 
than 5%, following the previously mentioned statistical procedure by Whooley et al. 29. All 
confounders and mediators fulfilling these criteria were included in a final multivariate 
model.
AMOS 19.0 was used for the confirmatory factor analysis (Amos Development Corporation, 
Meadville, Pennsylvania, USA); all other analyses were performed using PASW Statistics 
17.0 (IBM SPSS Statistics, Somers, New York, USA). For all analyses, a two-tailed P < 0.05 
significance level was adopted. If applicable, 95% confidence intervals were reported.
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rESuLTS
Characteristi cs of the total sample are described in Table 1. The overall sample was in 
relati vely good glycemic control (hbA1c mean 6.72, SD 0.82, range 4.70 – 14.90); however, 
29.8% of pati ents (1718 / 5772) had an hbA1c ≥ 7 %. A confi rmatory factor analysis confi rmed 
adequate fi t of the three factor EDS structure (depressed mood, anhedonia, anxiety) to 
our own data, with X2(24) = 229, p < 0.001 (likely due to the large sample size), RMSEA 
0.04 (90% CI 0.03 – 0.04), CFI = 0.99 and TLI = 0.98. All symptoms of emoti onal distress 
were signifi cantly correlated, with Pearson’s r = 0.53 for depression and anhedonia, 0.60 for 
depression and anxiety and 0.32 for anhedonia and anxiety (all p < 0.001). A high depressed 
mood score was present in 13.7% (793 / 5772), anhedonia in 12.7% (735 / 5772) and anxiety 
in 10.6% (614 / 5772) of the pati ents. While the majority reported symptoms from only one 
category (n = 857), 573 individuals experienced co-morbid emoti onal distress. Compared to 
their counterparts with low emoti onal distress, pati ents with a high depression, anhedonia 
or anxiety score were signifi cantly more likely to be women, to have a low educati onal level 
and to have a higher (conti nuous) BMI score, while they tended to consume fewer alcoholic 
beverages and engaged less in acti viti es requiring mild to moderate physical acti vity (Table 
1). Additi onally, those reporti ng high symptom levels of depressed mood were signifi cantly 
more likely to be non-Caucasian, to have a diabetes durati on of at least three years and 
to smoke. The same signifi cant results were found for those with anhedonia, while these 
pati ents were also slightly older and less likely to be in opti mal glycemic control or to engage 
in sporti ve physical acti viti es. The relati on between anhedonia and BMI was no longer 
signifi cant when BMI values were dichotomized to diff erenti ate obese individuals (BMI ≥ 
30) from those with lower body mass index.
Univariate logisti c regression analyses showed that only anhedonia signifi cantly predicted 
subopti mal hbA1c (OR 1.29, 95% CI 1.09 – 1.52), while both anxiety (OR 0.99, 95% CI 0.83 
– 1.19) and depressed mood (OR 1.04, 95% CI 0.88 – 1.22) did not. The odds rati o for the 
associati on between anhedonia and subopti mal glycemic control increased when using 
higher cut-off  values for subopti mal hbA1c: HbA1c > 7.5%: OR 1.70 (95% CI 1.38 – 2.09), 
HbA1c > 8%: OR 1.57 (95% CI 1.18 – 2.09) and hbA1c > 8.5%: OR 1.72 (95% CI 1.18 – 2.52). 
Anhedonia remained a signifi cant predictor of subopti mal glycemic control (OR 1.33, 95% CI 
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In a next step, potenti al confounding or mediati ng factors of the associati on between 
anhedonia and subopti mal glycemic control were examined. Of the selected candidate 
mediators, only alcohol consumpti on and the two measures of physical acti vity met both 
criterium 1 (anhedonia had to be associated with the mediator) and criterium 3 (the mediator 
had to be associated with glycemic control, adjusted for anhedonia) of the mediati on model 
(Table 2). 
table 2 Criteria 1 and 3 of the mediati on model
n step 1 a P value step 3 b P value
Potenti al mediators
BMI 4722 1.10 (0.92 – 1.31) 0.30 1.28 (1.13 – 1.45) <0.001
Smoking 5709 1.37 (1.11 – 1.69) 0.003 1.06 (0.90 – 1.24) 0.51
High alcohol intake 5667 0.67 (0.47 – 0.95) 0.03 0.76 (0.60 – 0.96) 0.02
Acti ve physical acti vity 5717 0.41 (0.35 – 0.48) <0.001 0.78 (0.69 – 0.89) <0.001
Sporti ve physical acti vity 5665 0.63 (0.53 – 0.74) <0.001 0.82 (0.73 – 0.92) 0.001
a Regressing the mediator on the independent variable (anhedonia); 
b Regressing the dependent variable (hbA1c) on the mediator, controlled for anhedonia
Although the Sobel test was in fact signifi cant for acti ve and sporti ve physical acti vity, none 
of the variables changed the strength of the associati on between anhedonia and subopti mal 
HbA1c by more than 5% (Table 3). Adjustment for acti ve and sporti ve physical acti vity had 
the largest eff ect, reducing the eff ect size by 4.7 and 2.1%, respecti vely. When considering 
potenti al confounding factors, only diabetes durati on changed the eff ect size for anhedonia 
by more than 5% (Table 3). Even though correcti on for diabetes durati on reduced the 
strength of the associati on, anhedonia remained an independent predictor of subopti mal 
glycemic control (OR 1.20, 95% CI 1.01 – 1.43; p = 0.036).
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table 3 Percent change in the strength of the association (OR) between anhedonia and suboptimal 
glycemic control (hbA1c ≥ 7) after adjustment for potential confounders and mediators






Before 0.002 1.289 (1.094 – 1.518) -0.5 -
After 0.003 1.282 (1.088 – 1.511)
Age 5,772
Before 0.002 1.289 (1.094 – 1.518) -0.1 -
After 0.002 1.288 (1.094 – 1.518)
Non-Caucasian 5,719
Before 0.004 1.276 (1.082 – 1.505) -1.2 -
After 0.006 1.261 (1.069 – 1.488)
Low education 5,553
Before 0.007 1.259 (1.064 – 1.489) +0.3 -
After 0.007 1.263 (1.067 – 1.496)
Clinical values
Diabetes duration ≥ 3 years 5,413
Before 0.005 1.274 (1.074 – 1.511) -5.6 -
After 0.036 1.203 (1.012 – 1.431)
POteNtiAL CONFOUNDeRs / MeDiAtORs
Clinical values
BMI (≥ 30) 4,722
Before 0.02 1.247 (1.036 – 1.500) -0.6 0.33
After 0.02 1.240 (1.031 – 1.493)
health behaviors
Smoking 5,709
Before 0.002 1.303 (1.105 – 1.537) -0.2 0.54
After 0.002 1.300 (1.102 – 1.534)
Alcohol intake 5,667
Before 0.003 1.280 (1.085 – 1.510) -0.5 0.13
After 0.004 1.273 (1.079 – 1.502)
Active physical activity 5,717
Before 0.003 1.286 (1.090 – 1.517) -4.7 <0.001
After 0.02 1.226 (1.037 – 1.449)
Sportive physical activity 5,665
Before 0.003 1.290 (1.093 – 1.522) -2.1 0.005
After 0.006 1.263 (1.070 – 1.492)
a Not restricted to the anhedonia data reported in the nested models displayed in the columns to the left, but using 
anhedonia data of total sample (n=5,772)
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DiSCuSSiON
In the present large sample of primary care pati ents with type 2 diabetes, preliminary 
evidence was found that within the spectrum of depression, parti cularly symptoms with an 
emphasis on reduced positi ve aff ect (anhedonia) are associated with subopti mal glycemic 
control, while symptoms focusing on negati ve emoti ons (dysphoria, anxiety) are not. Even 
aft er controlling for these negati ve emoti ons, diabetes pati ents with high levels of anhedonia 
had a 30% increased odds of having an hbA1c ≥ 7. Even though these fi ndings are preliminary, 
they are consistent with the results of a previous study in which positi ve aff ect was identi fi ed 
as an independent inverse correlate of HbA1c levels in older women without diabetes 
15 and 
add to a broader body of literature suggesti ng that (reduced) positi ve aff ect is associated with 
clinical outcomes above and beyond the presence of negati ve emoti ons 9-14.
The associati on between anhedonia and subopti mal glycemic control persisted aft er 
adjustment for potenti al demographic and clinical confounders, although it was somewhat 
att enuated when controlling for diabetes durati on. Moreover, none of the selected health 
behaviors (physical acti vity, smoking, alcohol consumpti on) had a substanti al mediati ng 
eff ect, suggesti ng that other, unmeasured factors may play a mediati ng role. As for 
physiological pathways, previous studies have postulated that the two core elements of 
depression may have disti nct neurochemical correlates, relati ng dysphoria and anhedonia 
to dysfuncti ons of the serotonin and dopamine systems, respecti vely 32. Even though poorly 
understood, dopamine appears to play an important role in the regulati on of glucose 
homeostasis. however, as the acti vati on of dopamine D2-like receptors expressed by 
pancreati c beta cells has been shown to inhibit glucose-sti mulated insulin secreti on 33, it 
is unlikely that the hypofuncti on of the dopaminergic system associated with anhedonia 
32 has a direct hyperglycemic eff ect. An alternati ve mechanism relates to dopaminergic 
involvement in the brain reward system and its ensuing impact on health behaviors. While 
we did not fi nd a noteworthy mediati ng role for smoking, alcohol consumpti on and physical 
acti vity, there are several other diabetes self-care acti viti es closely related to glycemic 
control that were not examined in the present study, including healthy eati ng, medicati on 
taking and self-monitoring of blood glucose levels 34. Eati ng behavior is of special interest to 
future research, as opioid and dopamine neurotransmitt er systems have been implicated in 
reward processes surrounding food consumpti on 35. Consumpti on of palatable foods (e.g. 
high-fat, high-sugar) can improve mood and miti gate the eff ects of stress 35. Anhedonic 
individuals, who by defi niti on have a decreased ability to experience pleasure, may be more 
dependent upon so-called “comfort foods” (rich in fat and carbohydrates) to raise hedonic 
tone 35. Consistent with this hypothesis, anhedonic individuals have been shown to be more 
prone to relapse aft er smoking cessati on, most likely because they are more suscepti ble to 
the eff ects of tobacco deprivati on on hedonic states 36.
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Non-adherence to treatment may represent an important pathway between emotional 
distress and poor diabetes outcomes 17. As anhedonia has been related to dysfunctions 
of the brain reward system and is usually characterized by an impaired responsiveness 
to rewarding stimuli 32, it may be that anhedonic patients are less likely to experience 
satisfaction or pleasure from achieving and maintaining adequate or good glycemic control. 
As a result, one can expect that these patients will be less likely to engage in adequate 
diabetes self-care behaviors. More studies are needed to understand the exact physiological 
and behavioral mechanisms in play.
Several study limitations need to be acknowledged. First, the study’s cross-sectional design 
prohibits any conclusions regarding causality, as anhedonia may also be the result of 
suboptimal glycemic control. Poor metabolic control can directly exacerbate mood symptoms 
or may contribute to patient burden and poor well-being by increasing an individual’s risk 
of developing micro- and macrovascular complications 37, 38. The latter hypothesis may also 
explain why higher diabetes duration was found to attenuate the association between 
anhedonia and glycemic control. Unfortunately, no data were available to examine the 
potential confounding role of medical co-morbidities. Secondly, in the operationalization of 
anhedonia we have mainly focused on the affective component of this construct (reduced 
positive affect), while we have not directly measured its behavioral correlates including 
neglect of pleasurable avocations and social withdrawal 7. Thirdly, we were not able to test 
potential mediation by physiological pathways, although these are likely to be implicated in 
anhedonia’s detrimental effect on health. Fourthly, measuring depressive symptomatology 
by means of a self-report questionnaire could have obscured the association between 
glycemic control and negative affect. A meta-analysis including 11 studies published prior 
to 2002 only found a significant association with hyperglycemia in studies that determined 
anxiety from diagnostic interviews 39, while results for depression also appear to be more 
pronounced when standardized interviews and diagnostic criteria rather than self-report 
questionnaires are used 4. Finally, although the present study is the first to address which 
features of depression are particularly associated with suboptimal glycemic control, 
no information was available regarding concurrent somatic or cognitive symptoms. As 
anhedonia is part of a “melancholic” symptom cluster that also includes diurnal variation of 
mood, early morning awakening, marked psychomotor retardation or agitation, significant 
anorexia or weight loss and excessive or inappropriate guilt 7, future studies examining 
the association between depression and glucose control should also incorporate a focus 
on depression subtypes, including melancholic and atypical depression. While focusing 
on symptom clusters is one way of examining the heterogeneity of depression, the course 
trajectory of these symptoms could be equally relevant for future research, as incident, 
relapsing-remitting and persistent depression subtypes may each be differently associated 
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with health outcomes. Strengths of the present study include the use of a validated measure 
to study the associati ons between disti nctly diff erent features of depression and glycemic 
control, and the inclusion of a large sample of primary care pati ents with type 2 diabetes. 
In conclusion, we found clinical evidence that on a symptom level, anhedonia (or the reduced 
capacity to experience positi ve aff ect) rather than measures of negati ve aff ect appears to be 
associated with subopti mal glycemic control. Studying diff erent symptoms and subtypes of 
depression, in parti cular anhedonia, may add to a bett er understanding of the relati onship 
between depression and glycemic control. A focus on diff erent depressive symptoms 
and subtypes fi ts well with research trends in psychiatry and cardiology, to “dismantle” 
depression into the elements that are adversely aff ecti ng health 40, 41. Prospecti ve studies are 
needed to clarify the directi onal nature of this relati onship and to test mediati on through 
other behavioral or physiological pathways. Given that a substanti al proporti on of depressed 
diabetes pati ents does not benefi t from the current pharmacological and psychotherapeuti c 
treatment modaliti es, future research should also examine whether tailoring depression 
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Depressive symptoms, cardiovascular disease and 
all-cause mortality in people with type 2 diabetes: 
a focus on depression symptom clusters 
and potenti al mechanisms





Background: Depression has been associated with the development of cardiovascular 
disease and all-cause mortality in people with type 2 diabetes. We examined whether 
symptoms related to the two core features of depression – dysphoria and anhedonia – and 
anxiety are differentially associated with these end points and whether there are symptom-
specific behavioral or pathophysiological mechanisms in play.
Methods: 1,465 people completed the Edinburgh Depression Scale (EDS – including 
subscales measuring dysphoria, anhedonia and anxiety) in 2005 and were followed until 
first cardiovascular hospitalization during follow-up, death, or the end of the study period 
(December 31, 2010). Cox regression analyses were used to determine whether there was 
a difference in time to hospitalization for a cardiovascular event or to all-cause mortality 
between people with a low versus a high dysphoria / anhedonia / anxiety score at baseline 
(adjusting for meaningful demographic and clinical confounders) and to identify mediating 
mechanisms.
Results: The prevalence of depression (EDS ≥ 12) was 12% (n = 182). At the end of follow-up, 
191 people had experienced a hospitalization for a cardiovascular event and 139 had died. 
Depression was associated with survival time (adjusted hR = 1.93, 95% CI 1.10 – 3.41), but 
not with time to first cardiovascular hospitalization. Dysphoria predicted a shorter time to 
first cardiovascular hospitalization during follow-up in univariable analysis only (unadjusted 
hR = 1.49, 1.02 – 2.17), while anxiety was associated with a longer time to event in the 
multivariable model (adjusted hR = 0.52, 0.29 – 0.92). Dysphoria and anxiety were not 
associated with survival time. however, at all time points people with anhedonia had an 
almost 2-fold increased risk to die compared to their counterparts without anhedonia, also 
after taking potential confounders into account. Physical activity met criteria for mediation, 
attenuating the hR for anhedonia by approximately 20%.
Conclusions: Symptom-clusters of negative emotions predicted time to first hospitalization 
for a cardiovascular event during follow-up, while symptoms of anhedonia were associated 
with shorter survival time. Mechanistic pathways, in particular physical activity, should be 
explored further.
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iNTrODuCTiON
Depression and diabetes are closely linked, with depression being a risk factor for the 
development of type 2 diabetes and the presence of type 2 diabetes contributi ng to the 
onset of depression 1, 2. The prevalence of depression is signifi cantly higher in people with 
type 2 diabetes compared with those without (18% vs. 10%, OR = 1.6, 95% CI 1.2 – 2.0) 
3. Individuals with previously diagnosed diabetes have an increased risk of depression 
relati ve to those with impaired glucose metabolism or undiagnosed diabetes 4. Moreover, 
depression (defi ned as a high level of depressive symptoms) appeared to be recurrent / 
persistent during a 2.5 year period in 66% of people with diabetes with a high baseline 
depression score 5. 
Importantly, co-morbid depression in diabetes not only poses a signifi cant threat to quality 
of life 6, but is also related to other health outcomes. A recent meta-analysis and systemati c 
review based on 16 longitudinal studies concluded that depression was associated with a 
shorter survival ti me in people with diabetes (hR of all-cause mortality = 1.46, 95% CI 1.29 
– 1.66) 7. Although based on only 5 studies, similar results were found for cardiovascular 
mortality (hR = 1.39, 95% CI = 1.11 – 1.73) 7. A growing number of studies also suggest 
that depression may predict the development of both macrovascular and microvascular 
complicati ons 8-15, with a research emphasis on more advanced conditi ons such as 
myocardial infarcti on, stroke and amputati ons and most studies covering samples from the 
United States of America.
In both psychiatry and cardiology, increased att enti on has focused on the heterogeneity 
of depression and its implicati ons for health 16. Depression is characterized by a range of 
symptoms and diff erent symptom clusters 17. Identi fi cati on of symptom clusters or subtypes 
of depression that are associated with the greatest risk of morbidity and mortality would 
facilitate both risk strati fi cati on in clinical practi ce and the design of eff ecti ve treatments 
18. One potenti ally relevant disti ncti on centers around the two core features of depression, 
namely dysphoria (depressed mood) and anhedonia (loss of interest or pleasure) 19. 
While dysphoria subsumes negati ve emoti ons including feelings of sadness or empti ness, 
anhedonia can be conceptualized as a conditi on in which positi ve aff ect is reduced 20. 
Anhedonia – or low positi ve aff ect – has been shown to predict cardiovascular conditi ons 
and mortality in community-dwelling elderly and people with established heart disease, 
even aft er taking the presence of negati ve emoti ons into account 21-26. Similar results for 
all-cause mortality have been found in people with diabetes using data from the Nati onal 
health and Nutriti on Examinati on Study I Epidemiologic Follow-Up Study 27. To date, the 
relati ve importance of anhedonia and dysphoria in predicti ng the development of vascular 
disease has not been studied among people with diabetes.
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In addition, the behavioral or pathophysiological pathways through which depression 
increases the risk of vascular morbidity and mortality remain unclear. Candidate mechanisms 
include suboptimal self-care behaviors and other (cardio)vascular risk factors such as 
obesity, hyperglycemia, hypertension, and high cholesterol 28-31. Which factors may underlie 
the development of cardiovascular disease in depressed people with diabetes and whether 
there are symptom-specific mechanisms in play is yet to be determined.
The aims of the present study were threefold. First, we examined whether depression was 
associated with hospitalization for cardiovascular disease and all-cause mortality in a large 
cohort of people with type 2 diabetes from The Netherlands. Second, we explored whether the 
two core features of depression – dysphoria and anhedonia – were differentially associated 
with these two end points. Knowing that anxiety symptoms may figure prominently in 
depression and appear to adversely affect patient outcomes 32, anxiety was included in the 
analyses as another measure of negative affect. Where previous studies have mainly focused 
on advanced diabetes complications, we have also included “milder” conditions, such as 
angina pectoris. Third, in case of a significant association between depression symptom 
clusters and cardiovascular disease and mortality, we sought to determine which behavioral 
or pathophysiological mechanisms might be involved in mediating any symptom-specific 
association(s) with adverse health outcomes.
MethODs
The DiaDDZoB (Diabetes, Depression, Type D personality Zuidoost-Brabant) Study was 
designed as a prospective cohort study among people with type 2 diabetes from primary 
care practices in South-East Brabant, The Netherlands 33. A total of 2,460 individuals (82% 
of those considered for study inclusion) participated in the 2005 baseline assessment, 
consisting of a nurse-led interview and the completion of a self-report questionnaire. To 
increase the accuracy of cardiovascular diagnoses and mortality records, record linkage was 
sought with the PhARMO Database Network 34, a population-based patient-centric data 
tracking system which started in 1986 that includes high quality and complete information 
of patient demographics, drug dispensings, hospitalizations, clinical laboratory, pathology 
and general practitioner information of 3.2 million community-dwelling inhabitants of 
65 municipal areas in The Netherlands. As both the DiaDDZoB and PhARMO databases 
only contain deidentified patient information, record linkage was realized based on the 
combination of date of birth, sex, first initial, first letter of family name, first letter of marital 
name (women only) and zip code. This procedure resulted in successful record linkage for 
81% (n = 1,982) of the original DiaDDZoB cohort. 
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The present sample (n = 1,465) includes all DiaDDZoB parti cipants for whom linkage with the 
PhARMO Database Network could be realized and who completed at least nine items of the 
EDS during the 2005 baseline assessment. These people did not diff er signifi cantly from the 
rest of the DiaDDZoB cohort (n = 995) with respect to sex, age, educati onal level, the presence 
of microvascular complicati ons, diabetes durati on, hbA1c and fasti ng glucose, body mass index, 
hDL cholesterol, systolic and diastolic blood pressure, ti me spent in acti viti es requiring mild to 
moderate physical acti vity, or alcohol consumpti on. however, they were somewhat less likely 
to have a non-western ethnicity (2% vs. 5%, p = 0.001), to be single (24% vs. 30%, p = 0.02), to 
engage in sporti ve physical acti vity (32% vs. 28%, p = 0.03), to smoke (14% vs. 19%, p = 0.003), 
to have kidney disease (3% vs. 5%, p = 0.047), or to have a history of cardiovascular disease 
(33% vs. 39%, p = 0.003), in parti cular arterial disease (21% vs. 28%, p < 0.001). In additi on, 
they had slightly lower mean levels of total cholesterol (4.5 vs. 4.7 mmol / l, p = 0.003) and LDL 
cholesterol (2.6 vs 2.7 mmol / l, p = 0.006). In the analyses relati ng to cardiovascular disease, 
parti cipants were followed from the baseline assessment in 2005 to the date of the fi rst 
cardiovascular hospitalizati on during follow-up, date of death, or the end of the study period 
(December 31, 2010), whichever occurred fi rst. As for all-cause mortality, follow-up extended 
to either date of death or the end of the study period (December 31, 2010). The DiaDDZoB 
study protocol was approved by the medical research ethics committ ee of a local hospital, 
the Máxima Medical Centre in Veldhoven (NL27239.015.09). Writt en informed consent was 
obtained from all parti cipants. The PhARMO compliance committ ee gave permission to 
establish the link between the DiaDDZoB cohort and the PhARMO Database Network. 
Assessment of depression
Symptoms of depression during the last seven days were assessed using the Dutch version of 
the Edinburgh Depression Scale (EDS) 35. Originally designed to assess postpartum depression 
36, this questi onnaire has now been validated in several other (male and female) strata, 
including people with type 2 diabetes in primary care 37. Total EDS scores are determined by 
summing the scores of all ten individual items (four-point scale for each item, total score range 
0 – 30), with higher scores indicati ng higher levels of depressive symptoms. A total score of 
12 or more is commonly used to identi fy people with depression 38. In the present study, total 
EDS scores were only calculated when at least 9 items were completed, replacing the missing 
value with the mean of the remaining items. Three diff erent EDS symptom dimensions have 
been identi fi ed: depressed mood or dysphoria (4 items; e.g. “I have felt sad or miserable”), 
anhedonia (2 items; e.g. “I have looked forward with enjoyment to things”), and anxiety (3 
items; e.g. “I have been anxious or worried for no good reason”) 39. In the present study, 
Cronbach’s alpha for the subscales was 0.72, 0.81 and 0.66, respecti vely. As the cut-off  of 
the ten-item EDS generally corresponds to the upper 90th percenti le score, high scores on its 
subscales were also defi ned using the 90th percenti le cut-off  (dysphoria ≥ 4, anhedonia ≥ 3, 
anxiety ≥ 6) in this study.
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Cardiovascular hospitalization and all-cause mortality
Date of death was established using the PhARMO Database Network and records provided by 
general practitioners / primary care practice nurses participating in the DiaDDZoB Study. The 
first cardiovascular event during follow-up was identified using PhARMO’s hospitalization 
database (Dutch hospital Data: LMR, available at http://www.dutchhospitaldata.nl), 
which includes detailed information concerning the primary (mandatory) and secondary 
(optional) discharge diagnoses, procedures and dates of hospital admission and discharge 
for admissions for more than 24 hours and admissions for less than 24 hours for which a bed 
is required. Descriptions and diagnostic codes (International Classification of Diseases, 9th 
edition) of the conditions that were included in the composite cardiovascular hospitalization 
endpoint can be found in Online Appendix Table 1.
Baseline demographics, medical history, clinical values and health behaviors
Information regarding sex, age, ethnicity ([white] western vs. non-[white] western), 
educational level (middle / high vs. low), marital status (having a partner vs. being single) 
and diabetes duration (less than three years vs. three years or more) was obtained during 
an interview with the person with diabetes by the primary care practice nurse or was part 
of the questionnaire booklet that had to be filled in at home. The primary care practice 
nurse took a medical history, after which all self-reported medical diagnoses were verified 
through inspection of the medical record. hyperglycemia treatment was determined from 
dispensing records in the six-month period leading up to the baseline assessment, using 
the community pharmacy drug dispensing records from the PhARMO Database Network. 
The Diagnostic Centre Eindhoven, a primary care diagnostic institute, provided results from 
standard care laboratory tests (fasting glucose, hbA1c, cholesterol, and albumin levels) and 
physical examinations (blood pressure, body mass index, eye screening). The results from 
yearly digital fundus photopgraphy were available to ascertain retinopathy (no / yes), while 
albumin level in a random urine sample was used as a proxy for nephropathy 40. Micro- 
and macroalbuminuria were defined as urine albumin concentrations 20 – 200 and > 200 
mg / l, respectively. Additional medical co-morbidities included cardiovascular disease 
(myocardial infarction, bypass / angioplasty, stroke and / or arterial disease) and other 
chronic conditions (kidney disease, asthma / chronic obstructive pulmonary disease [COPD], 
cancer, arthrosis and / or rheumatoid arthritis). health behaviors included smoking (no vs. 
one or more cigarettes / day), alcohol intake (≤ 14 vs. > 14 drinks / week), and physical 
activity, defined by hours of “active” (daily activities including gardening, walking, climbing 
stairs) and “sportive” activities (e.g. sports, fitness) per week.
7
DEPRESSIVE SYMPTOMS, CARDIOVASCULAR DISEASE AND ALL-CAUSE MORTALITY
121
stati sti cal analyses
Baseline diff erences in demographics, medical history, clinical characteristi cs and health 
behaviors between people with and without high depressive symptoms were examined using 
independent samples t-tests for conti nuous data and X2 or Fisher’s exact tests for categorical 
data, as appropriate. For both groups, ti me to fi rst hospitalizati on for a cardiovascular 
event during follow-up and survival ti me were visualized by means of Kaplan-Meier curves, 
using the log-rank test to compare the two survival curves. A univariable Cox regression 
analysis was used to provide an eff ect size for the associati on between depression and ti me 
to cardiovascular hospitalizati on / death, reporti ng the hazard rati o with corresponding 
95% confi dence interval. The proporti onal hazards assumpti on was checked by visual 
inspecti on of the Kaplan-Meier survival curves (using Cox regression with a ti me-dependent 
covariate only when these suggested violati on), and the harrel and Lee test based on the 
Schoenfeld residuals. To evaluate whether the associati on between depression and ti me to 
cardiovascular hospitalizati on / all-cause mortality was confounded by specifi c demographic 
or clinical factors, we calculated the percentage change in the regression coeffi  cient for 
depression before and aft er adjustment for individual candidate confounders 41. All variables 
resulti ng in a more than 10% change in the regression coeffi  cient were considered to be 
meaningful confounders 41 and were included in a multi variable-adjusted model. 
For all associati ons that became / remained signifi cant aft er taking confounding factors 
into account, potenti al pathophysiological and behavioral mediators were examined. To 
establish (plausible) mediati on, candidate mediators had to meet the four mediati on criteria 
formulated by Baron and Kenny 42. To this end, a series of linear, logisti c and Cox regression 
analyses were conducted. In a fi rst step, the independent variable had to be associated with 
the mediator (regressing the candidate mediator on depression). Second, the independent 
variable had to be associated with the dependent variable (as was done in the previously 
menti oned univariable Cox regression analysis, by regressing ti me to event on depression). 
Third, the mediator had to be associated with the dependent variable, aft er adjusti ng for 
the independent variable (regressing ti me to event on both the mediator and depression). 
Finally, the eff ect of the independent variable on the dependent variable in regression 3 had 
to be smaller than in step two. When a candidate variable met all four criteria, we evaluated 
the plausibility of the mediator by examining the magnitude of the change in a last step. 
To do so, we determined the percentage change in the eff ect size (hR) of the associati on 
between depression and ti me to event before and aft er adjustment for the potenti al 
mediator 43. If a variable resulted in a more than 5% change 43 and fulfi lled all four criteria 
by Baron and Kenny 42, it was marked as a plausible mediator. We repeated these analyses 
comparing people scoring low vs. high on dysphoria, anhedonia and anxiety, respecti vely. All 
analyses were performed using PASW Stati sti cs version 19 (IBM SPSS Stati sti cs, Somers, NY, 




Baseline demographics, clinical factors and health behaviors of the total sample (n = 1,465) 
are shown in Table 1. Twelve percent (n = 182) had an EDS-score ≥ 12. Compared with 
their non-depressed counterparts, participants with depression were more likely to be 
female, to have a non-western ethnicity, a low educational level and no partner. In addition, 
their medical history was more likely to include a diagnosis of a non-cardiovascular chronic 
medical condition, in particular asthma / COPD, arthrosis and rheumatoid arthritis. With 
respect to health behaviors, they were less likely to engage in activities requiring mild to 
moderate physical activity and more likely to smoke. 
Depression and cardiovascular hospitalization
During a mean follow-up period of 1,762 ± 470 days (range 14 – 1,964), 191 participants 
(13%) were hospitalized for cardiovascular disease. The most common cardiovascular 
hospitalization during follow-up was linked to a cardiac condition, most notably coronary 
atherosclerosis and heart failure (Table 2). No differences were found between people with 
and without depression with respect to the hospitalization rate of cardiovascular disease 
in general or specific diagnoses. When examining the Kaplan-Meier curves, we also did 
not observe a difference in time to first cardiovascular hospitalization during follow-up 
for both groups (log-rank test X2[1] = 0.03, p = 0.86), with a mean time to event of 1,823 
(95% CI 1,800 – 1,845) and 1,815 (95% CI 1,752 – 1,877) days for those without and with 
depression, respectively (Figure 1a). Neither the Kaplan-Meier plots nor the correlation 
between the Schoenfeld residuals and ranked survival time (r = -0.02, p = 0.80) suggested 
violation of the proportional hazards assumption. In univariable Cox regression analysis, the 
hR of a cardiovascular hospitalization was 1.04 (95% CI 0.68 – 1.59, p = 0.86). All selected 
demographical and clinical variables changed the regression coefficient for depression by 
more than 10% (Table 3), but none of these meaningful confounders yielded a significant 
association between depression and time to cardiovascular hospitalization. After 
simultaneous adjustment for all confounding factors in a multivariable model, the hR of 
cardiovascular hospitalization remained non-significant (0.84, 95% CI 0.48 – 1.47, p = 0.54).
Depression and all-cause mortality
At the end of the five-and-a-half year study period (mean follow-up 1,878 ± 306 days, range 
26 – 1,964), there were 114 (9%) deaths in people without depression compared to 25 
deaths (14%) in people with depression (p = 0.04). Depressed individuals had a 1.5 to 2-fold 
increased odds of all-cause mortality, also after adjustment for sex, age and cardiovascular 
disease history (Table 2). The survival curves for both groups also differed significantly (log-
rank test X2(1) = 4.64, p = 0.03), where people with depression had a shorter mean time 
to event than those without depression (1,886, 95% CI 1,870 – 1,902 vs. 1,825, 95% CI 
1,767 – 1,882 days; Figure 1b). Again, the proportional hazards assumption was satisfied 
(correlation between Schoenfeld residuals and ranked survival time r = -0.09, p = 0.30). 
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Female sex 0 51% (743/1465) 49% (622/1283) 67% (121/182) <0.001
Age, years 0 67 ± 10 67 ± 10 67 ± 10 0.88
Non-western ethnicity 17 2% (32/1448) 2% (21/1267) 6% (11/181) <0.001
Low educati onal level 65 64% (889/1400) 62% (757/1229) 77% (132/171) <0.001
Being single 15 24% (342/1450) 23% (287/1270) 31% (55/180) 0.02
Medical history
Cardiovascular disease 26 33% (478/1439) 33% (411/1259) 37% (67/180) 0.22
Myocardial infarcti on 29 11% (160/1436) 11% (139/1255) 12% (21/181) 0.83
Bypass / angioplasty 23 13% (190/1442) 13% (162/1261) 16% (28/181) 0.33
Stroke 23 7% (97/1442) 6% (81/1261) 9% (16/181) 0.23
Arterial disease 31 21% (306/1434) 21% (264/1254) 23% (42/180) 0.49
Microvascular disease 386 33% (358/1079) 32% (308/951) 39% (50/128) 0.13
Reti nopathy 397 5% (54/1068) 5% (46/944) 7% (8/124) 0.45
Micro- and / or 
macroalbuminuria
186 25% (321/1279) 25% (277/1121) 28% (44/158) 0.39
Other chronic conditi ons 18 48% (699/1447) 47% (592/1266) 59% (107/181) 0.002
Kidney disease 31 3% (49/1434) 3% (43/1253) 3% (6/181) 0.94
Asthma / COPD 25 12% (177/1440) 11% (144/1260) 18% (33/180) 0.008
Cancer 29 9% (133/1436) 9% (112/1256) 12% (21/180) 0.23
Arthrosis 19 32% (466/1446) 31% (390/1265) 42% (76/181) 0.003
Rheumatoid arthriti s 22 7% (102/1443) 7% (82/1261) 11% (20/182) 0.03
Clinical values
Hyperglycemia treatment 0 0.16
Lifestyle only 25% (368/1465) 26% (329/1283) 21% (39/182)
Oral agents, without insulin 70% (1021/1465) 70% (892/1283) 71% (129/182)
Insulin (with or without oral 
agents)
5% (76/1465) 5% (62/1283) 8% (14/182)
Diabetes durati on ≥ 3 years 17 60% (870/1448) 60% (756/1268) 63% (114/180) 0.34
HbA1c, % (mmol / mol) 26 6.7 ± 0.8 (50 ± 9) 6.7 ± 0.8 (50 ± 9) 6.7 ± 0.8 (49 ± 9) 0.75
Fasti ng glucose (mmol / l) 26 7.1 ± 1.6 7.2 ± 1.6 7.0 ± 1.5 0.20
Body Mass Index (kg / m2) 116 28.8 ± 4.7 28.8 ± 4.6 29.0 ± 5.0 0.56
Total cholesterol (mmol / l) 60 4.5 ± 1.0 4.5 ± 1.0 4.5 ± 1.1 0.75
LDL cholesterol (mmol / l) 84 2.6 ± 0.8 2.6 ± 0.8 2.5 ± 0.8 0.75
hDL cholesterol (mmol / l) 86 1.2 ± 0.4 1.2 ± 0.4 1.3 ± 0.3 0.75
Systolic blood pressure (mmhg) 59 141.7 ± 18.4 141.9 ± 18.4 140.2 ± 18.1 0.25
Diastolic blood pressure (mmhg) 59 78.1 ± 9.5 78.2 ± 9.4 77.7 ± 9.8 0.55
health behaviors
“Acti ve” physical acti vity 5 85% (1237/1460) 86% (1103/1279) 74% (134/181) <0.001
“Sporti ve” physical acti vity 21 32% (465/1444) 33% (416/1265) 27% (49/179) 0.14
Current smoking 4 14% (211/1461) 14% (174/1280) 20% (37/181) 0.01
Alcohol consumpti on 10 8% (116/1455) 9% (108/1274) 4% (8/181) 0.06














































a. Depression - cardiovascular hospitalization
 Depression - censored

























b. Depression - all-cause mortality
 Depression - censored
 No depression - censored
 Depression
 No depression
Figure 1 Kaplan-Meier curves EDS score < 12 vs. EDS score ≥ 12
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At any given time during the follow-up period, depressed individuals had a 1.6-fold increased 
risk to die compared to their non-depressed counterparts (95% CI 1.04 – 2.47, p = 0.03). 
Although sex and age were identified as meaningful confounders (Table 3), the association 
between depression and survival time remained significant after their individual influences 
were taken into account. however, the association was no longer significant when adjusting 
for educational level (hR = 1.55, 95% CI 0.98 – 2.44, p = 0.06), marital status (hR = 1.54, 95% 
CI 1.00 – 2.38, p = 0.05), the presence of microvascular disease (hR = 1.53, 95% CI 0.89 – 
2.62, p = 0.12) or a history of non-cardiovascular chronic medical conditions (hR = 1.49, 95% 
CI 0.97 – 2.31, p = 0.07). When entering all meaningful confounders at the same time in a 
multivariable Cox regression analysis, depression was significantly associated with survival 
time (hR = 1.93, 95% CI 1.10 – 3.41, p = 0.02).
table 3 Percent change in the regression coefficient for depression in the association with time to 










CVD MORt CVD MORt CVD MORt CVD MORt
Demographics
Female sex +71.1% +17.4% +9.6% +32.6% +9.1% 10.9% -8.4% +34.0%
Age, years +89.5% +11.5% +5.8% +3.7% -14.3% -10.0% -0.8% +11.9%
Low educational level +690.0% -10.8% -18.6% -24.8% -22.8% -7.6% +13.3% -15.0%
Being single +300.0% -12.0% -10.3% -41.9% -11.7% -13.6% 0% -1.1%
Medical history
Cardiovascular disease -69.8% -6.3% -4.7% -11.2% -32.6% -8.3% -8.9% +7.4%
Microvascular disease +361.5% -12.2% -12.8% -34.9% -136.4% -5.7% -4.7% +6.3%
Other chronic conditions -48.8% -15.2% -6.5% -33.6% -2.6% -4.8% +1.6% -9.8%
Diabetes duration ≥ 3 years -100.0% -3.7% -2.3% -8.3% -7.4% -8.0% -1.1% +3.3%
Dysphoria - - - - -56.2% -2.3% +72.5% -22.1%
Anhedonia - - -10.8% -86.1% - - +17.5% -36.4%
Anxiety - - +49.9% -37.1% +24.9% -6.5% - -
Ethnicity was not examined as a potential confouder, as only four people in the non-western group had a 
cardiovascular hospitalization and none died; CVD = hospitalization for cardiovascular disease; MORT = all-cause 
mortality
symptom clusters
All symptom clusters were significantly correlated, with Pearson’s r = 0.54 for dysphoria 
and anhedonia, 0.59 for dysphoria and anxiety and 0.32 for anhedonia and anxiety (all p < 
0.001). A high dysphoria score was present in 13% (n = 188), anhedonia in 12% (n = 170) and 
anxiety in 10% (n = 152) of the participants. While the majority reported symptoms from only 
one category (n = 211), 131 individuals experienced symptoms from two or three clusters. 
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People with a high dysphoria score were signifi cantly more likely to be hospitalized for 
cardiovascular disease, compared to their counterparts with low dysphoria symptoms (Table 
4). Dysphoria remained signifi cantly associated with increased odds of being hospitalized 
for a cardiovascular conditi on aft er adjustment for symptoms of anhedonia and anxiety, 
sex, age and cardiovascular disease history. Although no signifi cant univariable associati on 
was found, anxiety was associated with 0.48-fold decreased odds of cardiovascular 
hospitalizati on in the multi variable model. Anhedonia was the only dimension of depression 
that predicted all-cause mortality, in both unadjusted and adjusted analyses.
Aft er inspecti on of the Kaplan-Meier curves for cardiovascular hospitalizati on and all-cause 
mortality (Figure 2 a – f) and examinati on of the correlati on between the Schoenfeld residuals 
and ranked survival ti me (with r ranging between -0.09 and 0.01, all non-signifi cant), the 
proporti onal hazards assumpti on was verifi ed for all three symptom clusters. There was no 
diff erence in ti me to fi rst cardiovascular hospitalizati on during follow-up between people 
with and without anhedonia or between people with and without anxiety (Figure 2 a, c, 
e), but individuals reporti ng high dysphoria did have a shorter mean ti me to event than 
those without high dysphoria (1,758 [95% CI 1,687 – 1,830] vs. 1,831 [95% CI 1,809 – 1,853] 
days). When adjusti ng for the other two symptom clusters, similar results were found for 
dysphoria (hR = 1.73, 95% CI 1.12 – 2.66, p = 0.01) and anhedonia (hR = 1.15, 95% CI 0.73 
– 1.79, p = 0.55). however, the associati on between anxiety and ti me to cardiovascular 
hospitalizati on became signifi cant (hR = 0.52, 95% CI 0.29 – 0.92, p = 0.03). Aft er adjustment 
for all meaningful confounding factors (Table 3), neither anhedonia (hR = 0.83, 95% CI 0.47 
– 1.48, p = 0.53) nor dysphoria (hR = 1.55, 95% CI 0.91 – 2.64, p = 0.11) were signifi cantly 
associated with ti me to cardiovascular hospitalizati on. Anxiety did remain associated with a 
longer ti me to cardiovascular hospitalizati on (hR = 0.49, 95% CI 0.27 – 0.89, p = 0.02).
With respect to all-cause mortality, only anhedonia was signifi cantly associated with survival 
ti me in univariable analysis (Figure 2 b, d, f). People with a high score on the subscale 
measuring anhedonia had a shorter mean ti me to event (1,823 days, 95% CI 1,763 – 1,882) 
than those with low anhedonia-scores (1,886 days, 95% CI 1,870 – 1,901). Anhedonia 
remained a signifi cant predictor of survival ti me (hR = 1.78, 95% CI 1.11 – 2.84, p = 0.02), 
aft er adjustment for symptoms of anxiety (hR = 1.26, 95% CI 0.74 – 2.15, p = 0.40) and 
dysphoria (hR = 0.96, 95% CI 0.56 – 1.64, p = 0.87). Controlling for meaningful confounding 
factors (Table 3) att enuated the hR for anhedonia only slightly (hR = 1.72, 95% CI 1.11 – 2.65, 
p = 0.02). In these multi variable models, no signifi cant associati on was found for anxiety (hR 
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Mediati ng mechanisms
When examining the associati on between depression (EDS score ≥ 12) and all-cause mortality 
(Table 5), only “acti ve” physical acti vity met both criterion 1 (depression had to be associated 
with the mediator) and criterion 3 (the mediator had to be associated with survival ti me, 
adjusted for depression) of the mediati on model. Adjustment for acti ve physical acti vity 
reduced the strength of the associati on between depression and survival ti me by almost 
15% (adjusted hR = 1.38, 95% CI 0.89 – 2.14, p = 0.15). Additi on of physical acti vity to the 
confounder-adjusted model for depression showed similar results (adjusted hR = 1.58, 95% 
CI 0.89 – 2.82, p = 0.12, reducti on in hR of 18%). With respect to the symptom clusters, none 
of the selected pathophysiological and behavioral factors qualifi ed as a mediator for the 
(adjusted) associati on between anxiety and ti me to cardiovascular hospitalizati on. For the 
associati on between anhedonia and all-cause mortality, both measures of physical acti vity 
met the criteria for mediati on. While acti ve physical acti vity changed the strength of the 
associati on between anhedonia and survival ti me by 23% (adjusted hR = 1.42, 95% CI 0.92 – 
2.20, p = 0.12), adjustment for sporti ve physical acti vity only resulted in a 6% lower and sti ll 
signifi cant hR for anhedonia (1.77, 95% CI 1.15 – 2.71, p = 0.009). Repeati ng the mediati on 
analysis for the confounder-adjusted anhedonia model resulted in a 19% reducti on in eff ect 
size when acti ve physical acti vity was added to the model (hR = 1.41, 95% CI 0.90 – 2.20, p 
= 0.14).
DiSCuSSiON
In a sample of 1,465 people with type 2 diabetes, depression (defi ned as a high level of 
depressive symptoms) was not associated with ti me to cardiovascular hospitalizati on over 
a follow-up period of fi ve-and-a-half years, but did predict survival ti me. Aft er adjustment 
for demographic and clinical confounders, depressed individuals sti ll had an almost 2-fold 
increased risk to die from all-causes at any moment during follow-up compared to their 
non-depressed counterparts. With regard to diff erent symptoms of depression, symptom 
clusters focusing on negati ve emoti ons predicted ti me to fi rst cardiovascular hospitalizati on 
during follow-up. Dysphoria was associated with a shorter ti me to event, but this relati on 
was no longer signifi cant aft er taking confounding factors into account. The presence of 
anxiety symptoms was associated with a longer ti me to event, but only when adjusti ng for 
confounders. Reduced positi ve aff ect (anhedonia) was consistently associated with shorter 
ti me to death of all-causes. Mild to moderate physical acti vity was identi fi ed as a mediati ng 
mechanism in the associati on of depression in general and anhedonia, with survival ti me.
Previous studies have shown that depression is implicated in the onset or progression of 














































a. Dysphoria - cardiovascular hospitalization
 Dysphoria - censored
 No dysphoria - censored
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 No dysphoria
Log-rank test X^2(1) = 4.37, p = 0.04
No dysphoria mean days = 1831 (95% CI 1809 - 1853)
Dysphoria mean days = 1758 (95% CI 1687 - 1830)
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d. Anhedonia - all-cause mortality
 Anhedonia - censored
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 No anhedonia
Log-rank test X^2(1) = 7.79, p = 0.005
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e. xi ty - cardiov scular hospitalization
 xiety - censored
  xiety - censored
 xiety
  xiety
Log-rank test X^2(1) = 1.92, p = 0.17
No anxiety mean days = 1818 (95% CI 1795 - 1840)
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f. Anxiety - all-cause mortality
 Anxiety - censored
 No anxiety - censored
 Anxiety
 No anxiety
Log-rank test X^2(1) = 1.86, p = 0.17
No anxiety mean days = 1882 (95% CI 1866 - 1898)
Anxiety mean days = 1845 (95% CI 1785 - 1904)
Unadjusted HR = 1.40 (95% CI 0.86 - 2.27)
Figure 2 Kaplan-Meier curves low vs. high dysphoria, anhedonia, anxiety
7













































a. Dysphoria - cardiovascular hospitalization
 Dysphoria - censored
 No dysphoria - censored
 Dysphoria
 No dysphoria
Log-rank test X^2(1) = 4.37, p = 0.04
No dysphoria mean days = 1831 (95% CI 1809 - 1853)
Dysphoria mean days = 1758 (95% CI 1687 - 1830)























b. Dysphoria - all-cause mortality
 Dysphoria - censored
 No dysphoria - censored
 Dysphoria
 No dysphoria
Log-rank test X^2(1) = 1.32, p = 0.25
No dysphoria mean days = 1883 (95% CI 1867 - 1899)
Dysphoria mean days = 1845 (95% CI 1793 - 1898)




























































d. Anhedonia - all-cause mortality
 Anhedonia - censored
 No anhedonia - censored
 Anhedonia
 No anhedonia
Log-rank test X^2(1) = 7.79, p = 0.005
No anhedonia mean days = 1886 (95% CI 1870 - 1901)
Anhedonia mean days = 1823 (95% CI 1763 - 1882)








 Anhedonia - censored
 No anhedonia - censored
 Anhedonia
 No anhedonia
 t t   .64,   . 0
 anhed nia mean days = 1826 (95% CI 1804 - 1848)
Anhedonia ean days = 1790 (95  CI 1722 - 1858)
Unadjusted HR = 1.30 (95% CI 0.87 - 1.96)










































e. xi ty - cardiov scular hospitalization
 xiety - censored
  xiety - censored
 xiety
  xiety
Log-rank test X^2(1) = 1.92, p = 0.17
No anxiety mean days = 1818 (95% CI 1795 - 1840)
Anxiety mean days = 1859 (95% CI 1800 - 19 7)























f. Anxiety - all-cause mortality
 Anxiety - censored
 No anxiety - censored
 Anxiety
 No anxiety
Log-rank test X^2(1) = 1.86, p = 0.17
No anxiety mean days = 1882 (95% CI 1866 - 1898)
Anxiety mean days = 1845 (95% CI 1785 - 1904)
Unadjusted HR = 1.40 (95% CI 0.86 - 2.27)












































e. Anxiety - cardiovascular hospitalization
 Anxiety - censored
 No anxiety - censored
 Anxiety
 No anxiety
Log-rank test X^2(1) = 1.92, p = 0.17
No anxiety mean days = 1818 (95% CI 1795 - 1840)
Anxiety mean days = 1859 (95% CI 1800 - 1917)























f. Anxiety - all-cause mortality
 Anxiety - censored
 No anxiety - censored
 Anxiety
 No anxiety
Log-rank test X^2(1) = 1.86, p = 0.17
No anxiety mean days = 1882 (95% CI 1866 - 1898)
Anxiety mean days = 1845 (95% CI 1785 - 1904)
Unadjusted HR = 1.40 (95% CI 0.86 - 2.27)












































a. Dysphoria - cardiovascular hospitalization
 Dysphoria - censored
 No dysphoria - censored
 Dysphoria
 No dysphoria
Log-rank test X^2(1) = 4.37, p = 0.04
No dysphoria mean days = 1831 (95% CI 1809 - 1853)
Dysphoria mean days = 1758 (95% CI 1687 - 1830)























b. Dysphoria - all-cause mortality
 Dysphoria - censored
 No dysphoria - censored
 Dysphoria
 No dysphoria
Log-rank test X^2(1) = 1.32, p = 0.25
No dysphoria mean days = 1883 (95% CI 1867 - 1899)
Dysphoria mean days = 1845 (95% CI 1793 - 1898)




























































d. Anhedonia - all-cause mortality
 Anhedonia - censored
 No anhedonia - censored
 Anhedonia
 No anhedonia
Log-rank test X^2(1) = 7.79, p = 0.005
No anhedonia mean days = 86 (95% CI 1870 - 1901)
Anhedonia mean days = 1823 (95% CI 1763 - 1882)







Anhed nia - censored
anhed nia - censored
Anhed nia
anhed nia
 t t   .64,   . 0
anhed nia mean days = 1826 (95% CI 1804 - 1848)
Anhed nia ean days = 1790 (95  CI 1722 - 1858)











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































While ours is not the first study that did not confirm a positive assocation between 
depression and the development of cardiovascular disease in people with type 2 diabetes 
45, other studies do provide evidence for this link 8, 10. Differences in study population and 
methodology may help to explain some discrepancies in findings. For example, apart from 
diverging length of follow-up and confounder adjustment, we studied a predominantly 
white-western population who were treated in primary care practices and were in relatively 
good health. In addition, we identified cardiovascular events by using diagnostic codes linked 
to hospitalizations, while other studies have relied on medical record review and death 
certificate data 10 or self-report 8.  By relying on hospital data only, we may have missed 
fatal cardiovascular events outside the hospital or cardiovascular events for which hospital 
admission (more than 24 hours or less than 24 hours for which a bed is required) was not 
necessary. Previous work has focused mostly on composite endpoints including advanced 
cardiovascular disease, such as a combination of cardio- and cerebrovacular disease 8, 45 
or a more comprehensive combination of myocardial infarction, stroke, congestive heart 
failure, cardiovascular procedures, revascularization of the lower extremities and deaths 
due to coronary, cerebrovascular, or peripheral arterial disease 10. Apart from these “more 
advanced” events, we also included “milder” diagnoses such as transient ischemic attacks 
and angina pectoris that were serious enough to warrant hospital admission. Using a 
composite end point to capture the development of cardiovascular disease may increase 
the event rate and thus reduce sample size requirements, but can be difficult to interpret 
46. The magnitude of the association may differ markedly across individual components of 
composite cardiovascular outcomes, and results may be misleading if most events belong to 
a certain category 46. The number of people with specific cardiovascular hospitalizations was 
too small to examine the association between depression and specific CVD outcomes, such as 
“acute” and more chronic cardiac conditions, peripheral arterial disease and atherosclerotic 
processes affecting the brain. Preliminary findings from a small study among women with 
diabetes suggested that the development of coronary heart disease was significantly more 
rapid in participants with depression, but depression did not predict the development of 
clinically apparent peripheral or cerebrovascular disease 9. however, these results need to 
be interpreted with caution, as the analyses may have been unstable due to small sample 
sizes and numbers of outcome events 9. A study among more than 300,000 people free of 
cardiovascular disease at baseline concluded that people with type 2 diabetes alone and 
people with major depression alone were at approximately 30% increased risk for MI, while 
people with both type 2 diabetes and major depression were at 82% increased risk for MI 13.
In line with previous studies in the general population 47, people with established heart 
disease 44, and people with diabetes 7, we did see a clear association between depression 
and all-cause mortality, even when confounders such as sex, age and co-morbidities were 
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taken into account. It is hard to interpret these fi ndings, as the cause of death was unknown. 
Premature cardiovascular and microvacular conditi ons represent the most common cause 
of morbidity and mortality in people with diabetes 48, but diabetes is associated with a 
higher risk of death for many diseases, including several specifi c forms of cancer 49. Likewise, 
depression is a risk factor for all major disease-related causes of death 50. While depression 
has been associated with cardiovascular mortality in people with diabetes in some but 
not all studies 7, it may also play a role in deaths not caused by cancer or atheroscleroti c 
cardiovascular disease 51. 
When examining the potenti al role of specifi c symptom clusters (anxiety, anhedonia, and 
dysphoria), only anhedonia was consistently associated with survival ti me, but not with 
ti me to fi rst cardiovascular hospitalizati on during follow-up. Even though these fi ndings 
are preliminary, similar relati ons with all-cause mortality have been found in a community 
sample of older adults 22 and people with diabetes 27, even aft er adjustment for negati ve 
emoti ons. A populati on-based study among older adults also found an inverse associati on 
between positi ve aff ect and the incidence of stroke 21. Research in people with established 
cardiovascular disease also suggests an associati on of anhedonia with adverse clinical 
outcomes 23-25. however, these studies have used composite endpoints including both 
mortality and major adverse cardiac events and therefore, it is hard to disentangle whether 
the associati on with anhedonia holds for mortality only or also for the development of 
cardiovascular disease in these groups. When anhedonia, dysphoria and anxiety were 
considered simultaneously, only the two measures of negati ve aff ect showed an associati on 
with ti me to cardiovascular hospitalizati on. Aft er including meaningful confounders in the 
model, the associati on for dysphoria was no longer signifi cant. Research examining the 
associati on between anxiety and health is scarce. In the present study, anxiety was associated 
with a longer ti me to cardiovascular event, while studies in healthy individuals and people 
with established heart disease have suggested the opposite 52, 53. however, depending on 
the individual, anxiety can either operate as a health-promoti ng factor by increasing the 
number of health visits or as a health-compromising factor by promoti ng more avoidant 
coping strategies 54, 55.
The associati on between depression in general and anhedonia, and subsequent all-cause 
mortality was largely explained by physical inacti vity, in parti cular relati ng to daily acti viti es 
of mild to moderate intensity. Interesti ngly, none of the pathophysiological cardiovascular 
risk factors appeared to play a mediati ng role. Likewise, in the heart and Soul Study, a cohort 
of more than 1,000 people with stable coronary heart disease, the associati on between 
depressive symptoms and a composite cardiovascular outcome measure (heart failure, 
myocardial infarcti on, stroke, transient ischemic att ack and death) was also largely explained 
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by physical activity, while a range of pathophysiological factors (heart rate variability, 
norepinephrine and cortisol excretion, serotonin levels, C-reactive protein level, and levels 
of omega-3 fatty acids) only accounted for a small or negligible part of the association 43. 
Although mediation was not directly tested, the association between depression and adverse 
cardiovascular events – including deaths due to coronary, cerebrovascular, or peripheral 
arterial disease – in people with diabetes was somewhat attenuated after simultaneous 
addition of body mass index, smoking, limited physical activity and hbA1c 
10. While these 
factors appeared to be particularly important in cardiovascular-related mortality among 
persons with diabetes, they did not fully explain the association with all-cause mortality 51. 
Other potential mediating mechanisms – not necessarily restricted to cardiovascular disease 
- may also underlie the link between depression and excess mortality in diabetes 51, including 
other health behaviors such as medication taking and healthy diet and dysregulations of the 
hypothalamic-pituitary-adrenal-axis, sympathetic nervous system and inflammation 51, 56.
Research focusing on the associations between symptom clusters or depression subtypes, 
adverse health outcomes and potential mediating mechanisms is still within its early phases 
57. As for anhedonia, our results suggest that health behaviors – in particular physical 
activity – are an important element of future research and a target of new interventions. By 
definition, people with anhedonia display decreased interest and pleasure 19, elements that 
may tap into motivation for diabetes self-care. Anhedonia has been related to dysfunctions 
of the brain reward system and is usually characterized by an impaired responsiveness 
to rewarding stimuli 58. It may be that anhedonic individuals are less likely to experience 
satisfaction or pleasure from achieving or maintaining optimal diabetes self-management, 
and may therefore be less likely to engage in these self-care behaviors 59. The biological 
correlates of positive affect are only beginning to be described, but pathophysiological 
pathways may include the autonomic nervous system, the hypothalamus-pituitary-adrenal 
axis and the immune system 60. 
Distinguishing between symptoms of dysphoria and anhedonia appears to be a promising 
avenue for future research examining the heterogeneity of depression, but there might be 
more. Although current findings are inconsistent, risk stratification based on persistence 
/ recurrence and timing of onset of depressive symptoms has been marked a promising 
line of research in the field of cardiac psychology 18. In the present study, we focused on 
the predictive power of baseline anhedonia and dysphoria, irrespective of the course 
pattern of these symptoms. It makes sense to expect a greater health risk for those being 
exposed to depression over longer periods of time. however, it is also very well possible 
that depression is a factor predisposing an individual to the onset of vascular complications, 
without being the factor that maintains the development of these conditions once the 
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relevant pathophysiological processes have been acti vated 57. Other potenti ally relevant 
classifi cati ons include “cogniti ve” versus “somati c” symptoms of depression and depression 
subtypes such as melancholic and atypical depression 18, 59.
Apart from those already menti oned, several study limitati ons need to be acknowledged. 
First, dysphoria and anhedonia were derived from a self-report questi onnaire measuring 
depressive symptoms and not based on a diagnosti c psychiatric interview, which is 
considered the gold standard. Second, depressive symptoms and the potenti al behavioral 
and pathophysiological mediati ng factors were measured at the same point in ti me. 
Therefore, we cannot rule out the possibility that depression was caused by these factors or 
that they changed over the follow-up period. Strengths of the study include the large sample 
of people with type 2 diabetes, the longitudinal design, the innovati ve focus on symptom 
clusters within depression, the examinati on of both behavioral and pathophysiological 
candidate mediators, and our policy to examine cardiovascular hospitalizati on and all-cause 
mortality as separate endpoints.
Although both psychotherapeuti c and pharmacological interventi on strategies appear to 
be moderately eff ecti ve in reducing depressive symptoms in people with diabetes 61, 62, 
compelling evidence showing that the risk of vascular events and mortality can be reduced 
by treati ng depression is currently lacking. One randomized controlled trial in depressed 
older adults with diabetes based in primary care suggested that parti cipati on in a depression 
management program was associated with a decreased 5-year mortality risk (adjusted hR = 
0.49, 95% CI 0.24 – 0.98) 63, but this study has been heavily criti cized based on methodological 
grounds 64. Depression interventi on trials in people with established heart disease have not 
led to lower rates of recurrent cardiovascular events or death either 65. 
Our fi ndings add to a growing body of literature demonstrati ng a link between depression 
and adverse outcomes in people with diabetes, and suggest that studying diff erent symptom 
clusters of depression may add to a bett er understanding of the relati onship between 
depression, cardiovascular disease and mortality. In turn, these fi ndings may have important 
implicati ons for clinical practi ce. The treatment studies that have been done have not 
taken into account that depression is a highly heterogeneous conditi on and that diff erent 
symptoms of depression may have diverging eff ects on (diabetes) prognosis. By tailoring 
depression treatment to an individual’s predominant symptom cluster and related risk profi le 
and by directly targeti ng the underlying (vasculo)toxic mechanisms, we might opti mize our 
current treatment protocols and not only improve mood, but also diabetes outcomes. For 
example, preliminary evidence suggests that anti depressants enhancing dopaminergic and 
noradrenergic acti vity may off er a therapeuti c advantage over serotonergic anti depressants 
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in the treatment of symptoms associated with low positive affect 20. In addition, as the 
behavioral correlates of anhedonia include neglect of pleasurable avocations and social 
withdrawal 19, a renewal of interest and pleasure in these activities through behavioral 
activation may be of benefit to daily self-care behavior as well. Interventions that integrate 
efforts to improve diabetes management with strategies aimed at decreasing depressive 
symptoms in people with diabetes and co-morbid depression appear to be most promising 
61, 62.
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Online Appendix table 1 Descriptions and ICD-9 diagnostic codes of all conditions included in the 
composite cardiovascular disease hospitalization end point
Diagnosis iCD-9 code
HEArT
Acute myocardial infarction 410.xx
Intermediate coronary syndrome 411.1
Other acute and subacute forms of ischemic heart 
disease
411.8x
Old myocardial infarction 412
Other and unspecified angina pectoris 413.9
Coronary atherosclerosis 414.0x
Chronic total occlusion of coronary artery 414.2
Coronary atherosclerosis due to lipid rich plaque 414.3
Coronary atherosclerosis due to calcified coronary 
lesion
414.4
Other specified forms of chronic ischemic heart 
disease
414.8
Chronic ischemic heart disease, unspecified 414.9
Heart failure 428.xx
BrAiN
Occlusion and stenosis of precerebral arteries 433.xx
Occlusion of cerebral arteries 434.xx
Transient cerebral ischemia 435.xx
Other and ill-defined cerebrovascular disease 437.0, 437.1
PeRiPheRAL ARteRies (LOWeR eXtReMeties)
Peripheral arterial disease 250.70, 250.72, 440.2x, 440.3x, 440.4, 444.22, 444.81
ChAPteR 8
type D (distressed) personality in primary care pati ents 
with type 2 diabetes: validati on and clinical 
correlates of the Ds14 assessment
Nefs G, Pouwer F, Pop V, Denollet J




Objective: In cardiovascular research, Type D personality (high negative affectivity and social 
inhibition) has been associated with a more than 3-fold increased risk of adverse health 
outcomes. This study examined the validity and clinical correlates of the Type D construct as 
assessed by the Type D Scale-14 (DS14) in type 2 diabetes patients.
Methods: 1553 primary care patients with type 2 diabetes were assessed for demographic, 
clinical, lifestyle and psychological characteristics in 2007. A subgroup (n = 1012) completed 
the DS14 again 1 year later. 
Results: The two-factor model of the Type D construct was confirmed in exploratory and 
confirmatory factor analyses; results were stable across gender. The Negative Affectivity 
(NA) and Social Inhibition (SI) subscales had adequate reliability in both men and women, 
as measured by Cronbach’s alpha (NA = 0.87, SI = 0.83), lambda2 (NA = 0.87 / 0.88, SI = 
0.84), corrected item-total correlations (NA 0.47 – 0.77, SI 0.34 – 0.72) and mean inter-item 
correlations (NA = 0.50 / 0.51, SI = 0.42). One year test-retest reliability using intraclass 
correlation coefficients was 0.64 / 0.63 for NA and 0.73 / 0.65 for SI. Type D and non-Type D 
patients did not differ in vascular history or physiological risk factors, but Type D women had 
a more sedentary lifestyle (p = 0.003). Type D patients experienced less social support and 
more stressful life events, loneliness, and more depressed mood, anhedonia and anxiety (p 
< 0.001 for most variables). These differences were clinically significant (Cohen’s d > 0.60 for 
most variables).
Conclusion: Type D personality can be reliably assessed in primary care patients with type 2 
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iNTrODuCTiON
Premature cardiovascular and microvascular conditi ons represent the most common cause 
of morbidity and mortality in diabetes pati ents, while these individuals are also frequently 
confronted with emoti onal problems, including depression and anxiety 1. Several recent 
meta-analyses have demonstrated that negati ve emoti ons are implicated in the onset 
of cardiovascular conditi ons in healthy subjects 2, 3 and predict adverse cardiac outcomes 
in pati ents with established heart disease 2, 4. Most research has focused on depression, 
with several studies showing that depressed diabetes pati ents are at increased risk for the 
development of micro- and macrovascular complicati ons and mortality as well 5, 6. Less is 
known about the risk imposed by more general forms of psychological distress 7. 
Recently, the Type D or “distressed” personality has emerged as a risk factor for poor 
psychological and medical outcomes in cardiovascular 7 and other 8 pati ent populati ons. Type 
D is defi ned as the combinati on of two stable personality traits, i.e. “Negati ve Aff ecti vity” 
and “Social Inhibiti on”. Individuals with a Type D personality tend to experience negati ve 
emoti ons across ti me and situati ons, but are inclined to inhibit self-expression in order to 
avoid disapproval or rejecti on by others 9. While general negati ve aff ect has been shown to 
contribute to cardiovascular risk 10, social inhibiti on appears to potenti ate the adverse eff ect of 
negati ve emoti ons 11. Type D personality has been associated with a more than 3-fold increased 
risk of adverse events, including myocardial infarcti on, revascularizati on and (cardiac) death 
among individuals with cardiovascular disease 7. Since diabetes is associated with a high risk of 
cardiovascular complicati ons 12, Type D personality might also predict the risk of cardiovascular 
conditi ons in people with diabetes. In other pati ent populati ons, Type D personality has also 
been associated with depression, anxiety and poor mental health 7, 8, and diabetes pati ents 
with Type D personality may also represent a group at high risk for long-term emoti onal 
distress. however, no studies to date have examined the potenti al role of Type D personality 
in pati ents with diabetes.
The Type D scale (DS14) is a brief self-report measure of Type D personality that has been 
shown to possess adequate psychometric properti es in cardiac pati ents 9, 13-16, but has not 
been validated in pati ents with diabetes. Therefore, the primary aim of the present study 
was to examine the validity of the Type D personality construct and its assessment in a 
sample of primary care pati ents with type 2 diabetes. The second aim was to examine the 
clinical correlates of the Type D personality construct in this pati ent populati on. Based on the 
literature, we expected that individuals with Type D personality would be more likely to report 
poor mental health 7, 8, 17 and less likely to engage in adequate self-care acti viti es, parti cularly 
in terms of physical acti vity 18-20. Previous studies reported inconsistent fi ndings with respect 
to traditi onal cardiovascular risk factors. Some studies found that Type D was related to blood 
pressure, cholesterol levels and obesity 18-20, while other studies have failed to establish this 
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association 21, 22.  The third aim was to examine whether the Type D personality model would 
apply across men and women with diabetes 23. Preliminary evidence suggests that there 
might be gender differences with respect to the health correlates of Type D personality 18.
MethOD
Participants
The DiaDDZoB (Diabetes, Depression, Type D personality Zuidoost-Brabant) Study was 
designed as a prospective cohort study among primary care patients with type 2 diabetes 
in South-East Brabant, The Netherlands 24. A total of 2460 patients (82% of those considered 
for study inclusion) participated in the 2005 baseline assessment, consisting of a nurse-led 
interview and the completion of a self-report questionnaire. During follow-up waves in 2007 
(n = 2225) and 2008 (n = 2032), the DS14 was added to the standard assessment battery. 
The present sample includes all participants who completed the 14-item Type D scale (DS14) 
9 during the 2007 follow-up assessment (n = 1553). The study protocol was approved by 
the medical research ethics committee of a local hospital, the Máxima Medical Centre in 
Veldhoven (NL27239.015.09). Written informed consent was obtained from all participants.
type D personality
Type D personality was assessed using the DS14 9, consisting of two seven-item subscales of 
Negative Affectivity (NA) and Social inhibition (SI). The NA dimension comprises three lower-
order traits, including dysphoria (items 4, 7, 13), worry (items 2, 12) and irritability (items 5, 
9). The SI dimension also includes three lower-order traits: discomfort in social interactions 
(items 6, 8, 14), reticence (items 10, 11) and social poise (items 1, 3) 9. Items are scored on a 
five-point rating scale ranging from 0 (“false”) to 4 (“true”) (total score range 0 – 28 for each 
subscale). Individuals who obtain a score of ten or more on both scales are classified as Type 
D 9, with Item Response Theory analyses showing that all items have highest measurement 
precision around this cut-off and that DS14 measurements are equivalent across the general 
population and clinical groups 25. The DS14 has adequate psychometric qualities, is stable 
over time and is independent of mood and health status 9, 13-16, 21, 26. In the present study, a 
total of 1450 participants completed all DS14 items, while an additional 158 patients had 1 
to 13 missing values. The distribution of missing responses was fairly equal across all items, 
ranging from 2% for item 14 “When socializing, I don’t find the right things to talk about” to 
3% for item 5 “I am often irritated”. One exception was the first item of the questionnaire “I 
make contact easily when I meet people”, with only 0.6% not completing this particular item. 
Total scores on the NA and SI subscales were only calculated when at least 6 out of 7 subscale 
items were present. For cases with one missing DS14 item on either the NA or SI subscale, 
the missing value was replaced with the mean of the remaining six subscale items (n = 103), 
resulting in the final sample size of 1553.
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Depression, anhedonia and anxiety
Depressive symptoms during the last 7 days were assessed using the Dutch version of the 
Edinburgh Depression Scale (EDS) 27, a 10-item self-rati ng scale in which each item is scored 
on a four-point scale (total score range 0 – 30, with higher scores indicati ng higher levels of 
depressive symptoms). Total EDS scores were calculated for pati ents completi ng at least 9 
items. The EDS subscales “depressed mood”, “anhedonia” and “anxiety” (four, two and three 
EDS items, respecti vely) 28 were used as separate measures of emoti onal distress.
social support and loneliness
Social support was measured using O’hara’s modifi ed Social Support Scale 29, comprising 
three items ranging from 0 (“no support at all”) to 4 (“extensive support”). A single item was 
used to measure feelings of loneliness in the past 12 months (ranging from 1 “I never felt 
lonely” to 10 “I always felt lonely”). Additi onally, pati ents were asked if they had experienced 
a stressful life event in the previous 12 months (e.g. loss of a loved one, fi nancial problems, 
physical/mental abuse).
Demographic and clinical characteristi cs 
Sex, age, ethnicity, educati on level, marital status, cardiovascular disease history, current 
hyperglycemia treatment, diabetes durati on  and health behaviors were measured during 
an interview with the pati ent by the primary care nurse practi ti oner or were part of the 
questi onnaire booklet that had to be fi lled in at home. The results from standard care 
laboratory tests (including urinary albumin levels, hbA1c, fasti ng glucose, cholesterol) and 
physical examinati ons (blood pressure, body mass index, foot and eye screening) were 
provided by the Diagnosti c Centre Eindhoven, a primary care diagnosti c insti tute 24.
stati sti cal analyses
Sex diff erences in demographic, clinical and psychological characteristi cs in the total sample 
were examined using Χ2 tests (categorical data) and independent samples t-tests (conti nuous 
variables). Following a cross-validati on design, both men (n = 745) and women (n=808) were 
randomly divided in two groups of equal size to create separate samples for an exploratory 
(EFA) and confi rmatory factor analysis (CFA): (A) men EFA (n = 372), (B) men CFA (n = 373), 
(C) women EFA (n = 404), (D) women CFA (n = 404). In groups A and C, exploratory factor 
analysis with principal axis factor extracti on was used to examine the structural validity of 
the DS14. The decision about the number of factors to retain was guided by the eigenvalues 
from the unreduced correlati on matrix, using the Kaiser-Gutt man rule (eigenvalues > 1) and 
scree plot criterion.  As the factors of the DS14 were expected to be moderately correlated 13, 
14, 26, oblique rotati on of the initi al factor soluti on was applied to facilitate interpretati on of 
the factor structure. Items loading > |0.40| on one factor and < |0.30| on any other factor 
aft er rotati on were considered to meet criteria for simple structure 30. 
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In groups B and D, both the factor solution derived from the exploratory factor analysis 
and the previously defined two-factor structure 9 were tested using confirmatory factor 
analysis. Maximum likelihood estimation was employed to estimate all models. Although Χ2 
is frequently used as a goodness-of-fit index to determine overall model fit, this measure 
often leads to an incorrect rejection of model fit in larger samples 30. Therefore, additional fit 
statistics were examined, including the Root Mean Square Error of Approximation (RMSEA, 
90% confidence interval), the comparative fit index (CFI) and the Tucker-Lewis index (TLI). 
Acceptable model fit was defined as RMSEA < 0.08, CFI ≥ 0.90 and TLI ≥ 0.90 30. In all models, 
DS14 factors were allowed to covary; error-terms were correlated based on the previously 
hypothesized lower order constructs of the two DS14 subscales (Online Appendix Figure 1) 9. 
For convenience of data presentation in Table 2, reliability of the DS14 subscales was examined 
using the data of groups A and C (EFA groups), and included Cronbach’s alpha, Guttmans 
lambda2, mean inter-item correlations and corrected item-total correlations. Optimal values 
were ≥ 0.80 for Cronbach’s alpha, 0.20 – 0.50 for mean inter-item correlations and > 0.20 
for item-total correlations 26, 31. To examine the temporal stability of the Negative Affectivity 
and Social Inhibition subscales and Type D status (≥ 10 on both subscales) [9], intraclass 
correlation coefficients using 2-way random effect models and the consistency definition 32, 33 
and X2 tests were calculated. To assess the clinical correlates of Type D personality (defined as 
a score of ≥ 10 on both the Negative Affectivity and Social Inhibition subscale of the DS14 9) in 
the total sample, demographic, clinical, lifestyle and psychological characteristics of patients 
with and without Type D personality were compared using Χ² tests (categorical variables) 
and independent samples t-tests (continuous variables). Cohen’s d was used as an index 
of effect size. AMOS 18.0 was used for the confirmatory factor analyses; all other analyses 
were performed using PASW Statistics 17.0 (IBM SPSS Statistics, Somers, New York). Unless 
otherwise specified, p-values <0.05 were considered statistically significant.
rESuLTS
sample characteristics
The total sample consisted of 1553 patients (48% male), with a mean age of 68.6 ± 10.2 years 
(range 33.8 – 101.5), the majority (98%) was Caucasian. Most patients were treated with 
diet and oral antihyperglycemic agents (n = 1165, 76%) and were in relatively good glycemic 
control (mean hbA1c 6.8 ± 0.8), with a mean diabetes duration of 6.2 ± 4.9 years. Female 
participants were slightly older and were more likely to have a low education, no partner 
and a higher mean BMI (Table 1). Women also reported more loneliness and emotional 
distress (depressed mood, anhedonia and anxiety) and were more likely to have experienced 
a stressful life event during the past year. Microalbuminuria and a history of adverse cardiac 
events were more common in men.
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Age (years) 67.3 (10.0) 69.8 (10.2) <0.001
Non-Caucasian 2.2% (16/735) 2.6% (21/801) 0.69
Low educati onal level 52.6% (319/606) 75.4% (482/639) <0.001
Being single 16.8% (125/743) 36.0% (290/806) <0.001
Medical history
Macrovascular disease
Myocardial infarcti on 16.4% (115/700) 9.1% (69/757) <0.001
Bypass / angioplasty 20.0%(140/701) 10.6% (80/757) <0.001
Stroke 8.6% (60/699) 7.4% (56/756) 0.47
Arterial disease 33.8% (235/695) 32.8% (248/757) 0.71
Angina pectoris 16.2% (112/691) 11.9% (88/740) 0.02
Microvascular disease
Reti nopathy 4.0% (21/520) 3.0% (15/508) 0.44
Neuropathy 23.7% (154/651) 24.1% (162/671)
Ischemia 1.5% (10/651) 0.9% (6/671)
Wounds / ulcers 0.8% (5/651) 0.6% (4/671)
Excessive coldness 1.4% (9/651) 0.3% (2/671) 0.20
Microalbuminuria a 29.4% (151/514) 20.4% (98/480)
Macroalbuminuria b 2.9% (15/514) 2.7% (13/480) 0.004
Clinical values
Hyperglycemia treatment
No treatment 0.4% (3/740) 0.8% (6/800)
Diet only 16.2% (120/740) 13.9% (111/800)
Diet, oral agents 76.4% (565/740) 75.0% (600/800)
Diet, oral agents, insulin 6.5% (48/740) 9.0% (72/800)
Diet, insulin 0.4% (3/740) 1.4% (11/800)
Other 0.1% (1/740) 0.0% (0/800) 0.06
Diabetes durati on (years) 6.2 (4.7) 6.3 (5.0) 0.73
HbA1c (%) 6.7 (0.8) 6.8 (0.8) 0.76
Body Mass Index 28.6 (4.0) 30.5 (5.2) <0.001
Psychological factors
Negati ve Aff ecti vity 5.6 (5.4) 6.5 (5.8) 0.002
Social Inhibiti on 7.6 (5.5) 8.0 (5.7) 0.19
Type D 13.8% (103/745) 19.9% (161/808) 0.002
Total EDS depression score 5.0 (4.4) 6.9 (5.2) <0.001
Depressed mood (EDS) 1.1 (1.5) 1.8 (2.0) <0.001
Anhedonia (EDS) 0.7 (1.3) 1.0 (1.5) 0.001
Anxiety (EDS) 2.4 (1.9) 3.2 (2.1) <0.001
Social support 7.0 (3.8) 7.9 (3.8) <0.001
Loneliness 2.3 (1.9) 2.9 (2.1) <0.001
Stressful life event(s) 26.3% (193/733) 34.2% (271/793) 0.001
All values are mean (standard deviati on), unless otherwise specifi ed. Yates’ Correcti on for Conti nuity was applied 
in the computati on of X2 for all 2 x 2 tables. a Albumin concentrati on of 20 - 200 mg / l; b Albumin concentrati on of 




Both the Kaiser-Meyer-Olkin measure of sampling adequacy (men 0.90, women 0.91) and 
Bartlett’s test of sphericity (p < 0.001) verified the appropriateness of using factor analysis 
in groups A and C. For men, EFA yielded two factors with initial eigenvalue > 1 (5.9 and 1.8, 
respectively), accounting for 42% and 13% of the total item variance. The scree plot also 
indicated a last substantial drop and subsequent leveling of the curve after the second factor, 
justifying the retention of two factors. After rotation, all NA and SI items loaded between 0.48 
and 0.80 on their corresponding factor, with trivial cross-loadings (Table 2). In women, Kaiser’s 
criterion (initial eigenvalues 6.2 and 1.7; 45% and 12% explained variance) and scree plot 
(marked elbow after the second factor) also indicated a two-factor structure. Inspection of 
the factor loadings after rotation (Table 2) confirmed the presence of a “Negative Affectivity” 
and “Social Inhibition” subscale, although item 6 (“I often feel inhibited in social interactions”) 
revealed a significant cross-factor loading (0.44 for NA, 0.38 for SI). 
Confirmatory factor analysis
As the two-factor solution derived from the EFA for men was shown to correspond to the 
DS14 structure described in earlier studies, only the original model was cross-validated using 
CFA in group B. Fit statistics indicated acceptable or close to acceptable fit, X2(66) = 200, p 
< 0.001, RMSEA 0.07, 0.06 – 0.09, CFI = 0.94 and TLI = 0.92. Unstandardized / standardized 
parameter estimates and squared multiple correlations can be found in Online Appendix Table 
1. All freely estimated regression weights and variances (p< 0.001) and the covariances for NA 
/ SI, e2 / e12, e1 / e3 (p < 0.001) and e10 / e11 (p = 0.01) reached statistical significance. Each 
DS14 item loaded strongly on its designated factor, with standardized factor loadings ranging 
from 0.54 to 0.82 for NA and 0.35 to 0.78 for SI. Squared multiple correlations indicated that 
most items were meaningfully related to their respective DS14 factor (R2 range 0.29 – 0.68), 
although explained variance was somewhat lower for item 3 (“I often talk to strangers”; 12%). 
The correlation between the factors “Negative Affectivity” and “Social Inhibition” was 0.62.
In group D (CFA women), both the original two-factor model 9 and an adjusted model based on 
EFA results (exclusion of item 6) were tested. The fit indices of the original two-factor model 
confirmed acceptable fit, with X2(66) = 130, p < 0.001, RMSEA 0.05 (0.04 – 0.06), CFI = 0.97 and 
TLI = 0.96. Although the X2 difference test (X2diff(10) = 19, p = 0.04) indicated a somewhat better 
fit for the adjusted model (deletion of item 6), fit indices were highly similar (RMSEA = 0.05 
(0.04 – 0.06), CFI = 0.97, TLI = 0.96). Therefore, item 6 was retained in the CFA model. Similar 
to the results in group B, statistical significance among the freely estimated unstandardized 
parameters was found for all regression weights and variances in the theoretical model 
(Online Appendix Table 1). In addition to significant results for the covariances between NA / 
SI, e2 / e12, e1 / e3 and e10 / e11 (all p < 0.001), a p value of 0.001 was found for e5 / e9 and 
e8 / e14. With the exception of item 3 (0.20), all standardized factor loadings were high (range 
0.43 – 0.81). Explained variance was promising for the majority of items (R2 range 0.19 – 0.66), 
although the value for item 3 (4%) was considerably lower. “Negative Affectivity” and “Social 
Inhibition” correlated 0.76.
8














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































internal consistency and homogeneity
Reliability estimates for groups A and C were similar to the values found in the total samples 
of men and women (n = 745 and n = 808, respectively; data for total groups not shown). 
Cronbach’s alpha values for both DS14 subscales were high and stable across gender (0.87 
for NA, 0.83 for SI); lambda2 produced identical or only slightly higher values (Table 2). 
All corrected item-total correlations ranged from 0.34 to 0.77 and the mean inter-item 
correlations were within or just above the optimal range of 0.20 – 0.50. Dropping item 6 from 
the Social Inhibition subscale for women slightly lowered Cronbach’s alpha and lambda2 
(0.81 and 0.82, respectively) and overall produced minor changes in the corrected item-
total correlations (range 0.37 – 0.69), but did not change the mean inter-item correlation. 
temporal stability
Of the 1553 patients with valid DS14 data in 2007, 65% (n = 1012; 47% men) completed 
the questionnaire a second time 1 year later. Intraclass correlation coefficients for the DS14 
subscales were 0.64 (95% CI 0.58 – 0.69) and 0.63 (95% CI 0.57 – 0.68) for NA, and 0.73 
(95% CI 0.68 – 0.77) and 0.65 (95% CI 0.60 – 0.69) for SI in men and women, respectively. 
Examination of individual Type D / non-Type D classification revealed that 88% of all male 
patients remained in the same category (n = 39 for Type D, n = 379 for non-Type D). As for 
the women, Type D / non-Type D classification was confirmed 1 year later in 51 and 390 
patients, respectively (82%). 
Clinical correlates of type D personality
A total of 264 patients (17%) were classified as Type D (score of ≥ 10 on both the NA and 
SI subscale), with a higher rate for women than for men (20% vs 14%, p = 0.002). Patients 
with a Type D personality did not differ from their non-Type D counterparts with respect 
to diabetes duration, cardiovascular disease history, current microvascular complications 
or physiological cardiovascular risk factors, including glycemic control, cholesterol and 
blood pressure (Table 3). While there were no significant differences in health behaviors for 
men, women with a Type D personality were significantly less likely to engage in activities 
requiring mild to moderate physical activity (62% versus 74%, p = 0.003; Table 3). 
Concerning psychological functioning, patients with a Type D personality reported more 
loneliness and emotional distress, including symptoms of depressed mood, anhedonia and 
anxiety (Table 3). Type D patients also experienced lower levels of social support, although 
results failed to reach statistical significance in women (p = 0.07). The effect size of the 
difference in psychological functioning between men / women with and without a Type 
D personality was moderate to large (> |0.50|), with the exception of low social support 
(Cohen’s d = 0.32 for men and 0.15 for women; Figure 1). Finally, those with a Type D 
personality were more likely to have experienced a stressful life event in the past year (35% 
versus 25%, p = 0.05 in men; 48% versus 31%, p < 0.001 in women). 
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Figure 1 The eff ect size of the diff erence in psychological functi oning associated with Type D personality 
in men and women
Note. Cohen’s d was calculated using d = (mean variable Type D – mean variable non-Type D) / standard deviati on 
total group. 0.20 = small eff ect, 0.50 = moderate eff ect, 0.80 = large eff ect.
DiSCuSSiON
The present study is the fi rst to evaluate the validity of the Type D construct in pati ents 
with type 2 diabetes. The two-factor model of the DS14 measure was confi rmed in both 
exploratory and confi rmatory factor analyses, with the individual subscales Negati ve 
Aff ecti vity and Social Inhibiti on showing adequate reliability in terms of internal consistency, 
homogeneity and one-year temporal stability.
These fi ndings correspond to the results of previous validati on studies in healthy populati ons 
and populati ons with cardiovascular disorder 9, 13-16, 26. The prevalence of Type D found in our 
sample (17.0%) was relati vely low compared to the rates generally found in pati ents with 
cardiovascular disorders and the general populati on (approximately 20 – 35%), although 
similar esti mates have been reported 7, 17. The only other study examining Type D prevalence 
in diabetes pati ents (33%) was conducted in a younger sample (mean age 60.5) of pati ents 
with more advanced disease as evidenced by the presence of diabeti c foot syndrome 34. 
Our fi nding that Type D personality is strongly related to psychological distress is in line 
with the results from a recent meta-analysis and two systemati c reviews, indicati ng that 
Type D personality is associated with anxiety, depression and other symptoms of poor 
mental health in cardiovascular and non-cardiovascular pati ent groups and individuals 
from the general populati on 7, 8, 17. Even though Type D personality appears to identi fy those 
pati ents who are likely to experience emoti onal problems, Type D personality remains an 
independent predictor of clinical events in cardiovascular pati ents aft er adjustment for co-
occurring symptoms of depression 7.
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One potential mechanism through which Type D might exert a negative influence on 
health includes inadequate self-care behavior. In the present study, women with a Type D 
personality were significantly less likely to engage in day-to-day activities of light to moderate 
intensity. Other studies indicate that individuals with a Type D personality are less likely to 
exercise, follow a healthy diet or adhere to medication regimens than their non-Type D 
counterparts 18-20, 35, 36. Moreover, preliminary evidence suggests that healthy young adults 
and cardiac patients are less likely to get a regular medical checkup or to consult health 
practitioners in case of cardiac symptoms, respectively 35, 37. In addition, social inhibition may 
impede effective communication with health care providers and subsequently hinder the 
detection of health risk behaviors and potentially harmful disease symptoms. 
While these behavioral mechanisms may add to a better understanding of the relation 
between Type D personality and adverse clinical prognosis, postulated differences in 
self-care activities between Type D and non-Type D patients were not reflected in a less 
optimal cardiovascular risk profile in terms of glycemic control, cholesterol levels, blood 
pressure or vascular disease history in the present study. The low prevalence rate (17%) of 
Type D personality found in this sample may be one explanation. As there is no information 
available about the Type D status of non-participants, we cannot rule out the possibility that 
patients with a Type D personality were less inclined to participate. Even though the study’s 
self-report questionnaire was anonymous, the face-to-face interview with the primary care 
nurse practitioner could have been a social situation that was too discomforting for those 
with a Type D personality. A systematic opting-out of study participation by patients with a 
Type D personality could have diluted possible associations with traditional cardiovascular 
risk factors. In addition, this sample was in relatively good health, particularly in terms of 
glycemic control and cholesterol levels, making it more difficult to detect any meaningful 
differences in physical health between those with and without a Type D personality. The 
fact that we did not find any differences in cardiovascular disease history, the presence 
of microvascular conditions or physiological parameters between Type D and non-Type D 
patients does not preclude Type D as a risk marker for poor vascular outcomes in diabetes 
patients, however. Previous work in cardiovascular patients has shown that Type D is not 
confounded by disease severity or traditional physiological cardiovascular risk factors 16, 21, 22, 
suggesting that other pathways may be implicated, including dysfunctions of the autonomic 
nervous system, hypothalamic-pituitary-adrenal axis and immune system 7, 38.
Several methodological study limitations also need to be acknowledged. First, the present 
findings indicate that the DS14 can be administered in its original two-factor format in 
diabetes patients, but not all error covariances in the CFA models reached statistical 
significance. Reverse-wording (items 1 and 3) and very similarly worded items (e.g. item 10 
“I am a closed kind of person” and item 11 “I would rather keep other people at a distance”) 
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are known reasons for correlated errors 30. however, this cannot explain why some other 
closely related items did not covary (e.g. items 4 and 13). Our fi nal RMSEA values (0.07 
for men, 0.05 for women) indicate that more parsimonious soluti ons might be achieved 
when correcti ons are based on post hoc model modifi cati ons, although these should also 
have a theoreti cal justi fi cati on. Second, the one year stability of Type D status was high 
(approximately 85%), but we had no data on temporal changes over shorter or substanti ally 
longer ti me spans. While other studies support the noti on that both the Type D classifi cati on 
and the two separate subscales are stable over periods from 3 weeks up to 18 months 9, 13, 21, 
26, the test-retest reliability of Negati ve Aff ecti vity and Social Inhibiti on in the present study 
was somewhat lower than found in studies with shorter follow-up periods 9, 13, 26. Finally, our 
study only included type 2 diabetes pati ents who were treated in primary care setti  ngs. As 
these pati ents are usually in somewhat bett er glycemic control than outpati ents with type 
2 diabetes and have diff erent demographic and disease characteristi cs than those with type 
1 diabetes, our validati on results might not generalize to the total populati on of diabetes 
pati ents. 
Strengths of our study include the large number of parti cipants that allowed detailed testi ng 
of the psychometric characteristi cs of the DS14, using a cross-validati on design for both 
sexes. Other strong points are the wealth of detailed pati ent informati on that is available and 
the presence of longitudinal data to examine the temporal stability of Type D personality.
In conclusion, the DS14 is a valid and a reliable measure of Type D personality in both male and 
female primary care pati ents with type 2 diabetes mellitus, and is associated with loneliness 
and stressful life events, low social support and symptoms of depression, anhedonia and 
anxiety. As accumulati ng evidence endorses the negati ve impact of Type D personality on 
disease prognosis and psychological functi oning in cardiovascular populati ons 7, prospecti ve 
studies are now warranted to examine whether Type D personality is independently 
associated with adverse health outcomes in pati ents with diabetes as well. The preventi on 
or delay of vascular complicati ons consti tutes the main goal of diabetes treatment, and 
self-care acti viti es in terms of adherence to dietary, exercise and medicati on regimens play 
a crucial role in the successful management of this disease. however, no studies to date 
have addressed the health risks of Type D personality in diabetes populati ons. Although its 
clinical relevance for diabetes pati ents is yet to be determined, the assessment of Type D 
personality poses minimal burden to pati ents. This study shows that the DS14 may serve 
as a screening tool to identi fy those pati ents who require more clinical att enti on due to a 
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Online Appendix Figure 1 Original CFA model with correlated error terms
ChAPteR 9
type D personality, subopti mal health behaviors 
and emoti onal distress in people with diabetes: 
Diabetes MiLes – the Netherlands
Nefs G, Speight J, Pouwer F, Pop V, Bot M, Denollet J




Objective: In cardiovascular research, Type D personality – high negative affectivity (NA) 
and social inhibition (SI) – has been associated with a 2 to 3-fold increased risk of adverse 
prognosis. We examined the differential associations of Type D personality and its two 
constituent components with three potential risk mechanisms in people with diabetes: 
health behaviors, emotional distress and physiological factors.
Methods: 3,314 Dutch individuals with self-reported type 1 or type 2 diabetes completed an 
online survey, including the Type D Scale-14 and several measures of health-related behavior, 
emotional distress and physiological factors (hbA1c, high blood pressure, high cholesterol).
Results: Type D individuals were less likely to follow a healthy diet or to consult health 
professional(s) in case of problems with diabetes management than those scoring high on 
neither or only one component. They also reported more: barriers surrounding medication 
use, diabetes-specific social anxiety, loneliness and symptoms of depression and anxiety. 
The relation between Type D and infrequent exercise appeared to be driven by NA, while 
suboptimal foot inspection was linked to SI. No relevant differences were found with respect 
to other self-care measures or physiological risk factors. In multivariable logistic regression 
analyses, Type D personality was associated with a 2 to 3-fold increased odds of several 
suboptimal health-behaviors and related cognitions and a more than 15-fold increased 
odds of experiencing general emotional distress, after adjustment for demographics, clinical 
variables and the individual Type D components.
Conclusions: Although not specific for diabetes, the joint presence of NA and SI is particularly 
associated with several behavioral and emotional adversities in people with diabetes.
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iNTrODuCTiON 
Several studies have shown that specifi c negati ve emoti ons such as depression and anxiety 
are implicated in the onset or progression of vascular conditi ons in healthy individuals 1, 2, 
people with established heart disease 3, 4 and with type 1 or type 2 diabetes 5, 6. Previous 
research has suggested that a more general dispositi on toward negati ve aff ecti vity (NA) 
may also aff ect cardiovascular outcome 7. This risk appears to be especially pronounced in 
individuals who are also high in social inhibiti on (SI) 8. The combined tendency to experience 
negati ve emoti ons across ti me and situati ons (high NA) and to inhibit self-expression 
when with others (high SI) is termed Type D or “distressed” personality 9. Type D has been 
associated with a two- to three-fold increased risk of adverse health outcomes in people 
with a cardiovascular conditi on, including non-fatal myocardial infarcti on, revascularizati on 
and (cardiac) mortality 10, 11. To date, no studies have examined the health risks of Type D 
personality in people with diabetes, although premature cardiovascular and microvascular 
conditi ons represent the most common cause of morbidity and mortality in this group 12. 
One potenti al mechanism through which Type D personality might exert a negati ve 
infl uence on health includes subopti mal self-care behavior. A growing number of studies 
indicate that healthy individuals and people with a cardiac conditi on who have a Type D 
personality are less likely to exercise, follow a healthy diet or to take medicati on according 
to recommendati ons than their non-Type D counterparts 13-19. Moreover, preliminary 
evidence suggests that those with a Type D personality are less likely to get a regular medical 
checkup or to consult health practi ti oners in case of cardiac symptoms 13, 20. A primary care 
study among over 1,500 people with type 2 diabetes concluded that parti cipants with and 
without Type D personality did not diff er with respect to cardiovascular risk factors, but Type 
D women did have a more sedentary lifestyle 21.
Type D personality has also been associated with anxiety, depression and other indicators 
of subopti mal mental health in people with cardiovascular and non-cardiovascular 
conditi ons and individuals from the general populati on 10, 22, 23. A German study found 
signifi cant correlati ons between the two individual Type D components and measures of 
depression, anxiety and diabetes-related distress in a small group of people with diabeti c 
foot problems 24. In type 2 diabetes, the combinati on of NA and SI has been related to lower 
levels of perceived social support and more: stressful life events, loneliness and symptoms 
of depressed mood, anhedonia and anxiety 21. Type D personality may indirectly increase 
cardiovascular risk through its associati on with these negati ve emoti onal states.
however, it is unclear whether the combinati on of NA and SI is most strongly related to 
these measures or whether associati ons are mainly driven by one Type D component only. 
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Therefore, the aim of the present study was to explore whether Type D personality and its 
two constituent components – NA and SI – are differentially associated with three potential 
cardiovascular risk mechanisms in people with type 1 or type 2 diabetes: health behaviors, 
physiological risk factors and emotional distress. 
MethODs
Data were collected within the framework of Diabetes MILES - The Netherlands, a national 
online cross-sectional observational study among people with diabetes in The Netherlands 
25. Following the example of Diabetes MILES (Management and Impact for Long-term 
Empowerment and Success) - Australia 26, the primary aim of the Dutch study was to 
examine the psychosocial aspects of living with diabetes. In close cooperation with the 
Dutch Diabetes Association (Diabetesvereniging Nederland), all Dutch individuals having 
self-reported diabetes of any type aged ≥ 19 years were given the opportunity to participate 
in the online questionnaire survey in September – October 2011. Of the 4,590 individuals 
who had registered for participation at the study’s website, 3,960 (86%) opened the survey 
web application of whom 84% (n = 3,332) completed the entire survey. The present sample 
included all participants with self-reported type 1 or type 2 diabetes who completed the 
14-item Type D scale (DS14). The study protocol of Diabetes MILES – The Netherlands 
was approved by the Psychological Research Ethics Committee of Tilburg University, The 
Netherlands (EC-2011 5). As the study was web-based, digital informed consent was 
obtained from all participants.
Demographic and clinical characteristics
Self-reported demographic and clinical characteristics included sex, age, ethnic background, 
educational level, marital status, type of diabetes, diabetes duration, current hyperglycemia 
treatment, and physician diagnosed micro- and macrovascular complications. Participants 
were also asked to indicate whether a physician had diagnosed them with high blood 
pressure or high cholesterol. In addition, they had to specify their most recent hbA1c and 
their height / weight in order to calculate their Body Mass Index (BMI).
type D personality
Type D personality was assessed using the DS14 9, consisting of two seven-item subscales 
measuring NA and SI. Items are scored on a five-point rating scale ranging from 0 (“false”) 
to 4 (“true”), with total subscale scores between 0 – 28. Individuals scoring ten or more 
on both scales are classified as having Type D personality 9. The DS14 has been shown to 
possess adequate psychometric properties in several populations, including people with 
type 2 diabetes 9, 21.
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health behaviors
Diabetes-related self-care was examined using the Diabetes Self Care Inventory-Revised, a 
newly designed questi onnaire covering the frequency of a broad range of diabetes self-care 
acti viti es 25, 26. Topics included taking the required number of insulin injecti ons, adjusti ng 
insulin dosage / units for special occasions, taking the prescribed number of tablets to lower 
blood glucose level / cholesterol / blood pressure, following a healthy diet, meeti ng the 
nati onal norm for healthy exercise (all measured using a Likert-scale ranging from 0 “Never” 
to 4 “[Almost] always”), monitoring of blood glucose levels, inspecti on of feet (ti mes per 
week), and whether individuals were trying to achieve or maintain a healthy weight (yes 
/ no). In line with Diabetes MILES – Australia, we added smoking behavior to the list. The 
number of alcohol consumpti ons per week was measured using a single questi on.
Barriers to medicati on adherence and adherence-related behavior were assessed using the 
12-item Adherence Starts with Knowledge questi onnaire (ASK-12) 27. Dietary habits were 
measured using a purpose-designed food frequency questi onnaire, asking parti cipants to 
report the number of days per week (measured using a Likert-scale with 0 = 0 days, 1 = 1 – 3 
days, 2 = 4 – 5 days and 3 = 6 – 7 days) they generally consumed specifi c products, including 
≥ 2 pieces of fruit, ≥ 200 grams of vegetables, whole grain products, fatt y fi sh, full-fat milk 
products, full-fat cheese, non-lean meat, fried products, salt and sweets. The Dutch Eati ng 
Behavior Questi onnaire (DEBQ) was used to measure habitual eati ng style, with 13 items 
covering emoti onal eati ng (eati ng in response to emoti onal arousal), 10 items covering 
external eati ng (eati ng in response to external food cues, such as taste and smell) and 10 
items covering restrained eati ng (att empts to refrain from eati ng) 28. Physical acti vity levels 
in the last seven days (expressed as metabolic equivalent of task-minutes / week) were 
assessed using the Internati onal Physical Acti vity Questi onnaire short form (IPAQ-short) 29.
Medical appointment att endance rates were examined by adjusti ng the self-reported 
number of cancelled care appointments with diabetes and non-diabetes specifi c healthcare 
providers in the previous twelve months for the total number of care appointments in this 
period. Consultati on behavior was assessed using ten newly designed questi ons, asking 
parti cipants to rate on a 5-point scale (scored 0 [“Not true”] to 4 [“True”]) how likely it 
was that they would act or feel in a certain way in several scenarios involving contact 
with diabetes health care professional(s). Exploratory factor analysis showed a two-
factor structure (Online Appendix Table 1). Four items appeared to represent subopti mal 
consultati on behavior in case of problems with (the management of) diabetes, while four 
other items seemed to refl ect diabetes-specifi c social anxiety. Based on these fi ndings, we 
created two consultati on behavior subscales by summing the scores on the items concerned 
(total score range 0 – 16), with higher scores indicati ng more subopti mal consultati on 
behavior and more diabetes-specifi c social anxiety, respecti vely.
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General and diabetes-specific emotional distress
Symptoms of depression and anxiety during the previous two weeks were measured using 
the 9-item Patient health Questionnaire (PhQ-9) 30 and the 7-item General Anxiety Disorder 
questionnaire 31, respectively. A single item was used to measure feelings of loneliness in 
the past 12 months (ranging from 1 “I never felt lonely” to 10 “I always felt lonely”). The 20-
item Problem Areas in Diabetes (PAID) scale was included to assess diabetes-related distress 
32. The Consequences dimension of the Brief Illness Perception Questionnaire (BIPQ; “how 
much does your illness affect your life?”) was used to examine whether participants viewed 
their diabetes as having major consequences on their lives, with response options ranging 
from 0 (“no effect at all”) to 10 (“severely affects my life”) 33. As the BIPQ and the DEBQ were 
included in only two of five complementary questionnaire modules that were randomly 
assigned to subgroups of the total sample 25, results for these two measures could only be 
reported for 40%.
statistical analyses
To examine whether Type D personality and its individual components NA and SI were 
differentially related to demographical and clinical characteristics, health behaviors, 
physiological risk factors and emotional distress, participants were classified into one of four 
subgroups based on their DS14 scores: (i) those scoring low on both Type D components 
(NA- / SI-); (ii) those scoring high on SI only (NA- / SI+); (iii) those scoring high on NA only 
(NA+ / SI-); (iv) those scoring high on both NA and SI (Type D). Comparisons between these 
four subgroups were made using one-way between-groups ANOVAs (continuous variables) 
and X2 tests (categorical variables). An ANCOVA was applied for the number of cancelled care 
appointments during the previous twelve months, in order to adjust for the total number 
of care appointments in this period. To account for the number of individual statistical tests 
needed to analyze the ten DSCI-R items, a more stringent α level was used for the overall 
difference per item (Bonferroni correction 0.05 / 10 = 0.005). This procedure was also 
followed for the ten eating pattern questions. Three planned comparisons were specified 
(Type D vs. NA- / SI-, Type D vs. NA- / SI+, Type D vs. NA+ / SI-), using a Bonferroni adjusted 
α level of 0.05 / 3 ≈ 0.0167. Cohen’s d was used as an index of effect size for significant 
planned comparisons and was calculated by subtracting the mean of a certain variable for 
the comparison group of interest from the mean for the Type D group and dividing this 
number by the standard deviation of the two groups combined (with 0.20, 0.50 and 0.80 
indicating a small, moderate and large effect, respectively). 
For those variables showing a unique contribution of NA+ / SI+ in the univariable group 
comparisons, multivariable logistic regression analyses were used to determine whether 
the association for Type D personality held when using the NA- / SI- as the reference group 
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and adjusti ng for demographics (sex, age, educati onal level, being single), clinical factors 
(diabetes durati on, the presence of diabetes complicati ons) and the two individual Type 
D components. Dichotomizati on based on pre-defi ned cut-off  points, content of response 
categories and terti les was employed to improve clinical interpretability, by allowing a 
comparison of low – medium versus high risk groups. All analyses were performed using 
SPSS Version 19 (IBM SPSS Stati sti cs, Somers, New York). Unless otherwise specifi ed, 
stati sti cal signifi cance was taken at p < 0.05.
rESuLTS
The total sample consisted of 3,314 people (53% women, mean age 55 ± 14 years, age range 
19 – 90), of whom 43% had type 1 diabetes. Approximately half of the parti cipants with type 
1 diabetes (690 / 1,422) reported to use an insulin pump as their primary hyperglycemia 
treatment and 53% (993 / 1,890) of those with type 2 diabetes were managing their conditi on 
with insulin in general (pump and / or injecti ons). Twenty-nine per cent of the sample (n = 
952) was categorized as having Type D personality, while SI only and NA only were present 
in 17% (n = 562) and 15% (n = 492), respecti vely. These prevalence esti mates did not diff er 
when strati fying by diabetes type (p = 0.78). When comparing the four NA / SI groups with 
respect to demographics and clinical characteristi cs (Table 1), signifi cant overall diff erences 
were found for sex, age, partner status, diabetes durati on, hbA1c level, BMI and the presence 
of high cholesterol. Planned comparisons indicated that Type D individuals were somewhat 
younger than the other three groups and were less likely to have a partner. Compared to the 
reference group and the SI only group, Type D individuals had a higher mean BMI and were 
more likely to be female. Type D individuals were more likely to report high cholesterol than 
the reference group and had had diabetes for a signifi cantly shorter period of ti me than the 
SI only group. With respect to HbA1c level, the planned contrasts did not yield any signifi cant 
results for the comparisons of interest. Results for Type D personality in relati on to self-care 
behaviors and emoti onal distress were similar when strati fying by diabetes type (data not 
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self-care behaviors
The four groups did not diff er with respect to their self-reported use of insulin, oral 
hypoglycemic tablets, and cholesterol or blood pressure lowering agents (Table 2). however, 
Type D individuals reported signifi cantly more barriers to taking medicati ons (overall p < 
0.001; contrast Type D vs. SI only p < 0.001 and Cohen’s d = 0.44; contrast Type D vs. NA only 
p = 0.001 and Cohen’s d = 0.18). No associati on was found with insulin adjustments, blood 
glucose monitoring, alcohol consumpti on or trying to achieve or maintain a healthy weight. 
Type D personality was related to less frequent inspecti on of feet (with a non-signifi cant 
diff erence between the SI only and Type D group and an eff ect size of d = -0.16 for the Type 
D vs. NA only contrast at p = 0.005). Furthermore, Type D individuals were somewhat more 
likely to smoke than the SI only group (11% vs. 6%, p = 0.005), but not when compared to 
the reference group (p = 0.22) or NA only group (p = 0.62).
Individuals with a Type D personality were less likely to follow a healthy diet (Table 2; overall 
p < 0.001; all planned comparisons p < 0.001; Cohen’s d = -0.47, -0.26 and -0.20 for the 
contrast with the reference, SI only and NA only group, respecti vely). Signifi cant overall 
group diff erences were found for several specifi c dietary habits (Online Appendix Table 2), 
with Type D individuals being less likely to consume healthy foods (fruit, vegetables, whole 
grain products, fatt y fi sh) and more likely to consume less healthy foods (non-lean meat, 
fried products, sweets). Contrasts with the other three groups were either non-signifi cant 
or of fairly minor eff ect size (range Cohen’s d |0.13 – 0.29|). In the subsample completi ng 
the three DEBQ eati ng style subscales (n = 1,312 / 1,332), we found a signifi cant diff erence 
in emoti onal (p < 0.001), external (p < 0.001) and restraint eati ng (p = 0.001) average scale 
scores for the four NA / SI groups. Type D individuals were more inclined to eat in response 
to emoti onal arousal or to external food cues than the reference group (both p-values < 
0.001, Cohen’s d = 0.80 / 0.51) and SI only group (both p-values < 0.001, Cohen’s d = 0.62 
/ 0.32). For restrained eati ng, only the Type D vs. SI only contrast was signifi cant (p = 0.01, 
Cohen’s d = 0.22). 
There was a signifi cant overall group diff erence in physical acti vity (Table 2; p < 0.001). Type 
D individuals were less likely to meet the nati onal norm for healthy exercise when compared 
to the reference and SI only group (both p-values < 0.001, Cohen’s d = -0.30 / -0.26), but 
there was no signifi cant diff erence with the NA only group. When examining physical acti vity 
levels more closely using the IPAQ short form, the overall group eff ect (p < 0.001) was only 
refl ected in a signifi cant diff erence between Type D and the reference group (p < 0.001, 
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Type D individuals indicated they were less inclined to consult health professional(s) in case 
of problems with diabetes management (overall p < 0.001; contrast Type D vs. reference 
group p < 0.001 and Cohen’s d = 0.40; Type D vs. SI only p = 0.001 and Cohen’s d = 0.18; 
Type D vs. NA only p < 0.001 and Cohen’s d = 0.27). They also reported more diabetes-
specifi c social anxiety (overall p < 0.001; all contrasts p < 0.001, with Cohen’s d = 0.66, 0.52 
and 0.21 for the comparison with the reference, SI only and NA only group, respecti vely). 
There was a small but signifi cant diff erence between the four groups in the mean number 
of cancelled care appointments during the previous twelve months, aft er adjusti ng for the 
total number of care appointments in this period (n = 3,261; p < 0.001, parti al η2=0.005). 
The mean number of cancellati ons was signifi cantly higher in Type D individuals (adjusted 
mean [standard error] = 0.44 [0.03]) compared to the reference category (0.33 [0.03], p = 
0.01) and the SI only group (0.24 [0.04], p < 0.001), but not to the NA only group (0.45 [0.05], 
p = 0.92).
emoti onal distress
Type D individuals reported more loneliness, and symptoms of depression and anxiety than 
the other three groups (Table 3; p < 0.001). Large eff ect sizes were found for the comparison 
with the reference group (Cohen’s d = 1.17 / 1.14 / 1.16, respecti vely) and the SI only group 
(Cohen’s d = 0.84 / 0.95 / 0.99) and small to moderate eff ect sizes for the diff erence with the 
NA only group (Cohen’s d = 0.40 / 0.20 / 0.13). With respect to diabetes-specifi c distress, 
signifi cant overall diff erences were found in mean scores on the PAID and the consequences 
item of the B-IPQ (both overall p < 0.001). Type D individuals experienced more negati ve 
emoti ons related to living with diabetes and endorsed a larger impact of this conditi on on 
their life when compared with the reference group (Cohen’s d = 1.01 / 0.57) and the SI only 
group (Cohen’s d = 0.85 / 0.47), but not with the NA only group. 
Multi variable analyses
We dichotomized the PhQ-9 and GAD-7 scores using the validated cut-off  of ≥ 10. For the 
DSCI-R healthy eati ng item, this division was based on the response categories (0=Regularly, 
oft en, [almost] always, 1 = Someti mes, never). The split for the remaining variables was 
based on a comparison between the lowest and middle terti le (0 = no problems) and the 
highest terti le (1 = problems) of total scores. Aft er adjustment for demographics, clinical 
factors, NA only and SI only, Type D individuals had a more than 15-fold increased odds of 
reporti ng loneliness (OR = 15.32, 95% CI 11.95 – 19.64) and high depressive symptoms (OR 
= 28.99, 95% CI 17.03 – 49.34) when compared with the reference category. SI only and NA 
only were also associated with these emoti onal distress measures, with an adjusted OR of 
3.04 (2.26 – 4.09) and 7.70 (5.81 – 10.19) for loneliness, and 2.16 (1.03 – 4.51) and 21.71 
(12.44 – 37.88) for depressive symptoms. As only three people in the reference and SI only 
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In the multi variable models, Type D personality remained signifi cantly associated with 
subopti mal consultati on behavior (OR = 2.03, 1.69 – 2.44), diabetes-specifi c social anxiety 
(OR = 2.85, 2.35 – 3.45), the presence of barriers to medicati on taking (OR = 2.86, 2.36 – 
3.47), and subopti mal healthy eati ng (OR = 2.96, 95% CI 1.94 – 4.52). The two individual Type 
D components also signifi cantly increased the odds of these subopti mal health behaviors 
(range of ORs 1.35 – 1.85 for SI only and 1.36 – 2.38 for NA only), but the combinati on of NA 
and SI in Type D individuals consistently showed the strongest independent associati on with 













Figure 1 Odds of subopti mal health behaviors as a functi on of personality
Note. Multi variable logisti c regression analyses, displaying the odds of experiencing several subopti mal health 
behaviors for individuals with SI only, NA only and Type D personality (compared to the reference category), aft er 
adjustment for demographics and clinical factors. All personality variables were entered simultaneously in the 
regression models. Cut-off  was ≥ 3 for the subopti mal consultati on behavior subscale, ≥ 4 for the diabetes-specifi c 
social anxiety subscale, and ≥ 24 for the ASK-12.
DiSCuSSiON
In this large sample of people with type 1 or type 2 diabetes, Type D personality (the 
combinati on of NA and SI) was present in 29%. This esti mate did not diff er across diabetes 
type and is comparable to prevalence rates reported for the general populati on and people 
with cardiovascular and non-cardiovascular conditi ons 10, 22, 23, and for a sample of people who 
were hospitalized for diabeti c foot problems 24.  however, it is higher than the prevalence 
found in a study among people with type 2 diabetes in primary care (17%) 21, although 
similar esti mates have been reported previously 10, 23. Compared to those scoring high on 
neither or only one component, people with diabetes and Type D personality tended to 
have a less healthy diet, were less likely to consult their health professional(s), experienced 
more barriers regarding medicati on use, and reported more loneliness, more diabetes-
specifi c social anxiety, and more symptoms of anxiety and depression in general. NA (with 
or without SI) was associated with infrequent exercise, emoti onal and external eati ng style, 
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and diabetes-specific distress, and SI (with or without NA) with suboptimal inspection of 
feet. No relevant differences were found with respect to physiological risk factors, in line 
with the results from a study among people with type 2 diabetes where participants with 
and without Type D personality did not differ with respect to glycemic control, cholesterol 
levels and blood pressure 21. Previous research concluded that Type D is not confounded by 
traditional cardiovascular risk factors 10, suggesting that other pathways may be implicated. 
Extending earlier findings comparing people with and without Type D personality 10, 13-19, 22, 23, 
our results confirm that behavioral and emotional factors are viable candidates.
Previous efforts to relate personality dispositions to the consumption of specific dietary 
components such as fat and salt have generally produced inconsistent results 34. however, 
neuroticism has been positively related to skipping breakfast, dieting to lose weight, and 
unwillingness to try new foods, and negatively related to consumption of vegetables, fruit 
and brown bread 34. In the present study, the NA+ / SI+ (Type D) group was the least likely to 
follow a healthy diet on a regular basis. A strong tendency to eat in response to emotions or 
external cues was found in both Type D individuals and in those with NA only. 
With respect to physical activity, NA was more prominent in explaining exercise behavior 
than SI. Both neuroticism and introversion have been related to lower levels of exercise 
35, 36. The need to socialize and meeting people is a prominent exercise motive along the 
introversion-extraversion dimension, but neuroticism has been associated with a range of 
exercise barriers, including lack of motivation / desire, lack of energy and embarrassment 
at having a fitness evaluation 35. The passive stance enclosed in most of these barriers may 
be a stronger determinant of physical activity than social considerations and could be the 
main driving factor in the association between Type D personality and exercise documented 
in previous studies 15, 16, 18.
A recent study among individuals who were hospitalized for myocardial infarction concluded 
that the constituent components of Type D do interact to predict medication adherence, 
after controlling for the effects of each component separately 17. however, data from a 
sample with acute coronary syndrome attenuated this conclusion by suggesting the primacy 
of NA over the Type D personality construct in predicting medication adherence 37. Our 
results may add yet another dimension to this discussion by suggesting that it might not 
be the actual frequency of medication taking that is at stake for individuals with Type D 
personality, but their tendency to perceive more (potential) barriers to medication taking. 
Similar perceptual differences have been found in people with obstructive sleep apnea 
who were using continuous positive airway pressure (CPAP) treatment. Type D individuals 
reported a significantly higher frequency of side effects from the CPAP treatment, but also 
experienced the side effects as more troublesome 38. 
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Building upon previous studies reporti ng a relati on between Type D personality and 
subopti mal consultati on behavior 20, 39, our results suggest it is in fact the combinati on of 
NA and SI that bears the strongest associati on with the tendency not to consult health 
professionals in case of problems with diabetes management and diabetes-specifi c social 
anxiety related to the health care contact. Coupled with an inhibited interpersonal style, 
people with a Type D personality may be parti cularly inclined not to address topics that carry 
a high risk of negati ve evaluati on by health professionals, e.g. whether one is successfully 
managing his / her diabetes and health, and to enter the health care contact anti cipati ng 
direct or indirect judgmental interacti ons. They appear less likely to acti vely address any 
problems that arise and characteristi cally cope by using avoidance strategies such as 
resignati on and withdrawal 40. In additi on, they are more likely to endorse statements such 
as “One can do litt le or nothing for maintaining and improving one’s health status” 41. 
The joint presence of NA and SI showed the strongest associati on with mental health status 
in the present study. Type D personality has previously been associated with depression, 
anxiety, loneliness, inadequate social support, and stressful life events 10, 21-23, 40, 41. We extend 
these fi ndings by showing that higher symptom reports of general emoti onal distress in 
individuals with Type D personality are not fully explained by trait NA alone. People high on 
NA are quite likely to discuss their own thoughts, feelings and behaviors with other people 
42. Individuals with Type D personality may feel a similar need to express themselves, but 
they are held back by social evaluati on concerns which may add to their overall distress 
levels. Most strikingly, individuals with a Type D personality had a 15-fold increased odds 
of experiencing loneliness, even aft er adjustment for partner status and the two individual 
Type D components. Previous studies have linked Type D personality to self-reported social 
isolati on 41 and lower levels of perceived social support 13, 40. 
Of note, people with Type D personality and those with NA alone did not diff er with respect 
to diabetes-specifi c distress. In Type D research, few studies have focused on emoti onal 
functi oning related directly to the medical conditi on itself. Type D personality has been 
associated with more negati ve illness percepti ons in people with myocardial infarcti on and 
colorectal cancer 43, 44. however, most of these cogniti ve and emoti onal representati ons of 
illness appear to be driven by NA, irrespecti ve of standing on SI 44. One tentati ve hypothesis 
would be that, from the perspecti ve of an individual having a Type D personality, the distress 
directly linked to a concrete medical conditi on is somehow more socially acceptable than 
less tangible symptoms of depression or anxiety. While we did see a clear relati on between 




Limitations of the present study are its cross-sectional design, the use of self-report measures, 
a definition of optimal health-promoting behavior that did not account for maladaptive, 
hyper vigilant behavior (e.g. checking blood glucose levels significantly more often than 
needed), and the representativeness of the sample for the diabetes population at large. As 
described elsewhere 25, the Diabetes MILES – The Netherlands sample underrepresented 
people with type 2 diabetes managing their condition with a combination of lifestyle 
modifications and blood glucose lowering tablets, those from ethnic minority groups, and 
people with co-morbid vascular conditions. Strengths of the study include the large number 
of participants, the wide variety of health behavior and emotional distress measures, and 
the four-group stratification which allowed a more detailed analysis of the unique and 
shared health correlates of NA and SI.
In conclusion, people with diabetes and Type D personality appear to be less likely to eat 
healthy, are more likely to report barriers surrounding medication use, loneliness and 
symptoms of depression and anxiety, and are more reserved and anxious when it comes 
to health care contacts. Combined with a tendency to exercise infrequently and to eat in 
response to emotions and external stimuli, Type D delineates a group of people who may 
require special clinical attention. Further study is warranted to test the clinical relevance of 
Type D personality for people with diabetes in terms of clinical prognosis. Our study suggests 
that there are important individual differences in the way people perceive and manage 
their health. NA and SI do not cover all personality dimensions relevant to health, but their 
combination may help to identify those individuals who are at increased risk of suboptimal 
health behaviors and emotional distress and at the same time less likely to address these 
and other issues during medical visits. These individuals might benefit from a more patient-
tailored care approach, where health care providers are sensitive to their tendency to keep 
worries and problems to themselves. 
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Online Appendix table 1 Structural validity and reliability of the purpose-designed consultati on 
behavior questi onnaire
Factor i Factor ii Corrected item-total 
correlati ons
subopti mal consultati on behavior in case of problems
1 If new symptoms develop that worry me, I contact a 
health professional (R)
0.77 -0.11 0.49
2 If existi ng symptoms get worse, I contact a health 
professional (R)
0.77 -0.09 0.50
8 If I fi nd it diffi  cult to take my diabetes medicati on in the 
correct way, I disucss this with a health professional (R)
0.42 0.13 0.45
9 If I fi nd it diffi  cult to lead a healthier lifestyle (e.g. 
exercise more, eat healthier, quit smoking), I discuss 
this with a health professional (R)
0.40 0.16 0.43
Cronbach’s α = 0.67
Lambda2 = 0.68
MICC = 0.36
Diabetes-specifi c social anxiety
3 If I share my concerns about my diabetes with a health 
professional, he / she will think I am exaggerati ng
0.09 0.45 0.36
4 At a meeti ng with a health professional or a check-up, I 
am afraid to receive bad news about my diabetes
-0.11 0.49 0.34
7 If my blood glucose is oft en too high, I rather not tell a 
health professional
0.05 0.52 0.40
10 When things are not going well with my diabetes, a 
health professional will blame me
-0.01 0.57 0.41
Cronbach’s α = 0.59
Lambda2 = 0.59
MICC = 0.27
5 If I don’t understand what a health professional is 
saying, I ask for clarifi cati on (R)
0.25 0.25
6 If I disagree with a health professional, I will stand up 
for myself (R)
0.20 0.33
MIIC = mean inter-item correlati on; (R) = reverse coded; Bold: factor loadings ≥|0.30|
Simple structure: items loading >|0.40| on one factor and <|0.30| on any other factor aft er rotati on 
Exploratory factor analysis (principal axis factor extracti on, oblimin rotati on) yielded three factors with initi al 
eigenvalue > 1 (2.9, 1.4 and 1.02, respecti vely). however, as the scree plot showed a marked elbow aft er the 
second factor, two factors were retained. Kaiser-Meyer-Olkin measure of sampling adequacy = 0.76; Bartlett ’s test 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































summary and general discussion

10
SUMMARY AND GENERAL DISCUSSION
185
In the present Chapter, the main fi ndings of this thesis are summarized. This is followed 
by a discussion of methodological and conceptual considerati ons, clinical implicati ons, and 
suggesti ons for future directi ons.  
OVeRVieW OF MAiN FiNDiNGs
In Chapter 2, we examined the prevalence of depression in people with impaired glucose 
metabolism and undiagnosed diabetes relati ve to each other and to individuals with normal 
glucose metabolism and with previously diagnosed type 2 diabetes by reviewing the 
literature and conducti ng a meta-analysis of studies on this topic. The meta-analysis showed 
that the odds of depression was not increased in people with impaired glucose metabolism 
versus those with normal glucose metabolism (OR = 0.96, 95% CI 0.85 – 1.08). The odds of 
depression did not diff er between people with undiagnosed diabetes and those with either 
normal glucose metabolism (OR = 0.94, 95% CI 0.71 – 1.25) or impaired glucose metabolism 
(OR = 1.16, 95% CI 0.88 – 1.54). Finally, people with impaired glucose metabolism or 
undiagnosed diabetes both had a signifi cantly lower odds of depression compared with 
people with previously diagnosed type 2 diabetes (OR = 0.59, 95% CI 0.48 – 0.73 and OR 
= 0.57, 95% CI 0.45 – 0.74, respecti vely). These results indicate that higher blood glucose 
levels per se in the prediabetes or early diabetes stages are not associated with a higher 
prevalence of depression. Furthermore, they provide support for the “emoti onal burden 
hypothesis”, which states that the burden of knowing that you have diabetes and having 
a chronic conditi on that you have to manage or complicati ons to cope with contribute to 
higher levels of depression.
In Chapter 3, we described the rati onale and design of the DiaDDZoB (Diabetes, Depression, 
Type D personality Zuidoost-Brabant) Study. This prospecti ve cohort study aimed to examine: 
(1) the course of depression (defi ned as a score of ≥ 12 on the Edinburgh Depression 
Scale) in people with type 2 diabetes in primary care; (2) whether depression and Type D 
personality were associated with the development of microvascular complicati ons and / or 
macrovascular disease and with mortality; and (3) the behavioral and pathophysiological 
mechanisms that may mediate these associati ons. The baseline assessment took place in 
2005 (n = 2,460) and follow-up waves were realized in 2007 (n =  2,225) and 2008 (n = 2,032). 
Measurements included a nurse-led interview, a self-report questi onnaire and the results 
from regular care laboratory tests and physical examinati ons.
Chapter 4 examined the course (incidence, recurrence / persistence) of depression in 
people with type 2 diabetes, using data from the DiaDDZoB cohort, with three separate 
assessments during a 2.5 year period. In additi on, we tried to identi fy demographic, medical 
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and psychological risk factors predicting these different course patterns. A total of 630 
participants (26%) met the criterion for depression at one or more assessments. In the 
subgroup with no baseline depression, incident depression at follow-up was present in 14% 
(n = 310), while recurrence / persistence in those with baseline depression was found in 66% 
(n = 212). The presence of any depression was significantly associated with being female, 
low education, non-cardiovascular chronic diseases, stressful life events and a self-reported 
history of depression. Incident depression was predicted by female sex, low education and 
depression history, while people with a history of depression had a 2.5-fold increased odds 
of recurrent / persistent depression. Depression appears to be an important co-morbid 
health problem in people with type 2 diabetes, with one in seven people reporting incident 
depression during a 2.5 year period. Once present, depression often becomes a chronic / 
recurrent condition in this group. Self-reported history of depression was the only factor 
that consistently identified those individuals who had increased odds of experiencing any 
kind of depression during the study, even after taking demographics, medical co-morbidities 
and stressful life events into account.
In Chapter 5, we examined whether depression (Edinburgh Depression Scale total score ≥ 
12) was associated with time to insulin initiation in insulin-naïve people with type 2 diabetes 
from the DiaDDZoB cohort. The prevalence of depression was 12% (n = 168), and 253 (18%) 
participants had started insulin therapy over a mean follow-up period of 1,597 ± 537 days. 
People with depression were not more likely to start insulin therapy earlier or later than 
their non-depressed counterparts (hR = 0.98, 95% CI 0.66 – 1.45), also after adjustment 
for sex and age (hR = 0.95, 95% CI 0.64 – 1.42). Adding individual candidate confounders 
to the age- and sex-adjusted base model did not change the hR by more than 4% and 
the association remained non-significant. Additional studies in other samples, preferable 
incorporating more information about the decision making process behind insulin initiation, 
are needed to further elucidate whether or not depression is associated with (delayed) 
initiation of insulin therapy.
In Chapter 6, we used cross-sectional baseline data from the DIAZOB Primary Care Diabetes 
study, a dynamic cohort study of people with type 2 diabetes in primary care, to explore 
whether symptom clusters relating to the two core features of depression – dysphoria and 
anhedonia – were differentially associated with suboptimal glycemic control (hbA1c values ≥ 
7%; 53 mmol / mol). In univariable logistic regression analyses, anhedonia was significantly 
associated with suboptimal glycemic control (OR = 1.29, 95% CI 1.09 – 1.52), while both 
dysphoria (OR = 1.04, 95% CI 0.88 – 1.22) and anxiety (OR = 0.99, 95% CI 0.83 – 1.19) were 
not. The association between anhedonia and glycemic control remained significant after 
adjustment for dysphoria and anxiety (OR = 1.33, 95% CI 1.11 – 1.59). Alcohol consumption 
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and physical acti vity met criteria for mediati on, but did not change the strength of the 
associati on between anhedonia and glycemic control by more than 5%. Adjustment for 
diabetes durati on att enuated the associati on, but the associati on was sti ll signifi cant (OR = 
1.20, 95% CI 1.01 – 1.43). Studying diff erent symptom clusters of depression, in parti cular 
anhedonia, may add to a bett er understanding of a possible relati onship between depression 
and glycemic control.
Chapter 7 examined whether depression was associated with hospitalizati on for 
cardiovascular disease and all-cause mortality in the DiaDDZoB Study, and whether 
symptom clusters related to dysphoria, anhedonia and anxiety were diff erenti ally associated 
with these end points. In additi on, we sought to determine whether there were symptom-
specifi c behavioral or pathophysiological mechanisms in play. The prevalence of depression 
(Edinburgh Depression Scale total score ≥ 12) was 12% (n = 182). At the end of the fi ve-
and-a-half year follow-up, 191 people had experienced a cardiovascular hospitalizati on and 
139 had died. Depression was associated with survival ti me (adjusted hR = 1.93, 95% CI 
1.10 – 3.41), but did not predict ti me to cardiovascular hospitalizati on. Aft er adjustment for 
meaningful demographic and clinical confounders, depressed individuals sti ll had an almost 
2-fold increased risk to die from all-causes at any moment during follow-up compared with 
their non-depressed counterparts. With regard to diff erent (depression) symptom clusters, 
symptom clusters focusing on negati ve emoti ons predicted ti me to fi rst cardiovascular 
hospitalizati on during follow-up. Dysphoria was associated with a shorter ti me to event 
(unadjusted hR = 1.49, 95% CI 1.02 – 2.17), but this relati on was no longer signifi cant aft er 
taking confounding factors into account. The presence of anxiety symptoms was associated 
with a longer ti me to event, but only when adjusti ng for confounders (adjusted hR = 0.52, 
95% CI 0.29 – 0.92). Symptoms of anhedonia were consistently associated with shorter ti me 
to death of all-causes (adjusted hR = 1.72, 95% CI 1.11 – 2.65). Physical acti vity met criteria 
for mediati on, att enuati ng the hR for anhedonia by approximately 20%. Symptom-specifi c 
associati ons with health outcomes and mechanisti c pathways deserve further explorati on 
in other studies.
In Chapter 8, we examined the validity / reliability and clinical correlates of the Type D 
personality construct and its assessment in people with type 2 diabetes from the DiaDDZoB 
cohort. The 2-factor model of the Type D construct was confi rmed in exploratory and 
confi rmatory factor analyses; results were stable across gender. The Negati ve Aff ecti vity 
(NA) and Social Inhibiti on (SI) subscales had adequate reliability in both men and women, 
as measured by Cronbach’s alpha (NA = 0.87, SI = 0.83), lambda2 (NA = 0.87 / 0.88, SI = 
0.84), corrected item-total correlati ons (NA 0.47 – 0.77, SI 0.34 – 0.72) and mean inter-item 
correlati ons (NA = 0.50 / 0.51, SI = 0.42). One year test–retest reliability using intraclass 
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correlation coefficients was 0.64 / 0.63 for NA and 0.73 / 0.65 for SI. Type D and non-Type D 
individuals did not differ in vascular history or physiological risk factors, but Type D women 
had a more sedentary lifestyle (p = 0.003). Type D individuals experienced less social support 
and more stressful life events, loneliness, and more depressed mood, anhedonia and anxiety 
(p < 0.001 for most variables). These differences were clinically relevant (Cohen’s d > 0.60 for 
most variables, indicating moderate to large effect sizes). Type D personality can be reliably 
assessed in people with type 2 diabetes, and is associated with increased loneliness, stress 
and emotional distress in this group.
Chapter 9 aimed to explore whether Type D personality and its two constituent components 
– NA and SI – were differentially associated with three potential mechanisms that could 
link Type D personality with poor health outcomes (health behaviors, emotional distress, 
and pathophysiological factors) in people with type 1 or type 2 diabetes, using data from 
Diabetes MILES – The Netherlands. Compared with those scoring high on neither or 
only one component, people with diabetes and Type D personality tended to have a less 
healthy diet, were less likely to consult their health professional(s) in case of problems with 
diabetes management, experienced more barriers regarding medication use, and reported 
more loneliness, more diabetes-specific social anxiety, and more symptoms of anxiety and 
depression in general. NA (with or without SI) was associated with less frequent exercise, 
emotional and external eating style, and diabetes-specific distress, and SI (with or without 
NA) with suboptimal inspection of feet. No relevant differences were found with respect to 
other self-care measures or pathophysiological risk factors. In multivariable logistic regression 
analyses, Type D personality was associated with a 2 to 3-fold increased odds of several 
suboptimal health-behaviors and related cognitions and a more than 15-fold increased 
odds of experiencing general emotional distress, after adjustment for demographics, clinical 
variables and the individual Type D components. Assessing the joint presence of NA and 
SI may help to identify those individuals who are at increased risk of suboptimal health 
behaviors and emotional distress and at the same time less likely to address these and other 
issues during medical visits.
MethODOLOGiCAL AND CLiNiCAL CONsiDeRAtiONs
study design
All studies included in this thesis were based on cross-sectional or longitudinal observational 
data. Cross-sectional studies prohibit definite conclusions regarding causality. Prospective 
studies may give more insight in certain relations over time, but still do not provide conclusive 
proof for causality. Randomized controlled trials and experiments are currently the best way 
to study causal relationships, but may not always be feasible or ethical in clinical settings 1. 
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With respect to potenti al confounders, we have examined a range of demographic, medical 
and psychosocial factors. however, there always is the possibility of residual confounding 
by unmeasured or imperfectly measured factors, for example with respect to disease 
characteristi cs. Concerning the overall research paradigm, the associati ons of interest in 
the present thesis have all been studied at group level. While this approach may provide 
general insights into presumed relati ons, it may not always adequately refl ect the reality for 
individuals. When trying to understand complex phenomena such as the decision (not) to 
initi ate insulin, where a multi tude of individual pati ent-, provider- and health-care system 
factors play a role, more ideographic study designs may be of additi onal value.
study setti  ng
The majority of studies in this thesis were based on data from a cohort of people with 
type 2 diabetes, who were being treated in primary care practi ces. While this group covers 
the majority of people currently living with diabetes, it may be premature to generalize 
fi ndings in this group to the diabetes populati on at large. Dutch secondary care setti  ngs 
predominantly focus on people with type 1 diabetes or more complex type 2 diabetes, e.g. 
in case of multi ple long-term vascular complicati ons or problemati c diabetes regulati on, 
or when intensive blood glucose lowering regimens are required. Most people with type 
2 diabetes seen in primary care are in opti mal glycemic control and manage their diabetes 
with oral agents and lifestyle recommendati ons only. The prevalence of elevated depressive 
symptoms in chapter 4 (13 – 16%) was lower than previously found in outpati ent setti  ngs 2, 
but comparable to fi gures reported in populati on-based studies 3, 4. 
Compared with the rates generally found in people with cardiovascular disease and the 
general populati on (approximately 20 – 35%) 5, 6, the prevalence of Type D personality 
found in the DiaDDZoB Study (17%; chapter 8) was relati vely low, but similar esti mates have 
been reported 5, 6. A previous study among people who were hospitalized for diabeti c foot 
problems found a prevalence of 33%, but they were younger than the DiaDDZoB subsample 
(mean age 61 years vs. 69 years) and it was unclear whether they were normally seen in 
primary or secondary care. Chapter 9 found a similar rate of Type D personality for people 
with type 1 or type 2 diabetes (29%), but as primary health care setti  ng was not measured 
reliably in Diabetes MILES – The Netherlands, a comparison by primary / secondary care for 
the type 2 subsample could not be made. 
Diabetes type
While most studies examined people with type 2 diabetes in primary care, one chapter 
provided informati on about people with type 1 and type 2 diabetes, parti cipati ng in a 
nati onal online survey. Type 1 and type 2 diabetes diff er on several important aspects, 
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including etiology, clinical presentation and self-management activities, and at this stage 
it is unclear whether this is any different for the etiology and presentation of depression in 
both groups. Where possible, studies are advised to stratify results by diabetes type. The 
clinical correlates of Type D personality (chapter 9) were combined across diabetes type, but 
only after establishing that results were similar for type 1 and type 2 diabetes. Apart from 
chapter 9, diabetes status was based on diagnoses made in clinical practice. While this will 
be reliable for most individuals, there is always the possibility that less common diabetes 
types, such as latent auto-immune diabetes of adulthood, are misdiagnosed. Although the 
scope of this problem is not entirely clear, in a population-based sample of 2,350 Dutch 
individuals aged 50 – 74 years it was found that about 4% of people with known diabetes 
appear to have antibodies to GAD65 7. In studies where diabetes type is determined through 
self-report, such as in chapter 9, a certain margin of error cannot be ruled out either. For 
example, some people with type 2 diabetes using insulin treatment may have self-identified 
as having type 1 diabetes. 
Co-morbidities, complications and mortality
Problems relating to self-report of diabetes type apply to complications and co-morbidities 
as well, as some people may not be aware of specific diagnoses. In some of the studies 
included in the present thesis, we have addressed these issues by verifying self-reported 
diagnoses in the medical chart or by using data from a national hospital registry. however, 
even in these cases, researchers are dependent on the quality of diagnostics and registration 
inherent to these systems. A similar line of reasoning goes for the mortality data in chapter 
7, where (all-cause) mortality data were available from a range of different sources. 
the problem of overfitting in regression analyses
In several of the chapters in the present thesis, we have used logistic regression or survival 
analyses to examine correlates / predictors of binary outcomes or time-to-event data. An 
issue that needs to be considered when using these statistical methods is the problem of 
overfitting, i.e. capitalizing on the idiosyncrasies of the sample at hand 8.  Overfitted models 
may ask too much from the available data and generally occur when a model is too complex, 
consequently yielding overly optimistic results 8. Simulation studies have suggested that 
logistic regression and survival analyses will produce relatively unbiased estimates if the 
minimum number of events per predictor is approximately 10 9, 10. While this guideline does 
not appear to be violated in the chapters concerned, we have tried to interpret our results 
in cautious language where appropriate 8. Babyak (2004) has suggested several strategies 
to avoid or minimize overfitting 8. One option would be to increase a study’s follow-up time 
or to recruit more participants, in order to include more events in the planned regression 
analyses. Alternatively, the number of predictor variables in the model could be reduced by 
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combining theoreti cally related predictors into a single composite measure, as was done in 
Chapter 4 and 7 for microvascular complicati ons, cardiovascular disease, and other (chronic) 
medical conditi ons. While this approach preserves degrees of freedom in the model, this 
comes at a trade-off , as specifi c informati on about the individual components of the 
composite measure is lost 8.
Measuring mediati on
Central to the defi niti on of a mediati ng variable is that it is in the causal pathway between the 
independent variable and the outcome of interest 11. As noted before, causality cannot be 
inferred from observati onal studies, although ti me-varying factors are useful in this context 
11. Many observati onal studies (including chapter 6 and 7) examine potenti al mediati ng 
factors that are measured at the same point in ti me as the independent variable, making 
the relati on even more unclear. Despite these limitati ons, it may be informati ve to examine 
some basic relati ons between the variables of interest to get a fi rst glance of mediati on 12, 
as was done in these chapters. These procedures are to be preferred over strategies where 
all potenti al mediators are included in a multi variable model at the same ti me, as they may 
obscure an associati on that is actually present. however, studying potenti al behavioral and 
pathophysiological mediati ng mechanisms in isolati on ignores the fact that these factors 
are oft en interrelated and interdependent 13. Advanced computati onal models may provide 
one way of dealing with this complexity, but they are beyond the scope of regular medical 
stati sti cs 13 and may require a more ideographic approach before being used in large cohort 
studies. 
Measuring emoti onal distress in people with diabetes
The predominant conceptual model for understanding the problem of depression in people 
with diabetes is the syndromal  diagnosis of major depressive disorder 14. however, in 
terms of research, the vast majority of studies examining depression in diabetes – including 
the studies in the present thesis – have relied on self-report questi onnaires that assess 
symptoms of depression or distress 14. Most self-report measures contain some items 
that could be confounded with symptoms of subopti mal diabetes management, including 
fati gue, sleeping diffi  culti es and appeti te changes 15 and, thus, are not necessarily related to 
depression.  At present, it is also unclear whether specifi c depressive symptoms are more 
strongly related to adverse health outcomes in people with diabetes. Finally,  self-report 
questi onnaires of depression may also tap into a broader spectrum of emoti onal problems 
16 and may refl ect other types of distress including more general forms of distress 14, 16, 17. 
Type D personality refers to a general form of distress that is defi ned by the tendency to 
experience negati ve emoti ons (Negati ve Aff ecti vity or NA) and to inhibit self-expression 
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(Social Inhibition or SI) 5, 6, and that is assessed by an elevated score (≥ 10) on both the 
NA and SI subscales of the DS14 18. By comparing Type D individuals (NA+ / SI+) with an 
undifferentiated combination of the three non-Type D groups (NA- / SI+, NA+ / SI-, NA- 
/ SI-), it is assumed that these three groups all have similar levels of risk 19. however, a 
significant Type D versus non-Type D group comparison could also be due to other patterns, 
for example when a high risk in one of the three non-Type D groups is averaged with a low 
risk in the other two groups 19. Chapter 9 explored this issue by comparing clinical correlates 
across all four NA / SI groups, and found significant differences between the Type D group 
and the other three groups with respect to several health behaviors and emotional distress 
measures. however, it still remains unclear whether the health risks associated with Type 
D are due to the addition of individual effects for NA and SI, or whether there is a synergy 
between both subcomponents.
Given the construct and measurement overlap that has been identified across specific 
negative emotions such as depression and anxiety 20, there has been considerable debate 
as to whether it might be more appropriate to study a more general disposition toward 
negative affectivity when it comes to understanding the health risks of emotional distress 
21. There appears to be merit to both approaches, as previous work has suggested that 
there are both unique and shared effects of these negative emotions on the risk of incident 
coronary heart disease 21. The results of the present thesis imply that examining symptom 
clusters related to specific negative emotions does have additional value in understanding 
why some people are more likely to experience adverse health outcomes than others, as 
long as (the absence of) positive emotion is also taken into account. At the same time, our 
findings support previous assertions that symptoms of depression / anxiety may not only 
reflect episodic distress but also a more ingrained tendency to experience distress 5, which 
may partly account for the health risks ascribed to specific types of distress. Therefore, 
it appears best not to consider specific (e.g. dysphoria, anhedonia, anxiety) and general 
(e.g.  Type D personality) approaches to distress as incompatible, but rather as representing 
complementary perspectives to understand emotional functioning and health outcomes 5.
treatment of depression in people with diabetes
Depression is recognized and treated appropriately in fewer than half of depressed people 
with diabetes in primary care 22, 23. This may be due to an overlap among ‘’somatic’’ 
depression symptoms and symptoms of diabetes 15 or an overlap with symptoms that are 
related to increasing age. People with diabetes may also be reluctant to discuss emotional 
distress during routine care consultation 24. The results from chapter 4 suggest that a simple 
question about history of depression may help clinicians to identify those individuals who 
have an increased risk for depressive symptoms later on. however, case-finding alone does 
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not necessarily improve the management of depression 25, also in people with diabetes 26, 
indicati ng the need for additi onal care. A recent meta-analysis showed that pharmacological 
treatment, psychotherapeuti c interventi ons and diabetes self-management educati on 
improve mental health in people with diabetes who are emoti onally distressed 27. Some 
authors have suggested that we may maximize the eff ect of treatment in people with 
diabetes by combining treatment for depression with interventi ons focusing on diabetes 
management 28, 29. For example, a nurse-led care-management interventi on integrati ng the 
management of medical and psychological conditi ons improved both medical outcomes and 
depression in depressed people with diabetes, heart disease, or both 30. One area where 
such an integrati on of depression and self-care interventi ons might be easily achieved is 
behavioral acti vati on through exercise 29, as there is evidence supporti ng the benefi ts of 
exercise for improving both diabetes 31, 32 and mood 33, 34.
Personalized approach
A personalized approach to interventi on should also consider individual diff erences in the 
various determinants of emoti onal distress among people with diabetes. Understanding 
the diabetes-related factors that drive the experience of distress in people with diabetes is 
crucial to the development of appropriate interventi ons, and in many cases interventi ons 
that focus on addressing both distress and diabetes management are likely to have the 
strongest eff ect 14. Apart from diabetes related-factors, individual diff erences in personality 
should also be considered as a determinant of distress.  Type D personality may help to 
identi fy those individuals who are at increased risk of emoti onal distress or subopti mal 
health behaviors while, at the same ti me, being less likely to address these issues during 
medical visits. Findings from chapter 8 and 9 are consistent with previous studies 5, 35, 
suggesti ng that the NA and SI do signal important individual diff erences in the way people 
with diabetes perceive and manage their health. The fact that Type D refers to a personality 
construct does not necessarily imply that interventi ons in Type D individuals may not 
be benefi cial 35. People with Type D personality can learn new strategies to reduce their 
level of general distress 36. For example, mindfulness-based stress reducti on may reduce 
the negati ve aff ecti vity and social inhibiti on components of Type D 37, and has also been 
shown to improve health-related quality of life and mental health in adults with diabetes 
38. The variety of interventi ons delivered over the internet is growing rapidly, and e-health 
may also be an appropriate way to address the emoti onal problems of people with Type D 
personality. These interventi ons may not only reduce general emoti onal distress but also 
diabetes-specifi c distress when the content of web-based interventi ons are being modifi ed 




the temporal architecture of depression and diabetes
One of the issues that remain to be resolved is related to the temporal architecture of 
depression. Chapter 4 indicated that self-reported history of depression was the only factor 
that consistently identified those individuals who had increased odds of experiencing any 
kind of depression later on, even after controlling for demographics, medical co-morbidities, 
and stressful life events in the previous year. Knowing that depression may predate and even 
predict the onset of type 2 diabetes 40, 41, it may be worthwhile to explore the relation between 
depression and diabetes from a lifetime perspective. Although time- and resource intensive, 
important new insights might come from a study where a cohort of people without diabetes 
and without depression is followed over a longer period of time. By tracking the course 
of depression in terms of remission, relapse, recovery and recurrence 42 and by examining 
the timing of diabetes onset in this process, we may learn whether depression in diabetes 
represents an independent new episode or relapse of the initial episode that prompted the 
development of diabetes. Furthermore, such a study may shed more light on whether the 
onset and the course of depression in diabetes are predicted by the same factors as in the 
general population, or whether diabetes-specific factors are more important.  
Although such a design may be easier to implement for type 2 diabetes than for type 1 
diabetes due to its onset later in life, it is important to focus on depression in type 1 diabetes 
as well. There is a disconcerting shortage of published data available on the prevalence and 
treatment of depression and other types of emotional distress in type 1 diabetes 27, 43, and 
with the escalating rates of obesity found across all age groups 44, younger people with type 
2 diabetes may also become a special group of interest. Type 1 and type 2 diabetes differ 
on several important aspects, including etiology, clinical presentation and self-management 
activities, and it is premature to conclude at this stage that this is different for the etiology 
and presentation of depression in both groups. 
the heterogeneity of emotional distress in diabetes
More randomized controlled trials are needed to test collaborative care approaches that 
have a broader focus than just major depression, and offer suitable treatment for anxiety 
and diabetes-specific distress 45 as well as subclinical depressive symptoms. These studies 
may also determine whether screening is a necessary component of these enhanced care 
strategies 25, and whether stepped-care approaches in which individuals receive different 
types and intensities of services tailored to their observed outcomes 46 are the most effective 
and cost-efficient way of obtaining results. Given the low figures of emotional distress 
reported in the present thesis for people with type 2 diabetes in primary care, we may need 
to reconsider whether such resource-intensive approaches are suitable for all clinical settings.
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improving clinical outcomes and treatment for people with diabetes and depression
Given that a considerable number of people with diabetes do not respond to the current 
depression treatment modaliti es, future research eff orts are required to opti mize depression 
outcomes in this group 45. Disti nguishing major depression from other types of emoti onal 
distress may be one step, but the heterogeneity within depression should also be taken 
into account. Focusing treatments on the predominant symptomatology of an individual 
may improve the success rates of depression interventi ons 47, and could potenti ally also 
improve the increased risk of adverse events that has been observed among depressed 
people with diabetes 48, 49. Findings from the present thesis have suggested that diff erent 
symptom clusters may be diff erenti ally related to health outcomes in people with diabetes. 
These preliminary fi ndings merit further explorati on in other diabetes cohorts. If diff erent 
symptoms of depression indeed prove to have divergent associati ons with (diabetes) 
prognosis, we might opti mize outcomes for depressed people with diabetes by directly 
targeti ng the underlying (vasculo)toxic mechanisms as well. 
The potenti al mechanisms that may explain a link between depression (subtypes) and 
adverse health outcomes are generally divided into behavioral and pathophysiological 
pathways. Chapter 7 identi fi ed an important role for physical acti vity in explaining all-
cause mortality, which was not the case for other (cardio)vascular risk factors such as 
blood glucose, cholesterol and blood pressure. Because depression has been associated 
with a wide spectrum of mortality causes 50, 51, the mechanisms underlying the associati on 
between depression and excess mortality may not be restricted to cardiovascular disease. 
Other candidate pathways that were not addressed in the present thesis, but that may 
also link depression to mortality across diff erent conditi ons, include medicati on taking, 
dysregulati ons of the hPA-axis and the autonomic nervous system, and infl ammatory 
processes 13, 51. By supplementi ng our current cohort studies with paradigms encompassing 
comprehensive study of depression subtypes and their health outcomes in small groups of 
well-selected individuals may provide a plethora of relevant new insights that could inform 
the design of new cohort and treatment studies.
screening and treatment: who are we missing?
In order to put fi ndings relati ng to screening and treatment for emoti onal problems in 
the right perspecti ve, we need to know more about the people who are not parti cipati ng 
in screening procedures. Preliminary fi ndings suggest that the group who is missed by 
screening have higher HbA1c values, are younger, are more likely to smoke and show a high 
rate of not showing up at the outpati ent clinic for their appointment with the physician, 
characteristi cs that have all been related to depression 52. If we are systemati cally missing 
those people who may need our help most, we may need to rethink ways of reaching them. 
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Discrepancies between screening-results and the need for / acceptance of professional help
While the high prevalence of undertreatment may partly be due to the low recognition 
rates of mental health problems in people with diabetes 53, not all people who score 
positive on screening instruments will need or accept professional help. In a Dutch diabetes 
outpatient clinic, only one third of all people with elevated depressive symptoms and / 
or diabetes-related distress indicated an unmet need for which they would like a referral 
for additional psychosocial care 52. The remaining group was either not interested in 
additional care, indicated that they had already received help, or could not be reached 52. 
In a Croatian study among people with type 2 diabetes treated at a university clinic for 
diabetes, 77% of the participants reporting at least one elevated depressive symptom on 
a postal screening indicated a need for professional help 54. The reasons to decline help 
were unknown, although the authors speculated that these individuals may already receive 
treatment 54. Almost one-third of the participants who were deemed eligible for a behavioral 
treatment of subsyndromal depression declined participation, most frequently reporting 
competing priorities such as professional and family obligations or lack of time as reasons 
for nonparticipation 54. Comparing characteristics of people with and without an agreed 
referral for elevated depressive symptoms and / or diabetes-related distress in the MIND 
study showed that the first group was more likely to have a lower educational level, diabetes 
complications and higher hbA1c values 
55.
Why people may refuse professional help
As the number of people with screen-detected emotional problems accepting professional 
care is generally low, it would be interesting to explore the reasons behind this refusal 
in more detail. Emotional problems as measured with screening questionnaires may not 
always be severe enough to seriously disrupt daily life, and people may have other, sufficient 
resources available to cope with their emotional problems, including high levels of social 
support. Alternatively, people may be reluctant to seek or accept professional help because 
they minimize problems that are profoundly affecting them or their close ones due to pride 
or fear of stigma, or because they want to avoid shameful and sometimes confusing feelings. 
Where there is a clear need for professional care, we need to be sensitive to these potential 
barriers and think about other paradigms to make this care available. Although certainly 
not a treatment option for all problems, web-based interventions – where feedback is given 
in an indirect way - may help to remove some of the reservations people might have in 
accepting professional help. 
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type D personality and health outcomes in people with diabetes
Chapter 8 and 9 have suggested that Type D personality may be related to subopti mal self-
care behaviors and emoti onal distress in people with diabetes. Further study is warranted 
to determine the clinical relevance of Type D personality for people with diabetes in terms 
of clinical prognosis. These prospecti ve studies are advised to focus on other potenti al risk 
mechanisms as well, including dysregulati ons of the hypothalamic-pituitary-adrenal axis, 
sympatheti c nervous system and immune processes 56, and to examine whether any risks 
associated with Type D personality are driven by its NA or SI subcomponent only, or whether 
it is the combinati on of the two that poses a risk to health. In the upcoming years, the 
DiaDDZoB Study will provide some preliminary results with respect to these questi ons in 
a cohort of people with type 2 diabetes in primary care. Importantly, these associati ons 
should be addressed in other diabetes cohorts as well. Although earlier fi ndings have 
been reasonably consistent 5, 57, several recent studies have failed to establish a relati on 
between Type D personality and all-cause mortality 58-61. These later studies mostly focused 
on people with chronic heart failure, who are generally somewhat older than the samples 
with coronary artery disease examined in previous studies 57. Interesti ngly, depression and 
anxiety did not predict mortality in these studies either 58-61. It may be diffi  cult to establish 
a specifi c role of psychosocial factors in predicti ng mortality in older populati ons, because 
these individuals oft en have numerous co-morbid chronic medical conditi ons that may be 
implicated.
CONCLUDiNG ReMARKs
By acknowledging the heterogeneity of emoti onal distress in people with diabetes, 
we acknowledge that current clinical practi ce and research might benefi t from a more 
personalized approach. This may mean that we need to learn more about the usefulness 
of specifi c interventi ons and adjust our treatments for diff erent subgroups of people with 
diabetes 62, in order to successfully improve both emoti onal distress and diabetes outcomes. 
This paradigm shift  may start small, by reconsidering the potenti al importance of emoti onal 
problems in standard diabetes care. By emphasizing that emoti onal distress is common in 
people with diabetes – without overpathologizing problems – and by establishing a working 
relati on where people feel safe to discuss their concerns, health providers may encourage 





1. Bot M. Dynamics of depression and diabetes. Tilburg, The Netherlands: Tilburg University; 2012.
2. Pouwer F, Geelhoed-Duijvestijn Ph, Tack CJ, et al. Prevalence of comorbid depression is high in out-patients 
with type 1 or type 2 diabetes mellitus. Results from three out-patient clinics in the Netherlands. Diabet Med 
2010;27:217-24.
3. Pouwer F, Beekman AT, Nijpels G, et al. Rates and risks for co-morbid depression in patients with type 2 
diabetes mellitus: results from a community-based study. Diabetologia 2003;46:892-8.
4. Adriaanse MC, Dekker JM, heine RJ, et al. Symptoms of depression in people with impaired glucose 
metabolism or type 2 diabetes mellitus: The hoorn Study. Diabet Med 2008;25:843-9.
5. Denollet J, Schiffer AA, Spek V. A general propensity to psychological distress affects cardiovascular outcomes: 
evidence from research on the Type D (distressed) personality profile. Circ Cardiovasc Qual Outcomes 
2010;3:546-57.
6. Mols F, Denollet J. Type D personality in the general population: a systematic review of health status, 
mechanisms of disease, and work-related problems. health Qual Life Outcomes 2010;8:9.
7. Ruige JB, Batstra MR, Aanstoot hJ, et al. Low prevalence of antibodies to GAD65 in a 50- to 74-year-old general 
Dutch population. The hoorn Study. Diabetes Care 1997;20:1108-10.
8. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in 
regression-type models. Psychosom Med 2004;66:411-21.
9. Peduzzi P, Concato J, Feinstein AR, holford TR. Importance of events per independent variable in proportional 
hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-
10.
10. Peduzzi P, Concato J, Kemper E, holford TR, Feinstein AR. A simulation study of the number of events per 
variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9.
11. Vervloet MG, Twisk JW. Mortality reduction by vitamin D receptor activation in end-stage renal disease: a 
commentary on the robustness of current data. Nephrol Dial Transplant 2009;24:703-6.
12. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: 
conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-82.
13. de Jonge P, Rosmalen JG, Kema IP, et al. Psychophysiological biomarkers explaining the association between 
depression and prognosis in coronary artery patients: a critical review of the literature. Neurosci Biobehav Rev 
2010;35:84-90.
14. Gonzalez JS, Fisher L, Polonsky Wh. Depression in diabetes: have we been missing something important? 
Diabetes Care 2011;34:236-9.
15. Roy T, Lloyd CE, Pouwer F, holt RI, Sartorius N. Screening tools used for measuring depression among people 
with type 1 and type 2 diabetes: a systematic review. Diabet Med 2012;29:164-75.
16. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with 
diabetes: a meta-analysis. Diabetes Care 2001;24:1069-78.
17. Fisher L, Skaff MM, Mullan JT, et al. Clinical depression versus distress among patients with type 2 diabetes: 
not just a question of semantics. Diabetes Care 2007;30:542-8.
18. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. 
Psychosom Med 2005;67:89-97.
19. Smith TW. Toward a more systematic, cumulative, and applicable science of personality and health: lessons 
from Type D personality. Psychosom Med 2011;73:528-32.
20. Suls J, Bunde J. Anger, anxiety, and depression as risk factors for cardiovascular disease: the problems and 
implications of overlapping affective dispositions. Psychol Bull 2005;131:260-300.
21. Kubzansky LD, Cole SR, Kawachi I, Vokonas P, Sparrow D. Shared and unique contributions of anger, anxiety, 
and depression to coronary heart disease: a prospective study in the normative aging study. Ann Behav Med 
2006;31:21-9.
22. Katon WJ, Simon G, Russo J, et al. Quality of depression care in a population-based sample of patients with 
diabetes and major depression. Med Care 2004;42:1222-9.
23. Rubin RR, Ciechanowski P, Egede LE, Lin Eh, Lustman PJ. Recognizing and treating depression in patients with 
diabetes. Curr Diab Rep 2004;4:119-25.
10
SUMMARY AND GENERAL DISCUSSION
199
24. Snoek FJ, Kersch NY, Eldrup E, et al. Monitoring of Individual Needs in Diabetes (MIND): baseline data from the 
Cross-Nati onal Diabetes Atti  tudes, Wishes, and Needs (DAWN) MIND study. Diabetes Care 2011;34:601-3.
25. Gilbody S, Sheldon T, house A. Screening and case-fi nding instruments for depression: a meta-analysis. CMAJ 
2008;178:997-1003.
26. Pouwer F, Tack CJ, Geelhoed-Duijvesti jn Ph, et al. Limited eff ect of screening for depression with writt en 
feedback in outpati ents with diabetes mellitus: a randomised controlled trial. Diabetologia 2011;54:741-8.
27. van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Eff ect of interventi ons for major depressive disorder and 
signifi cant depressive symptoms in pati ents with diabetes mellitus: a systemati c review and meta-analysis. 
Gen hosp Psychiatry 2010;32:380-95.
28. Katon W. Depression and diabetes: unhealthy bedfellows. Depress Anxiety 2010;27:323-6.
29. Markowitz SM, Gonzalez JS, Wilkinson JL, Safren SA. A review of treati ng depression in diabetes: emerging 
fi ndings. Psychosomati cs 2011;52:1-18.
30. Katon WJ, Lin Eh, Von Korff  M, et al. Collaborati ve care for pati ents with depression and chronic illnesses. N 
Engl J Med 2010;363:2611-20.
31. American Diabetes Associati on: Standards of medical care in diabetes--2011. Diabetes Care 2011;34 Suppl 
1:S11-61.
32. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine 
and the American Diabetes Associati on: joint positi on statement. Diabetes Care 2010;33:e147-67.
33. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for depression. Cochrane 
Database Syst Rev 2009:CD004366.
34. Rimer J, Dwan K, Lawlor DA, et al. Exercise for depression. Cochrane Database Syst Rev 2012;7:CD004366.
35. Pelle AJ, Van den Broek KC, Denollet J. Interventi ons in the context of the distressed (Type D) personality. In: 
Dornelas EA, ed. Stress proof the heart: behavioral interventi ons for cardiac pati ents. Springer; 2012:167-98.
36. Tulloch h, Pelleti er R. Does personality matt er aft er all? Type D personality and its implicati ons for 
cardiovascular preventi on and rehabilitati on. CICRP 2008;16:1-4.
37. Nyklíček I, van Beugen S, Denollet J. Eff ects of mindfulness-based stress reducti on on distressed (Type D) 
personality traits: a randomized controlled trial. J Behav Med 2012; in press.
38. van Son J, Nyklíček I, Pop VJ, et al. The Eff ects of a Mindfulness-Based Interventi on on Emoti onal Distress, 
Quality-of-Life, and hbA1c in Outpati ents With Diabetes (DiaMind): A randomized controlled trial. Diabetes 
Care 2013;36:823-30.
39. van Bastelaar KM, Pouwer F, Cuijpers P, Riper h, Snoek FJ. Web-based depression treatment for type 1 and 
type 2 diabeti c pati ents: a randomized, controlled trial. Diabetes Care 2011;34:320-5.
40. Knol MJ, Twisk JW, Beekman AT, heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 
2 diabetes mellitus. A meta-analysis. Diabetologia 2006;49:837-45.
41. Mezuk B, Eaton WW, Albrecht S, Golden Sh. Depression and type 2 diabetes over the lifespan: a meta-analysis. 
Diabetes Care 2008;31:2383-90.
42. Frank E, Prien RF, Jarrett  RB, et al. Conceptualizati on and rati onale for consensus defi niti ons of terms in major 
depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5.
43. Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: 
systemati c literature review. Diabet Med 2006;23:445-8.
44. Zimmet P, Alberti  KG, Shaw J. Global and societal implicati ons of the diabetes epidemic. Nature 2001;414:782-7.
45. Pouwer F. Should we screen for emoti onal distress in type 2 diabetes mellitus? Nat Rev Endocrinol 2009;5:665-
71.
46. Katon WJ, Von Korff  M, Lin Eh, et al. The Pathways Study: a randomized trial of collaborati ve care in pati ents 
with diabetes and depression. Arch Gen Psychiatry 2004;61:1042-9.
47. Nutt  D, Demytt enaere K, Janka Z, et al. The other face of depression, reduced positi ve aff ect: the role of 
catecholamines in causati on and cure. J Psychopharmacol 2007;21:461-71.
48. Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults 
with and without diabetes. Diabetes Care 2005;28:1339-45.
49. Lin Eh, Rutt er CM, Katon W, et al. Depression and advanced complicati ons of diabetes: a prospecti ve cohort 
study. Diabetes Care 2010;33:264-9.
ChAPTER 10
200
50. Mykletun A, Bjerkeset O, Dewey M, Prince M, Overland S, Stewart R. Anxiety, depression, and cause-specific 
mortality: the hUNT study. Psychosom Med 2007;69:323-31.
51. Lin Eh, heckbert SR, Rutter CM, et al. Depression and increased mortality in diabetes: unexpected causes of 
death. Ann Fam Med 2009;7:414-21.
52. Fleer J, Tovote KA, Keers JC, et al. Screening for depression and diabetes-related distress in a diabetes 
outpatient clinic. Diabet Med 2013;30:88-94.
53. Li C, Ford ES, Zhao G, Balluz LS, Berry JT, Mokdad Ah. Undertreatment of mental health problems in adults 
with diagnosed diabetes and serious psychological distress: the behavioral risk factor surveillance system, 
2007. Diabetes Care 2010;33:1061-4.
54. Ajdukovic D, Pibernik-Okanovic M, Sekerija M, hermanns N. The reach of depression screening preceding 
treatment: are there patterns of patients’ self-selection? Int J Endocrinol 2012;2012:148145.
55. Snoek FJ, Kersch NY, Eldrup E, et al. Monitoring of Individual Needs in Diabetes (MIND)-2: Follow-up data from 
the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. Diabetes Care 2012;35:2128-32.
56. Kupper N, Denollet J. Type D personality as a prognostic factor in heart disease: assessment and mediating 
mechanisms. J Pers Assess 2007;89:265-76.
57. Grande G, Romppel M, Barth J. Association between Type D personality and prognosis in patients with 
cardiovascular diseases: a systematic review and meta-analysis. Ann Behav Med 2012;43:299-310.
58. Pelle AJ, Pedersen SS, Schiffer AA, Szabo B, Widdershoven JW, Denollet J. Psychological distress and mortality 
in systolic heart failure. Circ heart Fail 2010;3:261-7.
59. Grande G, Romppel M, Vesper JM, Schubmann R, Glaesmer H, Herrmann-Lingen C. Type D personality and 
all-cause mortality in cardiac patients--data from a German cohort study. Psychosom Med 2011;73:548-56.
60. Coyne JC, Jaarsma T, Luttik ML, van Sonderen E, van Veldhuisen DJ, Sanderman R. Lack of prognostic value of 
Type D personality for mortality in a large sample of heart failure patients. Psychosom Med 2011;73:557-62.
61. Volz A, Schmid JP, Zwahlen M, Kohls S, Saner h, Barth J. Predictors of readmission and health related quality 
of life in patients with chronic heart failure: a comparison of different psychosocial aspects. J Behav Med 
2011;34:13-22.
62. Petrak F, herpertz S. Treatment of depression in diabetes: an update. Curr Opin Psychiatry 2009;22:211-7.
CHAPTEr 11
Nederlandse samenvatti  ng (summary in Dutch)
Dankwoord (Acknowledgements)
List of publicati ons
About the author

Nederlandse samenvatti  ng (summary in Dutch)

11




Wereldwijd krijgt een groeiend aantal mensen te maken met diabetes, een chronische 
stofwisselingsziekte waarbij sprake is van verhoogde bloedsuikerwaardes als gevolg van een 
tekort en / of een verminderde werkzaamheid van insuline. In Nederland zijn er ongeveer 
één miljoen mensen met diabetes, van wie een kwart niet weet dat ze deze aandoening 
hebben. Er bestaan verschillende vormen van diabetes, die vaak een verschillende 
oorzaak en presentati e hebben. Bij ongeveer 90% van de mensen met diabetes is sprake 
van diabetes type 2. Deze vorm van diabetes ontstaat vaak op middelbare of oudere 
leeft ijd, maar wordt vanwege zijn samenhang met overgewicht steeds vaker vastgesteld 
bij jongvolwassen en kinderen. Een andere belangrijke vorm is diabetes type 1 (5 – 10%), 
veroorzaakt door vernieti ging van cellen in de alvleesklier die verantwoordelijk zijn voor de 
aanmaak van insuline. Deze aandoening ontwikkelt zich over het algemeen bij kinderen en 
jongvolwassenen, maar kan in principe op alle leeft ijden ontstaan.
De meeste mensen zijn in staat om met diabetes een pretti  g leven te leiden, maar voor een 
aantal kan het soms moeilijk zijn om te gaan met de diagnose, de zelfzorg en de (dreiging 
van) complicati es van de diabetes. Zo kunnen mensen op korte termijn te maken krijgen 
met te lage (hypo’s) of te hoge (hypers) waardes van de bloedsuikers. Op langere termijn 
kunnen hart- en vaatziekten en beschadigingen aan de kleine bloedvaatjes van bijvoorbeeld 
de ogen, nieren en zenuwen (microvasculaire complicati es) ontstaan. het is mogelijk om 
deze vaataandoeningen te voorkomen of te vertragen door het nastreven van een zo 
opti maal mogelijke regeling van bloedsuikerwaardes en andere risicofactoren voor hart- 
en vaatziekten, zoals bloeddruk en cholesterol. De hieruit voortkomende zelfzorg voor de 
diabetes bestaat uit verschillende acti viteiten, waaronder het dagelijks gebruik van tablett en 
en / of insuline, het regelmati g meten van bloedsuikerwaardes, voetzorg, gezond eetgedrag 
(en voor sommigen het tellen van koolhydraten) en voldoende lichaamsbeweging. het is dan 
ook niet verwonderlijk dat diabetes en de complicati es van diabetes een negati eve invloed 
kunnen hebben op het emoti oneel welbevinden en de kwaliteit van leven van mensen 
die met deze aandoening leven. Op hun beurt kunnen emoti onele problemen de zelfzorg 
voor de diabetes behoorlijk bemoeilijken en de kans op negati eve gezondheidsuitkomsten 
verhogen.
Depressie komt vaak voor bij mensen met diabetes
Depressie komt voor bij 10 – 30% van de mensen met diabetes, ongeveer tweemaal zo vaak 
als bij mensen zonder deze aandoening. Vaak wordt gebruik gemaakt van vragenlijsten om 
de aanwezigheid van verhoogde depressieve symptomen in kaart te brengen, maar een 
depressieve stoornis kan alleen vastgesteld worden met een diagnosti sch interview. Studies 
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die depressie meten aan de hand van een vragenlijst vinden vaak hogere percentages 
sombere deelnemers dan studies die gebruik hebben gemaakt van een interview. Bij mensen 
met diabetes hangt depressie niet alleen samen met zogenoemde “patiënt-gerapporteerde 
uitkomstmaten” als kwaliteit van leven, maar er lijkt ook een link te zijn met andere 
negatieve gezondheidsuitkomsten. Zo zijn er studies die een relatie hebben gevonden 
tussen depressie en verhoogde bloedsuikerwaardes, de ontwikkeling van microvasculaire 
complicaties en hart- en vaatziekte, en vroegtijdige sterfte. 
Doel van dit proefschrift
In de afgelopen twintig jaar zijn we veel te weten gekomen over de relatie tussen diabetes 
en emotionele problemen. Er zijn echter nog verschillende vragen onbeantwoord gebleven. 
Dit proefschrift gaat in op de volgende vragen:
- Kunnen hoge bloedsuikerwaardes en /  of de last van het leven met diabetes het grote 
aantal mensen met diabetes en depressie verklaren?
- Wat is het verloop van depressie bij mensen met diabetes type 2?
- hangt depressie samen met het moment waarop met insulinetherapie wordt gestart bij 
mensen met diabetes type 2?
- hangen symptomen die te maken hebben met de twee hoofdkenmerken van depressie 
(dysforie, anhedonie) op een andere manier samen met gezondheidsuitkomsten bij 
mensen met diabetes type 2? Spelen gezondheidsgedrag en verstoorde lichaamsfuncties 
als hoge bloedsuikerwaardes, verhoogd cholesterol, en hoge bloeddruk hierbij een rol?
- Wat is de rol van andere, meer chronische emotionele problemen bij mensen met 
diabetes?
Beter begrijpen van het grote aantal mensen met diabetes en depressie
Momenteel begrijpen we nog niet precies waarom depressie vaker voorkomt bij mensen 
met diabetes dan bij mensen zonder deze chronische aandoening. Een mogelijke reden zou 
kunnen zijn dat mensen met diabetes eerder depressief raken, omdat zij iedere dag rekening 
moeten houden met hun aandoening en om moeten gaan met (de dreiging van) complicaties 
van de diabetes. In dat geval zou depressie vaker moeten voorkomen bij mensen bij wie 
diabetes type 2 is vastgesteld dan bij mensen die niet weten dat ze diabetes type 2 hebben 
of bij mensen bij wie sprake is van een voorstadium van diabetes type 2 (pre-diabetes). 
Deze twee laatste groepen hoeven immers (nog) niet om te gaan met het feit dat ze een 
chronische aandoening hebben die dagelijkse zelfzorg vereist. Een andere mogelijkheid 
is dat depressie direct voortkomt uit lichamelijke veranderingen door de diabetes, zoals 
hoge bloedsuikers. Als hoge bloedsuikers inderdaad direct de stemming beïnvloeden, dan 
verwachten we dat mensen met een normale suikerstofwisseling minder vaak depressieve 
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klachten rapporteren dan mensen die hogere bloedsuikers hebben, zoals mensen met pre-
diabetes en mensen met nog niet ontdekte diabetes type 2. 
Om deze twee mogelijke verklaringen verder te onderzoeken, hebben we in hoofdstuk 2 alle 
bestaande studies in kaart gebracht die hebben gekeken naar het voorkomen van depressie 
bij mensen met pre-diabetes of ongediagnosti ceerde diabetes ten opzichte van mensen 
met een normale suikerstofwisseling of mensen met eerder vastgestelde diabetes type 2. 
Uit dit literatuuronderzoek bleek dat depressie niet vaker voorkwam bij mensen met pre-
diabetes of met ongediagnosti ceerde diabetes in vergelijking met mensen met een normale 
suikerstofwisseling. Bij deze twee groepen was echter minder vaak sprake van depressie dan 
bij mensen die eerder de diagnose diabetes type 2 hadden gekregen. Het lijkt er dus op dat 
depressie niet zozeer samenhangt met de hoogte van de bloedsuikers op zich, maar meer 
met de emoti onele last die de diagnose en zelfzorg van diabetes met zich meebrengen.
Het verloop van depressieve symptomen bij mensen met diabetes
Studies in de algemene bevolking en in de eerste lijn hebben laten zien dat depressie 
(gemeten met een diagnosti sch interview of een vragenlijst) voor veel mensen een 
chronische en terugkerende aandoening is. Over het verloop van depressie bij mensen met 
diabetes is veel minder bekend. De studies die zijn verricht suggereren dat depressie in 
deze groep ook een ongunsti g beloop kent, maar hebben verschillende tekortkomingen. 
Zo onderzochten ze meestal maar een klein aantal mensen met diabetes, hadden ze vaak 
maar twee momenten waarop depressie werd gemeten, of brachten ze het verloop van de 
problemen in kaart bij mensen die deelnamen aan een interventi e die de klachten mogelijk 
kon beïnvloeden. Ook over de factoren die het verloop van depressie kunnen voorspellen, 
weten we maar weinig. 
Meer informati e over het beloop van depressie en de gezondheidsrisico’s van emoti onele 
problemen komt mogelijk voort uit de DiaDDZoB (Diabetes, Depression, Type D personality 
Zuidoost-Brabant) Studie. In hoofdstuk 3 beschrijven we het idee achter en het ontwerp van 
deze studie die een grote groep mensen met diabetes type 2 in de eerste lijn volgt in de ti jd. 
De belangrijkste doelen van de studie waren (1) het in kaart brengen van het verloop van 
depressie, gemeten met een vragenlijst, in deze groep; (2) te onderzoeken of depressie en 
Type D persoonlijkheid samenhangen met de ontwikkeling van microvasculaire complicati es 
en hart- en vaatziekten, en met vroegti jdig overlijden;  en (3) te kijken of gezondheidsgedrag 
en verstoringen in normale lichaamsfuncti es daarbij een mogelijke verklaring vormen. 
De eerste meti ng vond plaats in 2005 (2460 deelnemers) en vervolgmeti ngen werden 
gerealiseerd in 2007 (2225 deelnemers) en 2008 (2032 deelnemers). Er werd gebruik 
gemaakt van een interview door de prakti jkondersteuner, een vragenlijst die de persoon 
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zelf moest invullen, en de resultaten van laboratoriumonderzoek en lichamelijk onderzoek 
dat binnen de normale zorg werd uitgevoerd. 
Gebruikmakend van informatie die binnen de DiaDDZoB Studie tijdens drie meetmomenten 
in een periode van 2 ½ jaar is verzameld, beschrijft hoofdstuk 4 het verloop van depressie 
bij mensen met diabetes type 2. In totaal had één op de vier deelnemers ten minste één 
keer een verhoogde score op de gebruikte depressievragenlijst. In de groep die bij start 
van de studie geen depressieve symptomen rapporteerde, was op een later meetmoment 
bij 14% wel sprake van depressieve symptomen. Twee-derde van de deelnemers die bij 
aanvang van de studie depressieve symptomen rapporteerden, had later in de studie ook 
een verhoogde score op de depressievragenlijst. Depressie, gemeten met een vragenlijst, 
lijkt dus regelmatig voor te komen bij mensen met diabetes type 2 en is vaak chronisch / 
terugkerend in deze groep. het rapporteren van eerdere depressie(s) was de enige factor die 
consistent voorspelde wie tijdens de studie met depressie te maken kreeg, zelfs als rekening 
gehouden werd met leeftijd, geslacht, opleiding, burgerlijke status, de aanwezigheid van 
andere medische aandoeningen, en stressvolle gebeurtenissen in het afgelopen jaar.
Depressie en start met insulinetherapie
Omdat er bij diabetes type 1 sprake is van een absoluut tekort aan insuline, moet er meteen 
na de diagnose begonnen worden met extra toediening van insuline. Bij diabetes type 2 
spelen een verminderde gevoeligheid voor insuline in het lichaam en een abnormale 
afscheiding van insuline een rol. hierbij kan vaak eerst geprobeerd worden de bloedsuikers 
omlaag te krijgen met een gezonde leefstijl of tabletten die de bloedsuikers verlagen. Een 
groot aantal mensen met diabetes type 2 zal uiteindelijk toch insuline moeten gaan gebruiken 
om de bloedsuikerwaardes te reguleren. Momenteel is het onduidelijk of depressie een 
rol speelt bij het bepalen van het moment waarop gestart wordt met insulinetherapie. 
Er zijn aanwijzingen dat de aanwezigheid van depressieve symptomen bij mensen met 
diabetes type 2 die nog geen insuline gebruiken samenhangt met een negatievere kijk 
op insulinetherapie. Dit zou ervoor kunnen zorgen dat mensen die depressieve klachten 
rapporteren de start met insulinetherapie proberen uit te stellen. Het is ook mogelijk dat 
depressie een eerdere start met insulinetherapie nodig maakt, omdat het samenhangt met 
een minder optimale zelfzorg en hogere bloedsuikerwaardes.
In hoofdstuk 5 is daarom gekeken of depressie, gemeten met een vragenlijst, samenhangt 
met een eerdere start van insulinetherapie bij mensen met diabetes type 2 die nog geen 
insuline gebruiken. Naast informatie uit de DiaDDZoB Studie werd hierbij gebruik gemaakt 
van medicatievoorschriften uit een grote landelijke database (PhARMO Database Network). 
In een periode van 5 ½ jaar startte 18% van de deelnemers met insulinetherapie. Mensen 
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met een verhoogde score op de depressievragenlijst startt en niet vroeger of later met 
insulinetherapie dan mensen die geen verhoogde score lieten zien, zelfs niet als rekening 
gehouden werd met geslacht, leeft ijd, bloedsuikerspiegels en andere factoren die mogelijk 
een rol zouden kunnen spelen bij het besluit te starten met insuline. Er is meer informati e 
nodig over het beslisproces rondom de start met insuline (zowel wat betreft  de persoon met 
diabetes zelf, de zorgverlener en het zorgsysteem) om met meer zekerheid vast te stellen of 
depressie inderdaad niet samenhangt met het moment waarop met insulinetherapie wordt 
begonnen.
De diversiteit van depressie en de gevolgen daarvan voor mensen met diabetes
Naast een per persoon wisselende combinati e van problemen op het gebied van eetlust / 
gewicht, slaap, concentrati e, vermoeidheid, traagheid / onrust, waardeloosheid / schuld, of 
gedachten aan (zelf)dood  is er bij een depressieve stoornis alti jd sprake van ten minste één 
van twee kernsymptomen: een depressieve stemming (ook wel dysforie genoemd) en / of 
een duidelijk verminderde interesse of plezier in acti viteiten (anhedonie). Dysforie omvat 
negati eve emoti es zoals gevoelens van droefh eid en leegheid, terwijl het bij anhedonie 
eerder lijkt te gaan om de afwezigheid van positi eve emoti es. Er zijn aanwijzingen dat 
symptomen die samenhangen met anhedonie een sterkere samenhang vertonen met 
gezondheid dan symptomen die betrekking hebben op dysforie. Zo is bij ouderen uit de 
algemene bevolking en mensen met hartaandoeningen gevonden dat de afwezigheid van 
positi eve emoti es samenhangt met de ontwikkeling van cardiovasculaire aandoeningen en 
met vroegti jdig overlijden. Over het belang van dysforie en anhedonie voor de gezondheid 
van mensen met diabetes is nog weinig bekend.
In hoofdstuk 6 werd daarom gebruik gemaakt van data uit de DIAZOB Primary Care Diabetes 
studie, een studie in de eerste lijn die een grote groep mensen met diabetes type 2 over de 
ti jd volgt, om te bekijken of symptomen die betrekking hebben op dysforie op een andere 
manier samenhangen met een minder opti male instelling van de diabetes, gemeten met 
behulp van het HbA1c, dan symptomen van anhedonie. Hierbij bleek dat alleen anhedonie 
– en niet dysforie of angst – samenhing met een minder opti maal hbA1c. Alcoholgebruik, 
lichaamsbeweging en de duur van de diabetes leken hierbij een mogelijke rol te spelen, 
maar vormden geen van allen een afdoende en overtuigende verklaring voor de gevonden 
relati e tussen anhedonie en hbA1c.
hoofdstuk 7 onderzocht vervolgens of dysforie, anhedonie en angst ziekenhuisopnames 
voor hart- en vaatziekte en sterft e konden voorspellen in de DiaDDZoB Studie. Ook hier werd 
gebruik gemaakt van informati e die beschikbaar was in het PhARMO Database Network, 
ditmaal met betrekking tot ziekenhuisopnames en overlijden. Na 5 ½ jaar was 13% van de 
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deelnemers ten minste één keer in het ziekenhuis opgenomen geweest vanwege hart- en 
vaatziekte en 10% van de deelnemers bleek overleden te zijn. Dysforie hing samen met een 
kortere tijd tot de eerste ziekenhuisopname, maar deze relatie bleek niet overeind te blijven 
als rekening werd gehouden met demografische en medische factoren. In dat geval bleek 
angst wel samen te hangen met een langere tijd tot de eerste ziekenhuisopname. In alle 
scenario’s voorspelden symptomen van anhedonie vroegtijdig overlijden. Lichaamsbeweging 
leek hierbij een belangrijke verklarende rol te spelen.
Type D persoonlijkheid (“binnenvetters”)
Een aantal recente studies heeft laten zien dat depressie de ontwikkeling van 
microvasculaire complicaties en hart- en vaatziekte kan voorspellen bij mensen met 
diabetes. Meetinstrumenten die gebruikt worden om depressie in kaart te brengen 
hebben echter vaak betrekking op de afgelopen 1 – 2 weken, terwijl het vaak jaren duurt 
voordat complicaties zich aandienen. We weten weinig over de gezondheidsrisico’s van 
langer durende emotionele problemen, bijvoorbeeld die te maken hebben met individuele 
verschillen in persoonlijkheid. In de afgelopen jaren zijn er verschillende studies verschenen 
die hebben laten zien dat mensen met een hart- en vaatziekte en een zogenaamde Type D 
persoonlijkheid een groter risico lopen op bijvoorbeeld het doormaken van een hartinfarct, 
het moeten ondergaan van medische ingrepen om de bloedcirculatie te herstellen, en 
vroegtijdig overlijden. Mensen met Type D persoonlijkheid ervaren veel negatieve emoties 
(negatieve affectiviteit), maar zijn tegelijkertijd geneigd deze emoties niet te uiten (sociale 
inhibitie) uit angst voor kritiek of afwijzing van anderen. Type D persoonlijkheid wordt 
meestal gemeten met de Type D schaal (DS14), maar we weten niet of we dit instrument 
zonder meer ook bij mensen met diabetes kunnen toepassen.
hoofdstuk 8 onderzocht daarom de validiteit (meet de vragenlijst wat hij zou moeten 
meten) en de betrouwbaarheid (is de vragenlijst consistent) van de DS14 bij mensen met 
diabetes type 2 uit de DiaDDZoB Studie. De vragenlijst bleek inderdaad twee verschillende 
factoren te meten, te weten negatieve affectiviteit en sociale inhibitie. De betrouwbaarheid 
van deze twee schalen was voldoende, ook als de vragenlijst na een jaar opnieuw werd 
ingevuld. Deze resultaten werden gevonden voor zowel mannen als vrouwen en suggereren 
dat de DS14 inderdaad toegepast kan worden bij mensen met diabetes. In een volgende 
stap werd gekeken of mensen met Type D persoonlijkheid verschilden van mensen zonder 
Type D persoonlijkheid wat betreft demografische en klinische kenmerken. Er bleken geen 
verschillen te bestaan tussen deelnemers met en zonder Type D persoonlijkheid wat betreft 
de aanwezigheid van hart- en vaatziekte of risicofactoren voor vaataandoeningen, zoals 
bloeddruk, cholesterol en bloedsuikers. Wel waren vrouwen met een Type D persoonlijkheid 
minder vaak lichamelijk actief. Deelnemers met een Type D persoonlijkheid rapporteerden 
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verder minder sociale steun en meer stressvolle gebeurtenissen, eenzaamheid, en meer 
dysforie, anhedonie en angst. 
Een mogelijke weg waarlangs Type D persoonlijkheid de gezondheid negati ef zou kunnen 
beïnvloeden, is minder opti maal gezondheidsgedrag. Eerder onderzoek onder verschillende 
groepen (gezonde jongvolwassenen, algemene bevolking, mensen die een hoog risico lopen 
op het ontwikkelen van hart- en vaatziekte, mensen met bestaande hart- en vaatziekte) 
suggereert dat mensen met Type D persoonlijkheid minder vaak lichamelijk acti ef zijn 
en gezond eten, minder vaak adviezen van zorgverleners met betrekking tot medicati e 
opvolgen, en minder vaak contact opnemen met zorgverleners als daar een goede reden 
voor is. Type D persoonlijkheid lijkt ook samen te hangen met angst, depressie en andere 
emoti onele problemen, en zou via deze negati eve emoti es ook indirect van invloed kunnen 
zijn op de gezondheid. het is echter onduidelijk of het hierbij gaat om de combinati e van 
negati eve aff ecti viteit en sociale inhibiti e, of dat slechts één van de onderdelen van Type D 
persoonlijkheid een rol speelt.
In hoofdstuk 9 werd daarom gekeken of Type D persoonlijkheid en diens twee onderdelen 
– negati eve aff ecti viteit en sociale inhibiti e – op een andere manier samenhangen met 
gezondheidsgedrag, emoti onele problemen en verstoorde lichaamsfuncti es als hoge 
bloeddruk, verhoogd cholesterol en hoge bloedsuikers bij mensen met diabetes type 1 of 
type 2. hierbij werd gebruik gemaakt van gegevens uit Diabetes MILES – The Netherlands, 
een landelijk online vragenlijstonderzoek onder volwassen Nederlanders met diabetes. 
In vergelijking met mensen die op geen of slechts één onderdeel hoog scoorden, aten 
deelnemers met Type D persoonlijkheid minder vaak gezond, waren ze minder geneigd 
contact op te nemen met zorgverleners als er problemen rondom de zelfzorg waren, 
ervoeren ze meer problemen rondom het gebruik van medicati e, en rapporteerden ze meer 
eenzaamheid, diabetes-specifi eke sociale angst en symptomen van angst en depressie in 
het algemeen. Negati eve aff ecti viteit (met of zonder de aanwezigheid van sociale inhibiti e) 
hing samen met minder lichaamsbeweging, de neiging te eten bij emoti es of prikkels 
van buitenaf, en zorgen rondom de diabetes. Sociale inhibiti e (met of zonder negati eve 
aff ecti viteit) hing op zijn beurt samen met een minder frequente controle van de voeten. 
Er werden geen verschillen gevonden wat betreft  ander gezondheidsgedrag of verstoorde 
lichaamsfuncti es. Door te kijken naar de aanwezigheid van zowel negati eve aff ecti viteit als 
sociale inhibiti e kunnen we mogelijk mensen herkennen die eerder te maken krijgen met 
minder opti maal gezondheidsgedrag en emoti onele problemen, en tegelijkerti jd minder 




De belangrijkste bevindingen van dit proefschrift suggereren dat er voor mensen met 
diabetes en emotionele problemen op zowel lichamelijk als geestelijk gebied nog de nodige 
gezondheidswinst te behalen valt. Zorgverleners kunnen hierbij meer aandacht geven aan 
de diversiteit van symptomen binnen depressie en tegelijkertijd breder kijken dan depressie 
op zich, door ook rekening te houden met eerder doorgemaakte depressieve episodes 
en persoonlijkheid. Een aanzienlijk aantal mensen met diabetes heeft momenteel niet 
of onvoldoende baat bij de huidige behandelingen voor depressie. Op de juiste manier 
onderscheid maken tussen een depressieve stoornis en andere vormen van emotionele 
problemen bij mensen met diabetes lijkt een goede eerste stap om hier verbetering in te 
brengen, maar er moet ook rekening gehouden worden met de diversiteit binnen depressie 
zelf. Door de behandeling te richten op de meest op de voorgrond staande symptomen 
van een persoon zouden we de succespercentages van depressie-interventies kunnen 
verbeteren, en mogelijk ook een deel van het gezondheidsrisico wegnemen dat aan 
depressie kleeft. Een persoonsgerichte aanpak wat betreft de keuze van interventies dient 
ook rekening te houden met individuele verschillen in de factoren die een rol spelen bij 
het ontstaan en voortduren van emotionele problemen bij mensen met diabetes. Omdat 
diabetes en emotionele problemen zo nauw met elkaar samenhangen, lijkt het zinvol om 
interventies die zich richten op emotionele problemen te combineren met interventies die 
focussen op zelfzorg voor de diabetes. 
Individuele verschillen in persoonlijkheid kunnen een andere leidraad vormen bij de keuze 
voor geschikte interventies. Zo kan Type D persoonlijkheid helpen om personen op te sporen 
die een grote kans hebben om emotionele problemen te ervaren en problemen te hebben 
met de zelfzorg, terwijl ze minder geneigd zijn deze problemen te bespreken met hun 
zorgverlener. Als zorgverleners moeten we oog hebben voor deze mogelijke barrières en 
nadenken over andere vormen waarop we onze zorg toch beschikbaar kunnen stellen. het 
bieden van de mogelijkheid een interventie te volgen via het internet, waarbij er op afstand 
toch feedback wordt gegeven, zou een deel van de terughoudendheid in het accepteren van 
hulp kunnen wegnemen. Een eerste verandering ligt echter in de aandacht die we binnen 
de standaardzorg voor diabetes aan emotionele problemen geven. Door te benadrukken 
dat emotionele problemen regelmatig voorkomen bij mensen met diabetes – zonder dat we 
deze groter maken dan ze zijn – en door te investeren in een werkrelatie waarin mensen zich 
veilig voelen hun zorgen te bespreken, kunnen we als zorgverleners een grotere bereidheid 






het was een zware bevalling, maar na vier jaar is dit ei dan toch eindelijk gelegd... Dit 
proefschrift  zou er niet zijn geweest zonder de directe of indirecte hulp en steun van een 
heleboel mensen, waar ik erg dankbaar voor ben! Een aantal mensen wil ik hier graag 
speciaal noemen.
Allereerst dank aan alle mensen met diabetes die hebben meegewerkt aan de DiaDDZoB 
Study en Diabetes MILES – The Netherlands. Zonder uw bereidheid al die vragenlijsten over 
(het leven met) diabetes in te vullen, was dit proefschrift  er niet geweest. In het bijzonder 
dank aan Diabetesvereniging Nederland, die een zeer acti eve rol heeft  gespeeld in het 
werven van deelnemers voor Diabetes MILES – The Netherlands.
Dank ook aan Simone Vinke van Ridderprint voor het verzorgen van de lay-out en omslag 
van dit proefschrift .
Mijn drie promotoren:
Frans, ik ben je veel dank verschuldigd voor alle kansen die je me de afgelopen vier jaar 
hebt gegeven en het vertrouwen dat je in me hebt gesteld, niet alleen op het vlak van mijn 
promoti eonderzoek maar ook wat betreft  de samenwerking met collega’s uit het buitenland 
en het onderwijs. Ik heb het heel erg gewaardeerd dat de deur alti jd openstond en dat ik 
alti jd even twee minuutjes kon storen, waarop het antwoord standaard was dat het er ook 
wel een paar meer mochten zijn. Ik kijk ernaar uit om samen van de komende twee jaar een 
succesverhaal te maken!
Victor, in ieder teamverband is een anker nodig en wat mij betreft  ben jij dat anker geweest 
in de afgelopen vier jaar. Niet alleen om me met beide benen op de grond te houden, maar 
vooral ook om kriti sch te blijven op mijn eigen werk. Veel dank voor jouw klinische blik als 
arts en de verbazingwekkende snelheid waarmee je mijn stukken van feedback voorziet 
(soms zelfs om half één ‘s nachts...).
Johan, ik denk dat de meeste dingen wel gezegd zijn op de dag waarop ik mijn proefschrift  
heb ingeleverd. Ik ben je heel erg dankbaar voor je hulp en steun ti jdens die laatste cruciale 
weken, en voor het feit dat je de afgelopen jaren ondanks de drukke agenda alti jd ti jd voor 
me hebt vrijgemaakt als dat nodig was. Ik heb heel veel waardering en respect voor jouw 
vermogen en bereidheid om problemen vanuit het perspecti ef van de aio te zien. Je hebt in 
de afgelopen jaren een prachti ge onderzoeksgroep opgebouwd, en ik vind het een eer dat 
ik daar nog twee jaar als post-doc onderzoeker in mee mag draaien.
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I would like to thank the members of the committee, Prof. Dr. Guus van Heck, Prof. Dr. 
Norbert Hermanns, Prof. Dr. Richard Holt, Prof. Dr. Peter de Jonge, Dr. Marcel Adriaanse, and 
Dr. Paula Mommersteeg, for their time to read this thesis and for their valuable feedback.
I would also like to thank all (co)-authors who have contributed to the contents of this 
thesis: Arie Nouwen, Isabela Caramlau, Martin Connock, Kirsty Winkley, Cathy Lloyd, Mark 
Peyrot, Colette Wijnands – van Gent, hein Kramer, Jane Speight, and Mariska Bot. I am very 
grateful for your valuable input.
Dank ook aan Wobbe Zijlstra, voor alle hulp bij de statistische analyses en voor het 
ochtendlijke buurtpraatje met de “I’ve got the 1 - ß” mok in de hand, waar ik nog steeds om 
moet lachen.
Veel dank gaat verder uit naar Praktijkondersteuning Zuidoost-Brabant (PoZoB). Arnold 
Romeijnders en Niels van Elderen: ik ben jullie erg dankbaar dat jullie me in de gelegenheid 
hebben gesteld om aan de slag te gaan met jullie prachtige eerstelijnsdata. Colette, dank 
voor al jouw praktische en inhoudelijke hulp in de afgelopen jaren, ik heb veel respect voor 
de manier waarop jij de DIAZOB data-tientonner op koers houdt. Martha, dank voor de 
gezelligheid op de dagen dat ik bij PoZoB aanwezig was.
Ook ben ik veel dank verschuldigd aan de mensen bij PHARMO, in het bijzonder Chanine 
Velthuizen,  Ernst de Graag,  Fernie Penning – van Beest, heleen van Engeland, huub van der 
Linden, Rients van Wijngaarden, en Ron Herings. Dank voor het mogelijk maken van de kop-
peling tussen de DiaDDZoB data en het PhARMO Database Network, voor het beschikbaar 
stellen van jullie prachtige data en voor alle gastvrijheid en hulp die ik afgelopen zomer heb 
gekregen.
Ingrid, dank dat jij me destijds als beginnende docent onder je hoede hebt genomen, 
en mijn enthousiasme voor het onderwijs hebt aangewakkerd. Ik ben heel blij dat ik via 
de screeningsstudie in het TweeSteden ziekenhuis nog steeds een beroep kan doen 
op je grondige vakkennis. Dank ook voor alle gezellige etentjes in de afgelopen jaren, je 
vriendschap, en je betrokkenheid bij het reilen en zeilen op de universiteit.
Marlène, dank voor onze bijzonder prettige samenwerking, ik heb veel van je geleerd in 





Marjolein, dank dat je me zo gastvrij in je eigen huis in Noorwegen hebt ontvangen afgelopen 
januari. Ik heb genoten van mijn ti jd bij jullie, zowel qua werk als qua vrije ti jd, en ik kijk uit 
naar onze verdere samenwerking!
I would like to thank the research group of Prof. Jane Speight at the Australian Centre for 
Behavioural Research in Diabetes for the wonderful ti me I spent with them in Melbourne 
in 2011. I am very grateful that you gave me the opportunity to work with such an excellent 
team and for making me feel so welcome. A special thank you goes out to Christel and Jess. 
Christel, veel dank voor jouw goede zorg ti jdens mijn verblijf en voor je vriendschap. Ik 
heb heel veel bewondering en respect voor jouw besluit de “Australian challenge” aan te 
gaan. Trekken we er snel weer eens samen op uit? Jess, I have learned so much from you in 
the ti me we spent together, not only about doing research but also about life. Apart from 
gaining a colleague, I have gained a very dear friend, and I am very grateful for your warm 
support.
Verder wil ik mijn (ex)collega’s van Tilburg University bedanken voor de fi jne samenwerking 
en voor de gezelligheid ti jdens en buiten het werk. In het bijzonder wil ik daarbij noemen 
Antoinett e, Corinne, Erla, Fleur, helma, Jenny, Lianne, Mariëlle, Marion, Mariska, Marleen, 
Olga, Renée en Simone. Dank voor alle taart- en theemomentjes, borrels, etentjes, 
Sinterklaasvieringen, wandelingen in het bos, en alle lieve woorden en emails van steun in de 
laatste maanden voor de proefschrift  deadline. Ook dank aan de overige “diabetes”collega’s; 
we vormen samen een leuke onderzoeksgroep!
Mariska, dank voor onze fi jne samenwerking bij het opzett en en uitvoeren van Diabetes 
MILES - The Netherlands. het was een enorme klus, maar we hebben het volbracht... Ik ben 
heel blij dat we dit met z’n tweeën hebben kunnen doen, en ben je dankbaar voor alles wat 
ik onderweg van je geleerd heb. hopelijk reis je af en toe nog even af naar het zuiden, om 
bij te praten.
Speciale dank gaat uit naar mijn twee paranimfen, Marion en Olga. Zonder jullie was dit 
proefschrift  nooit op ti jd afgekomen. Ik ben jullie heel, heel dankbaar dat jullie bereid waren 
je dagenlang bezig te houden met de opmaak en referenti es, zodat ik me volledig kon richten 
op de inhoud. Ik ben blij dat ik op zulke lieve kamergenoten heb kunnen terugvallen in de 
zware laatste maanden. het feit dat jullie op de dag van de deadline beiden al een kwarti er 
in de startblokken zaten toen ik om 07:15u zelf arriveerde, zegt genoeg. Dank dat jullie ook 
achter me staan op 31 mei, en dat ik op mijn beurt iets terug zal / heb kunnen doen door 
achter jullie te staan bij jullie verdediging.
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Marion, lieverd ;) Dank voor alle gezelligheid in de afgelopen vier jaar, je steun, ons wekelijkse 
“klaaguurtje”, en de levenslessen die je me tussen de bedrijven door ook nog wist mee te 
geven. Van de leuze  “het wordt vanzelf de dag erna” maak ik nog altijd dankbaar gebruik bij 
lastige presentaties. Dank ook voor de gezellige diabetescongressen waar we de afgelopen 
jaren samen naar toe zijn gegaan, waar we toch maar mooi Britten, Duitsers en vooral 
Italianen hebben getrotseerd... het is wel stil op de universiteit nu je hier niet meer werkt, 
maar het is snel weer tijd voor een gezamenlijk etentje, en ik hoop dat we in de toekomst via 
PoZoB ook op het gebied van onderzoek weer samen zullen kunnen werken.
Lieve Olga, tja, ik weet niet of een enkele paragraaf genoeg is om je te bedanken voor 
de afgelopen vier jaar. Naast het ter beschikking stellen van een onuitputtelijke voorraad 
zakdoekjes, ibuprofens, markeerstiften, dropjes en liga-koeken, had jij altijd tijd voor een 
kop thee (in jouw geval Wienermelange...) als ik een luisterend oor nodig had en mocht ik 
altijd een beroep doen op jouw grondige kennis over statistiek en het doen van onderzoek. 
Op heel veel moeilijke momenten in de afgelopen vier jaar heb jij me weer terug in het zadel 
geholpen, net zoals jij er was om de succesjes met me te vieren. Ik ben heel dankbaar voor je 
vriendschap en blij te weten dat ik altijd op jou kan terugvallen. Ik kijk ernaar uit om samen 
aan ons post-doc avontuur te beginnen.
Diana, Jan & Daniëlle, Elske en Anouk: Dank voor de gezellige etentjes, spelletjesmiddagen 
en verjaardagen die een welkome afwisseling waren op het schrijven van dit proefschrift. 
Daan (& de mannen): dank voor je trouwe vriendschap en voor het feit dat je me altijd weer 
laat zien dat er nog een hoop leuke andere dingen in het leven zijn dan werk :)
Peter en Ellen: Dank voor jullie interesse en steun in de afgelopen jaren; ik ben heel blij met 
jullie als schoonouders! 
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kan bouwen... Nicole, ik ben heel blij met zo’n lief schoonzusje!
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één met veel hobbels geweest, maar jij bent er alti jd geweest met een troostende schouder 
en een zakdoek voor de tranen. Dank voor alle liefde en steun die je Bas en mij hebt gegeven 
om hier te komen.
Lieve Lennert, van alle mensen in dit dankwoord ben ik jou het meeste dank verschuldigd. 
Voor jou is dit promoti etraject ook niet alti jd even makkelijk geweest. Dank dat je er toch 
alti jd voor me bent, voor je geduld, je liefde, je vertrouwen, en voor het feit dat jij op de rem 
trapt als ik weer eens in de zevende versnelling doorschiet... Dit jaar zijn we ti en jaar samen 
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Graag nodig ik u uit voor 
het bijwonen van de 
openbare verdediging 
van mijn proefschrift
Diabetes and emotional distress:
the need for a personalized approach
op vrijdag 31 mei 2013
in de aula van Tilburg University
Warandelaan 2, Tilburg
De plechtigheid start om 14:00 uur 
met een inleidende presentatie.
De academische zitting begint
om 14:15 uur.
Aansluitend is er een 
receptie ter plaatse.
Giesje Nefs
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